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Introduction
A couple of years ago, a case of a hemangioblastoma (HB) that we encountered
triggered a long and animated discussion with our neuropathologist. The issues
raised and the questions posed regarding the intriguing histopathological and
molecular genetic features of HBs inspired us to the studies described in this
thesis. 
HBs are highly vascularized benign tumors predominantly located in the
cerebellum. They occur as sporadic tumors and as a manifestation of von
Hippel-Lindau (VHL) disease, a hereditary tumor syndrome that results from
a germline mutation in the VHL tumor suppressor gene (TSG).1 We chose to
focus our studies especially on sporadic HBs as the majority of HBs occur
sporadically and the genetic background of sporadic tumors has not been
elucidated. Our initial investigations suggested the involvement of multiple
chromosomes in sporadic HBs. We extended our studies in that direction and
compared the chromosomal abnormalities of sporadic and hereditary HBs in
order to further clarify the genetic background of the sporadic tumors. 
Molecular genetic changes in the VHL TSG have been reported in sporadic
tumors as well. The identification of the VHL gene, and the subsequent
unraveling of the functions of the VHL protein (pVHL), has given insight in the
mechanisms leading to the rich vascular network of HBs. The exceptionally
high vascularity is a histopathological hallmark of these tumors. However, VHL
gene inactivation and loss of pVHL does not fully explain the mechanisms of
tumor initiation.2 Thus, even in VHL-associated HBs, inactivation of the VHL
gene alone is probably not sufficient to initiate tumors, and other genes may
act in collaboration with VHL. The identification of chromosomal abnormalities
may help to detect the genes involved in the development of sporadic HBs, as
well as additional genes involved in hereditary HBs. Unraveling of the genetic
pathways of HBs may give insight in oncogenic mechanisms in general, and
may lead to the identification of new therapeutic targets.
Aim and outline of the thesis
The aim of our studies was to elucidate the genetic background of sporadic
HBs. 
13
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Chapter 1
At the time we started our investigations, molecular genetic studies in sporadic
HBs had been focused on mutations or loss of the VHL gene on chromosome
3p. The few cytogenetic studies of HBs had not revealed any additional
chromosomal abnormalities. 
Our first aim of study was to screen the genome of sporadic HBs in order to
identify chromosomal regions of interest (in addition to 3p25-26), which might
contain genes involved in the oncogenesis of these tumors. For this purpose,
we used comparative genomic hybridization (CGH). With this technique,
screening of the whole genome of a tumor is possible in a single experiment.
CGH analysis assesses chromosomal imbalances, e.g. loss or gain of (part of
a) chromosome(s). A lost chromosome may contain a TSG, while a gain of
chromosome may indicate the presence of an oncogene. 
The chromosomal imbalances identified by CGH in 10 sporadic HBs are
described in  Chapter 2. We suggested a specific sequence of chromosomal
abnormalities in sporadic HBs, and compared our CGH results with the genetic
pathways as reported in sporadic renal cell carcinomas (RCCs) and
pheochromocytomas, two other tumor types that are relatively frequent in VHL
disease. The finding of multiple chromosomal abnormalities in addition to loss
of chromosome 3 supported our suggestion that the genetic pathways leading
to sporadic HBs differ from the pathways involved in VHL-associated HBs.
Based on these results, we extended our studies to a larger group of sporadic
HBs and to VHL-associated HBs, in order to compare the chromosomal
aberrations detected by CGH in both tumor types (Chapter 3). Since the
importance of the VHL gene in the oncogenesis of sporadic HBs has not been
elucidated, we also performed mutation analysis of the VHL gene in all tumors.
Genetic heterogeneity between sporadic and hereditary HBs was also suggested
in this second study.
The results of the study described in Chapter 3 prompted us to screen five
sporadic HBs with 32K array CGH. Array CGH allows for detailed screening of
the genome, as its resolution is much higher than conventional CGH.
Mircodeletions and mico–amplifications can be detected by array CGH. The
results are described in Chapter 4.
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A couple of years ago, the cyclin D1 (CCND1) gene has been reported as an
important target gene of pVHL. The CCND1 gene is an oncogene, and
overexpression of its protein cyclin D1 has been reported in multiple tumors.
Moreover, a common polymorphism of the CCND1 gene has been associated
with prognosis of various cancers. The CCND1 genotype has also been
suggested as a genetic modifier in VHL disease. 
We assessed cyclin D1 expression and the influence of CCND1 genotype in
sporadic HBs in Chapter 5. 
During our studies we were confronted with an intriguing patient with VHL
disease. The value of molecular analysis, including CGH, loss of heterozygosity
(LOH), and VHL mutation analysis, as a tool in the differential diagnosis of VHL-
associated tumors, is demonstrated in this patient in Chapter 6.
The exceptionally high vascularity of HBs is illustrated in 3D images of the tumor
vasculature (Chapter 7). We describe a new technique for 3D reconstruction
of the microvasculature (and other microscopic structures) of both normal and
pathological tissue. This technique also allows for simultaneous visualization
of different components of the vessel wall (e.g. endothelial cells and activated
pericytes). 
In Chapter 8 the results of all of the described studies are summarized and
discussed in the light of recent advantages in the field of sporadic HBs. 
This thesis starts with a review of the current knowledge of the clinical,
histopathological, and molecular genetic aspects of sporadic and VHL-associated
HBs. A brief description of the molecular genetic techniques used in our studies,
e.g. LOH, CGH, and array CGH follows at the end of this chapter.
General introduction 
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Review of the clinical, histopathological, and
molecular genetic features of hemangioblastomas
Clinical features  
Definition
The formal introduction of capillary HBs as a cystic or solid cerebellar tumor
category dates form the classic publications by Arvid Lindau (1926), and by
Harvey Cushing and Percival Bailey (1928).3-5 Cushing and Bailey first coined
the word hemangioblastoma, and defined pathological criteria to separate these
tumors form vascular malformations. However, the first description of a
cerebellar HB was made more than fifty years earlier.4,5 In the World Health
Organization (WHO) Classification of Tumors of 2000, HBs are classified as
grade 1 (benign) tumors of uncertain histogenesis.6
The Swedish pathologist Arvid Lindau was the first to link the cerebellar and
spinal tumors to retinal vascular malformations, as described by the German
ophthalmologist Eugen von Hippel in 1911, and to cysts of the kidneys, pancreas,
and epididymis.3 He called this syndrome ‘Angiomatosis des Zentralnerven-
systems’.3,5 The syndrome is nowadays known as von Hippel-Lindau (VHL)
disease and recognized as an autosomal dominant inherited tumor syndrome.1
VHL disease is characterized by a predisposition to form HBs of the retina and
central nervous system (CNS), clear cell renal cell carcinomas (RCCs),
pheochromocytomas, neuroendocrine pancreatic tumors, endolymphatic sac
tumors (ELSTs), and cyst(adenoma)s in the kidney, pancreas, epididymis and
broad ligament. Although HBs are a major manifestation of VHL disease, the
majority of HBs occur as sporadic tumors. The histopathological and clinical
features of VHL-associated and sporadic HBs are identical in most aspects and
are therefore reviewed together. Where appropriate, differences are specified
(Table 1). 
Location
HBs account for 1-2.5% of all intracranial neoplasms.4,7,8 They occur
predominantly in the cerebellum (75%), are less commonly seen in the
brainstem (10%), and spinal cord (15%), and rarely occur supratentorial.9,10
The majority of sporadic HBs is located in the cerebellum, whereas VHL-
16
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associated HBs are often multiple, and located at various sites. Tumors located
in the cerebellum are mainly found in the hemispheres, and less frequently in
the vermis.4,8 Brainstem tumors are located in the medulla oblongata,
particularly at the area postrema.4,11 Spinal HBs account for about 5% of all
spinal tumors, are mostly located in the posterior half of the spinal cord, and
are found in diminishing frequency from cervical to lumbar areas.4,11
HBs can even be found at the lumbosacral nerve roots and at the filum
terminale.12 Extradural HBs are rare.4,13 Hemangioblastomatosis,
dissemination to spinal cord and subarachnoid space, is extremely rare but
has been reported in sporadic HBs.14
Symptoms
Clinical symptoms depend on the site and size of the CNS HB.10-12 In sporadic
HBs, symptoms generally present in the 5th and 6th decade,15,16 whereas VHL-
associated HBs present at an earlier age.1 HBs occur rarely under the age of
18.18 Symptoms of increased intracranial pressure predominate in patients with
cerebellar lesions. Headache is the most frequent initial symptom in these
patients (12-21%), followed by nausea, vomiting, gait ataxia, dysmetria,
dysarthria, diplopia, and vertigo.4,10,11 Hydrocephalus may result in rapid
decompensation with papilledema. Gait ataxia, dysphagia, motor deficits, and
sensory deficits, are described in patients with brain stem lesions.4,10,11 Pain
and paresthesia are the most common symptoms in spinal HB, followed by
sensory and motor deficits, and urine incontinence.10,11 Neurological
General introduction 
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Table 1 Differences between sporadic and hereditary HBs
% of all
HBs
Solitary
tumor
Predominant
location
Mean age
of onset
(years)
Recurrence after
treatment
Sporadic HB 75% Often Cerebellum 45 y Rare
Hereditary
HB
25% Rare Various CNS
sites
33 y More often
HB=hemangioblastoma; CNS=central nervous system. Ref 1,4,10,15-17
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Chapter 1
examination is normal in patients with small lesions. Despite the high
vascularity of HBs, subarachnoid or intra-parenchymal hemorrhage is
rare.4,10,19
Symptoms are related to a mass effect, and most symptomatic cerebellar and
brainstem HBs are associated with a cyst, whereas asymptomatic tumors have
cysts in only 13% of cases.11,20,21 Symptomatic spinal tumors are often
associated with syringomyelia.4,20 The cerebellar cysts are usually much larger
than the tumor itself. The tendency of HBs to form expanding cysts can cause
life-threatening complications, such as hydrocephalus, raised intracranial
pressure, and brain herniation. HBs frequently show a pattern of growth in which
they enlarge for a period of time (growth phase) and then enter a period of
arrested growth (quiescent phase), which may last several years. Symptomatic
HBs grow faster than asymptomatic tumors, and cysts enlarge faster than the
solid part of the tumor.11 However, no threshold tumor size or threshold rate of
growth has been identified that reliably predicts an association with either
symptoms or a cyst. Such an association would be of value to determine the
optimal timing to start treatment. The role of possible modifiers of tumor growth,
such as genetic factors, puberty, pregnancy, menopause, aging, and hormonal
therapy is not yet clear.11
Neuroimaging 
The diagnostic method of choice for HBs of the cranialspinal axis is gadolinium-
enhanced T1-weighted MRI.4,22
The tumors can easily be identified by MRI. T2-weighted or FLAIR (fluid-
attenuated inversion recovery) MRI is used to quantify cysts and peritumoral
edema. Both angiography and CT scan have been replaced by MRI.
Radiologically, cerebellar HBs are traditionally described in four types: type 1
(5%) is a simple cyst without a macroscopic nodule; type 2 is a cyst with a
mural nodule (60%) (Figure 1); type 3 is a solid tumor (26%); and type 4 is
a solid tumor with small internal cysts (9%).9,23
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Clinical criteria of von Hippel-Lindau disease
In approximately 25% of patients a HB is a manifestation of VHL disease.4,10,12
HBs of the CNS are the most common tumors in VHL disease, affecting 60-
80% of all patients.11,12,24 VHL disease is a hereditary disorder, with a birth
incidence of  1: 36.000, and more than 90% penetrance by 65 years of age.25,26
The diagnosis is often based on clinical criteria, including the family history.
Typical VHL-associated tumors are HBs of the retina or CNS, clear cell RCCs,
pheochromocytomas, ELSTs, and multiple pancreatic cysts. Renal or epididymal
cysts occur frequently in the normal population, and are therefore less specific
for VHL disease. 
The clinical diagnosis of VHL disease is established in a patient with a typical
VHL-associated tumor and a positive family history for VHL disease. Patients
with no relevant family history must have two or more HBs, or one HB in
combination with another typical VHL-associated tumor, to meet the diagnostic
criteria.1,27
Specific correlations of genotype and phenotype have been demonstrated in
VHL families. Type 1 families have a reduced risk of pheochromocytomas,
whereas they can develop all other VHL-associated tumor types. Type 2 families
develop pheochromocytomas, in combination with either a low-risk (type 2A)
or high-risk (type 2B) for clear cell RCCs, or pheochromocytomas alone (type
General introduction 
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Figure 1 Typcial hemangioblastoma with 
contrast-enhancing nidus and large cyst 
(T1-weighted MRI). Compression of the
fourth ventricle induced hydrocephalus. The
patient experienced right-sided ataxia, pro-
gressive headache, nausea, and vomiting. 
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2C). Most families have VHL type 1, while type 2B is the most common type
in families with pheochromocytomas (Table 2).28-33
Management of patients
Screening of patients with a hemangioblastoma
Since HBs are the presenting manifestation in 40% of VHL patients, all patients
with a HB require screening for VHL disease. As VHL-associated HBs present
at a mean age of 33 years, and occur often at multiple sites along the
craniospinal as, young patients with multiple tumors are particularly at risk to
have VHL disease.11,12,15 HBs are together with clear cell RCC the leading cause
of morbidity and mortality in VHL disease. Early detection and treatment of
VHL-associated tumors improve the prognosis of VHL patients. Therefore,
clinical and radiological screening programs are recommended at regular
intervals for VHL patients, as well as for patients at risk for VHL disease (Table
3).1,34
20
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Table 2 Clinical classification of VHL phenotypes
VHL
type
Retinal
HB
CNS
HB
RCC Pheo
1 + + + -
2A + + - +
2B + + + +
2C - - - +
HB=hemangioblastoma;
RCC= clear cell renal cell carcinoma;
Pheo=pheochromocytoma
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Moreover, genetic screening for germline mutations is recommended in all HB
patients younger than 50 years, because 4-14% of patients without clinical,
radiological, or familial evidence for VHL disease appears to be carrier of a VHL
gene mutation.35-38 After genetic screening is performed, monitoring can be
directed at those patients carrying a mutation (Table 4).
General introduction 
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Table 3 Recommended periodic screening in individuals at risk for VHL disease
Adapted from Hes et al,34 with permission
ycneuqerf ,ega tratStseT
ylraey   ,sraey 01yrotsih lacideM
Clinical examination, blood pressure 10 years,   yearly
Blood counts and serum chemistry (creatinine) 10 years,   yearly
ylraey   ,sraey 01senirhpenatem yraniru h 42
ylraey   ,sraey 5  ypocsomlahthpO
Ultrasound abdomen: kidneys, pancreas,
liver
10 years,   1-yearly*
MRI abdomen
MRI (with gadolinium) craniospinal axis
10 years,   2-yearly*
15 years,   2-yearly
noitacidni nOslanac yrotidua lanretni IRM **
noitacidni nOmargoiduA **
noitacidni nOnoitanimaxe lacigolorueN ***
* every year either ultrasound or MRI abdomen;
**
symptoms: hearing loss, tinnitus, vertigo;
***neurological symptoms, or tumors on MRI craniospinal axis.
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Surgery
The standard treatment is complete surgical removal of the solid part of the
HB.10,11,15,40 Curation is the goal of surgery, and although postoperative
mortality was as high as 10% in earlier years, most HBs of the craniospinal
axis can be safely completely removed nowadays.1,15,41 However, even after
microsurgical removal recurrences occur in 6-12% after a median time of 11
years (range 3- 35 years), and mortality is high in these patients.15,17
Stereotactic radiosurgery is an alternative treatment for brainstem or cerebellar
tumors, especially for patients with limited surgical options.42-44 A solitary small
or medium sized tumor (diameter < 1-2 cm) usually shrinks or stops growing
after radiosurgery, and a margin dose of 20 Gray is likely to be sufficient.
However, an associated cyst often does not respond to radiosurgery of the solid
part of the tumor, and formation of a de novo cyst after treatment is possible.
In some cases repeated surgical evacuation of the cyst is required. Therefore,
for a single sporadic cystic HB surgical removal is recommended.42
22
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Table 4 Recommended screening for germline mutation of VHL gene.
Adapted from Hes et al,39 with permission from the Endocrine Society
• Patients with a classical VHL-syndrome, fulfilling clinical criteria, and/or
their first-grade relatives
• A member of a family with a known VHL germline mutation
• A patient with a high-risk for VHL, e.g.
Multiple VHL-tumors in an organ
Bilateral VHL-tumors
Two or more VHL-organ systems involved
One VHL-tumor at an early age (< 50 year for HB and
                    pheochromocytomas, and < 30 year for RCC)
• A patient with one VHL-tumor and from a family with only HBs, or RCCs,
or pheochromocytomas
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Histopathological features
HBs are generally well-circumscribed tumors that appear bright red at
macroscopy.45 Histologically, HBs are characterized by two main components:
vacuolated, often large tumor cells (stromal cells) and a rich capillary network.
Intratumoral hemorrhages and cysts are common. The numerous lipid-
containing vacuoles of the stromal cells account for the typically clear cell
morphology (Figure 2). 
The clear cell morphology can sometimes lead to differential diagnostic
problems with metastatic clear cell RCC, especially since this renal cancer is
also part of VHL disease. The stromal cells represent the neoplastic component
of the tumor.46,47
The abundant vascular network of a HB consists of numerous, often delicate,
capillaries with endothelium surrounded by pericytes. Pericytes stabilize vessel
walls and regulate several endothelial functions, such as permeability,
proliferation, and vascular branching. Activated pericytes are found in vessels
participating in angiogenesis. The amount of activated pericytes on vessels in
different tumor types is variable, and has been reported to range from 30-
97% (mean 69%) in HBs.48,49
Most symptomatic HBs are associated with a cyst, which is usually larger than
the associated tumor.11,20 Symptomatic spinal tumors are often associated with
syringomyelia.4,11 The mechanisms underlying cyst development are only
recently understood.21 Cyst formation is initiated by increased tumor vascular
permeability and increased interstitial pressure in the tumor, leading to plasma
23
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Figure 2 Histological features of HBs. Stromal cells with ample clear, vacuolated cytoplasm
(HE) (A). Immunostaining of endothelial cells with anti-CD34 (B). Immunostaining of acti-
vated pericytes with α-smooth muscle actin (C).
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extravasation into surrounding tissue. When the capacity of the surrounding
tissue to absorb extravasated fluid is exceeded, peritumoral edema and
subsequent cyst formation occurs. In a recent study, the mean time required
for peritumoral edema to evolve into a cyst in HBs was 36 +/-23 months.21
Origin
The origin of the neoplastic stromal cells in HBs is still matter of debate. No
similar cell type has been described in the developing or adult CNS, and studies
to determine the histogenesis of these cells by using electronmicroscopy and
immunohistochemistry have reported conflicting results. Lindau originally
suggested an angiomesenchymal misdevelopment at the third month of fetal
life. At that time, vascular mesenchym is situated on the posterior medullary
velum, and as cerebellar hemispheres also begin to develop, part of the vascular
mesenchym might be drawn into the cerebellum, and represent the origin of
subsequent tumor development.50 This theory has given the tumor its name.
The suggestion that stromal cells share a common angioblastic/mesenchymal
ancestry with endothelial cells and pericytes supports the theory of Lindau.51-
53 However, astrocytic, pericytic/smooth muscle cell, fibrohistocytic, and
neuroendrocrine origin have been proposed as well.54-57 In 2000, the WHO
classified HBs as tumors of uncertain histogenesis.6 Recently, new evidence
for a developmental, angiomesenchymal origin, confirming the originally
hypothesis of Lindau, has been provided.58,59
Molecular genetic features
Von Hippel-Lindau disease
VHL disease is an autosomal dominant inherited syndrome, which results from
a germline mutation in the VHL tumor suppressor gene (TSG). This gene is
located on chromosome 3p25-26, and was first identified in 1993.60 The VHL
gene is a relatively small gene of approximately 14,500 basepairs. The protein
coding region is divided into three exons, and the protein product (pVHL)
contains 213 aminoacids.60
Identification of germline mutations is possible in up to 100% of VHL families,
and more than 150 different germline VHL mutations linked to VHL disease
24
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have been reported so far.29,30,61-63 Mutations leading to loss of function of
pVHL, e.g. (micro) deletions, insertions, splice site or nonsense mutations, are
mostly found in VHL type 1 families.  VHL type 2 families (with pheochromo-
cytomas) almost invariably harbor specific missense (substitution of only one
aminoacid) mutations, leading to an altered function of pVHL.28-33,39 It is
presumed that the genotype-phenotype correlations reflect the degree to which
the functions of pVHL are quantitatively or qualitatively altered by different
VHL mutations; development of pheochromocytomas requires at least partial
pVHL function.64
Because of the variability in expression of VHL disease in and between families,
it has been suggested that in addition to the germline mutation external factors,
such as environmental or life style factors, or additional genes, play a role.65
Knudson’s two-hit hypothesis
Most patients with VHL disease inherit a germline mutation of the gene from
an affected parent, and a normal (wild-type) gene from the unaffected parent.
VHL disease is considered to fit Knudson’s two-hit hypothesis of TSGs;
inactivation of both alleles of a TSG is required to initiate tumor formation
(Figure 3).66 The VHL germline mutation is present in all cells of a VHL patient.
However, only the cells in the specific VHL target organs that undergo somatic
inactivation of the remaining wild-type allele develop tumors.61,67,68 Somatic
inactivation of the remaining VHL allele can occur by mutation of the VHL gene,
loss of the chromosome part containing this gene, or promoter
hypermethylation inhibiting the transcription of the VHL gene.61,67. Deletions
of part of a chromosome are often analyzed by loss of heterozygosity (LOH)
analysis. This technique is described briefly at the end of this chapter.
The VHL gene in sporadic tumors
In most VHL-associated tumors the germline mutation is combined with LOH
at 3p.61,68 Inactivation of the VHL gene also plays a role in the oncogenesis of
the sporadic counterparts of VHL-tumors;2,16 LOH at 3p is found in up to 84-
98% of sporadic clear cell RCCs, somatic VHL gene mutations are reported in
46-57%,69-71 and hypermethylation in approximately 5-19%.2,72,73 According
to Knudson’s two-hit hypothesis, inactivation of both alleles of a TSG is required
25
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to inactivate the gene. However, in most studies the frequency of biallelic
inactivation is not determined. In one study of sporadic clear cell RCCs
inactivation of both alleles of the VHL gene by LOH, somatic inactivation, or
hypermethylation, was found in only 44%.74 Somatic mutation of the VHL gene
combined with LOH at 3p has been reported in 33-46% of sporadic RCCs.69,70
In sporadic HBs, somatic mutations of the VHL gene were detected in 10-41%
(mean 25%), and LOH at 3p was found in 20-53%.38,61,75-77 In two studies on
sporadic HBs hypermethylation of the VHL gene promoter was not found.61,77
Inactivation of both alleles of the VHL gene was detected in only one (8%) of
13 sporadic HBs compared with 13 (62%) of 21 VHL-associated tumors.61
Somatic VHL mutations are rare in sporadic pheochromocytomas, the frequency
of LOH at 3p is relatively low (24%), and hypermethylation has not been
reported.2,78
26
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Figure 3 Knudson’s two-hit model for tumor suppressor genes (TSGs).66 A normal cell con-
tains two intact alleles of a TSG (left). All cells from carriers of a germline mutation already
contain one abnormal allele of the gene (middle), and only one additional somatic hit is
required for inactivation of the TSG and initiation of tumorigenesis (right). In a tumor cell
from patients with a sporadic tumor two separate somatic hits are required. 
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Other tumor suppressor genes
Since inactivation of both alleles of the VHL gene is infrequently found in sporadic
tumors, the function of VHL may not be completely lost in the majority of these
tumors and other TSGs on chromosome 3p or elsewhere in the genome may
be important in the development of these tumors as well. A role for TSGs at
3p12-14 and 3p21.3 in the tumorigenesis of sporadic and VHL-associated clear
cell RCCs has been proposed, but involvement of these putative TSGs in HBs
has not been reported so far.73,79,80
27
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Figure 4 The oxygen-dependent degradation of HIF-1α by pVHL. The pVHL contains two
functional domains (α and β). The α-domain binds to a multiprotein complex, containing
Elongin B and C, Cul2, RBx1, and E2. The β-domain binds directly to its substrate, HIF-1α.
VHL protein inhibits HIF activity under normal oxygen conditions (normoxia) by targeting 
the HIF-1α subunit for ubiquitination. The polyubiquitinated HIF-1α is destroyed by the 
proteosome. Under hypoxic conditions, hydroxylation of HIF does not take place, and the
nonhydroxylated HIF-1α subunits are not recognized by pVHL. Consequently, HIF-1α is 
stabilized and activates transcription of its target genes. Damage or loss of function of 
pVHL also leads to upregulation of HIF target genes, and resembles the hypoxia pathway.
Adapted from Hes et al,39 with permission from the Endocrine Society.
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Genes located at chromosomes other than chromosome 3 may be involved in
sporadic VHL-tumors. In sporadic and VHL-associated clear cell RCCs, DNA copy
number changes of several chromosomes have been found, including loss of
1q, 4q, 6q, 8p, 9p,14q, and 19, and gain of 5q, 7, 17q, and Xq.81-88 In
pheochromocytomas, besides loss of chromosome 3, loss of chromosome 11
is found in VHL-associated tumors, and loss of 1q, and 3q in sporadic
tumors.89,90 At the start of our studies, no cytogenetic abnormalities in HBs
had been reported.91,92
Function of VHL protein
Lack of pVHL induces intracellular metabolic changes that closely resemble
changes observed in oxidative stress. The α-domain of pVHL binds to a protein
called elongin C, which binds to a complex containing elongin B, cullin-2 (CUL2),
Rbx, and E2 to form an ubiquitin ligase complex which targets specific proteins
for polyubiquitylation and subsequent proteosomal degradation.64,93-96
Many of the genes that are regulated by hypoxia, including vascular endothelial
growth factor (VEGF) and erythropoietin (Epo), are under the control of a
transcription factor called hypoxia-inducible factor (HIF). The pVHL-elongin-
CUL2 complex directs the polyubiquitylation, and hence destruction, of the α-
subunits of HIF-1 and HIF-2 in the presence of oxygen.64,93 In hypoxic
conditions, the HIF-α subunits accumulate and activate transcription of
hypoxia-inducible genes, many of which are important in regulating
angiogenesis, cell growth, and cell survival (Figure 4). 
Cells lacking pVHL are unable to degrade HIF-α subunits, irrespective of changes
in oxygen, and upregulation of HIF target gene occurs.97,98 HIF target genes
include VEGF, Epo, plasminogen activator inhibitor 1 (PAI-1), glucose
transporter 1 (Glut1), glycolytic enzymes, carbonic anhydrases (CA-9 and-12),
platelet-derived growth factor (PDGF), and transforming growth factor (TGF-
α and –β).99-102 In HBs, expression of HIF-1 and 2α and its target genes VEGF,
PDGF-B, Epo, Glut1, CA-9 and -12, TGF-α and epidermal growth factor receptor
(EGFR), fibroblast growth factor (FGF), and placental growth factor (PlGF) has
been reported.48,99,100,103-107
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VHL inactivation in tumors 
Although the VHL gene and its principal target HIF-1α are expressed in all
tissues, VHL inactivation is linked to only a small subset of tumors (e.g. HBs,
RCCs, pheochromocytomas), and tumorigenesis appears to depend on tissue
context (e.g. CNS, kidney, adrenals). The mechanisms for the organ-specific
tumorigenesis in VHL disease remain to be elucidated. Stromal and endothelial
cells in HBs express a number of (angiogenic) growth factors and their
receptors, e.g. VEGF and VEGF-receptor (VEGFR)-1 and 2, and TGF-α and EGFR,
suggesting paracrine as well as autocrine growth-factor loops.47,103-105,108
Overexpression of VEGF and PDGF-B is likely responsible for the
hypervascularity of HBs, as these factors are potent mitogens for endothelial
cells and pericytes, respectively.109 VEGF also increases the permeability of
endothelium (hence its alternative name Vascular Permeability Factor, VPF) and
the tendency of HBs to form cysts is linked to this function of VEGF.21,103
In the kidney of VHL patients, the epithelial cells lining of pre-neoplastic renal
cysts show loss of pVHL function and overexpression of HIF and HIF target
genes.110 As in HBs, VEGF and PDGF-B account for the highly vascular nature
of these tumors. Moreover, the renal tububar epithelial cells are particularly
sensitive to the mitogenic effects of TGF-α/EGFR, and overproduction of TGF-
α has been linked to renal cyst formation.64,111 However, additional genetic
alterations are probably required for conversion of the cysts to RCCs, while
the VHL gene serves as a gatekeeper TSG.2 The role of pVHL and HIF in
pheochromocytomas remains to be elucidated, as regulation of HIF seems
normal in these tumors.39
Alternative functions of pVHL
Upregulation of angiogenic growth factors by the activated HIF pathway
provides an explanation for the angiogenic phenotype of the VHL-associated
HBs and RCCs. It has been demonstrated that HIF activation occurs at a very
early stage in the evolution of renal tumors. However, it remains to be clarified
how the loss of VHL triggers oncogenesis and whether HIF mediates it.110
Genotype-phenotype correlations in VHL disease suggest that pVHL has
functions independent of its role in HIF regulation. In type 2C VHL disease
(pheochromocytomas only), the ability to polyubiquitylate the HIF-α subunits
is retained, and thus development of pheochromocytomas is likely linked to a
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pVHL loss of function unrelated to HIF.2,112 It has been suggested that a gain
of function of pVHL may be involved in VHL type 2C tumors.39 Furthermore,
VHL mutants linked to type 2A and type 2B (low vs high risk for RCC, resp)
are both unable to properly regulate HIF, suggesting that the risk of RCC is
modified by a different and additional pVHL function.2
A number of putative pVHL functions involving cellular processes have been
identified including fibronectin binding and extracellular matrix assembly,
interaction with atypical protein kinase C (a regulator of cell polarity and cell
growth) among other substrates, regulation of mRNA stability, cytoskeletal
stability, cell cycle exit control, and differentiation.2,98,113-118 Whether some
of these functions are HIF-dependent is still unclear. Cells lacking pVHL do not
deposit a proper extracellular fibronectin matrix, secrete higher levels of
metalloproteases, are more invasive, and because epithelial cell behavior is
influenced by interactions with the extracellular matrix, show increased
proliferation compared to cells with normal pVHL.2,113,118 In this way, altered
extracellular matrix production may contribute to tumorigenesis after pVHL
inactivation. 
VHL protein targets; cyclin D1
The identification of novel pVHL targets using gene expression analysis might
provide further insights into mechanisms of pVHL tumor suppressor activity. The
pVHL targets include genes that are regulated by HIF and hypoxia, as well as
other genes that control cell growth, cellular metabolism, differentiation,
extracellular matrix breakdown, and angiogenesis.119-123 One of these genes is
the CCND1, that encodes a protein (cyclin D1) that plays a critical role in the
control of the cell cycle at the G1 (resting phase)/S (DNA synthesis) checkpoint.124
Overexpression of cylin D1 releases a cell from its normal cell cycle controls and
facilitates transformation to a tumor cell. Overexpression of cyclin D1 is a feature
of many cancers.125 It has been shown that inactivation of pVHL induces
upregulation of cyclin D1. Whether this occurs by a HIF and/or hypoxia-dependent
pathway is not yet clear.120,123,126,127 The finding in some studies that CCND1 is
hypoxia-inducible in RCC cell lines but not in other tumor cell lines, has led to
the suggestion that a distinct hypoxia-related signaling pathway exists in renal
cells, which contributes to the tissue selectivity of VHL-associated
tumors.120,123,128 Overexpression of cyclin D1 in cells lacking pVHL might explain
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why tumor cells are not capable to exit the cell cycle.117 Although the (putative)
functions of the majority of the novel pVHL target genes suggest a contribution
of these genes to tumor development after pVHL inactivation, the exact
mechanisms are still speculative.  
CCND1 genotype 
In VHL disease, both inter- and intrafamilial variability in tumor expression is
well recognized and differences in tumor-susceptibility have been attributed
to allelic heterogeneity; e.g. specific missense germline mutations confer a
high risk for pheochromocytoma, whereas large deletions or protein-truncating
mutations confer a low risk. However, susceptibility to retinal and CNS HBs
and most RCCs are not influenced by the type of underlying germline
mutation.65 It has been suggested that in these cases genetic and/or
environmental modifier effects account for the phenotypic variation.65,123 One
of the potential genetic modifiers is the CCND1 genotype.
The CCND1 gene contains a common G→A polymorphism (870 G>A) within
the splice donor region of exon 4 that modulates mRNA splicing. This
polymorphism has been reported to influence susceptibility to various
cancers.129-132 In VHL disease, the G-allele was associated with an increased
number of retinal HBs, and a trend to an earlier onset of CNS HBs, whereas
no increased susceptibility to RCCs was found.123
Targeted therapy 
Agents that are directed against HIF responsive growth factors such as VEGF,
PDGF-B, and TGF-α, and their receptors, have been investigated as potential
treatment for HBs and RCCs.133 Most preclinical and early clinical studies are
performed in RCCs, and VEGF antagonists and EGFR inhibitors have shown
activity in these studies.64 A significant, although modest, prolongation in time
to progression of metastatic RCC has been shown in a clinical randomized trial
of bevacizumab, a VEGF neutralizing antibody. However, only 10% of patients
had partial tumor response, and a survival benefit was not observed. Mild toxic
effects were reported, with hypertension and proteinuria predominating.134
There have been case reports on the use of targeted therapy for VHL-associated
HBs. One VHL patient with an optic nerve HB had a dramatic and sustained
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improvement in visual acuity following treatment with SU5416, which is an
inhibitor of the VEGF receptor. Tumor regression was not observed, however,
and clinical improvement might be attributed to blocking of the vascular
permeability effects of VEGF resulting in decreased peritumoral edema.135 In
three patients with CNS HBs who were also treated with SU5416, no significant
reduction in tumor size was noted. However, these patients unexpectedly
developed polycythemia, which might be due to an increased production of
Epo, increased susceptibility of red blood cell precursors to Epo, or an
interaction of SU5416 with other receptors critical for erythropoiesis.136 One
patient with multiple cerebellar and spinal cord HBs and leptomeningeal spread
after surgery was treated with a small molecule inhibitor of the EGFR tyrosine
kinase (OSI-774;TarcevaTM). This patient showed subjective improvement in
neurological symptoms, and a minor reduction in size of two cerebellar HBs.137
Other agents with antiangiogenic properties, such as thalidomide and interferon
-2α, also showed no tumor shrinkage in patients with HBs, although tumor
progression was halted during treatment.138,139
These studies suggest that VEGF inhibition alone is unlikely to cause regression
of established, mature blood vessels, and future treatments should consider
pathways other than that mediated by VEGF.133 Compounds targeting (mature)
endothelial cells and pericytes might cause regression of established tumors.
Combinations of antiangiogenic agents with agents that block tumor cell
autocrine loops, such as TGF-α/ EGFR might be promising alternatives.133,134,140
In conclusion, as yet no therapeutic agent or combination of agents is available
for use against HBs or RCCs in general clinical practice. 
Molecular genetic techniques
Several techniques can be used to detect abnormalities of chromosomes or
genes in tumors. Some methods are especially used for screening purposes,
others are performed when more detailed information of (part of) a specific
chromosomal region or gene is required. In this section the methods that were
used in the molecular genetic studies described in this thesis are briefly
discussed.
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Loss of heterozygosity
Loss of parts of chromosomes (loss of alleles) is a frequent event in tumors,
and loss of heterozygosity (LOH) analysis is often used to detect these allelic
imbalances. For LOH, tumor DNA as well as matched control/normal DNA
(blood) of the patient is generally required. PCR (polymerase chain reaction)
is used for amplification of a DNA fragment containing a highly polymorphic
microsatellite repeat, for example a CA-repeat. The size of this fragment
depends on the amount of CA’s and differs within the population. Usually, a
difference exists in fragment length of the paternal and maternal allele. The
amplified PCR fragments are separated by gel-electrophoresis (Figure 5). When
only one fragment is detected in the matched control DNA both alleles are of
the same size (homozygous) and the marker is considered to be non-
informative. Allelic loss can only be identified for heterozygous loci as it is
detected by an imbalance between both alleles in the tumor DNA in comparison
to the matched control DNA. In an alternative LOH procedure, paired normal
DNA is not a necessity when a set of highly polymorphic markers is analyzed,
the rationale being that the use of a set of these markers dramatically reduces
33
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Figure 5 Loss of heterozygosity (LOH) analysis. PCR fragments are separated by either
polyacrylamide gel-electrophoresis and visualized by autoradiography (left) or by capillary
gel-electrophoresis after using fluorescent primers (right). Normal (N) and tumor (T) DNA of
the same patient are compared and only one of both alleles was present in the tumor.
Adapted from141, with permission.
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the possibility that detection of a single allele for all markers is caused by similar
sizes of both alleles.141 By LOH only one locus of interest can be analyzed per
experiment.
Mutation analysis
A sensitive method for analysis of gene mutations is direct sequencing. The
sequence of the four nucleotides (A, C, T, or G) of the DNA fragment containing
the region of interest is analyzed and compared to the normal sequence to
detect deletions, insertions, or mutations. For direct sequencing a single primer
is used (either forward or reverse) that is adjacent to the region to be
sequenced. During PCR amplification the polymerase enzyme ads dNTPs
(deoxynucleotide-triphosphates; either C, G, A, or T) to the free end of the
primer (3’ hydroxyl group) extending it along the template and forming covalent
bonds between the dNTP subunits. Additionally, in a sequence reaction
dideoxynucleotides (ddNTPs) are present for all four bases each labeled with
a specific fluorochrome. The significance of such a modified base is that
polymerization is halted when the modified base is incorporated into the growing
DNA strand synthesized from the template. The result is a population of
fragments of different sizes. The size of each fragment corresponds to the
distance from the terminating base of the primer. When all fragments are
separated by size, and the fluorescent-labeled nucleotide at the end of each
fragment is detected by a laser, the orginal sequence can be reconstructed.
Depending on the size of the fragment to be sequenced different (overlapping)
primer sets are usually required.  A change in the nucleotide-sequence of the
gene can induce a substitution of an aminoacid and subsequently alter the
function of the protein (Figure 6). 
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Figure 6 Sequence-analysis. The sequence of the bases of a DNA fragment is determined by
the colored spike-pattern. The normal nucleotide sequence is indicated above. This sample
contains at position 667 (arrow) a substitution of C for A (667A→C), leading to a change in
an aminoacid (Threonine to Proline). A=adenine;T=thymine;G=guanine;C=cytosine.
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Comparative genomic hybridization
CGH has the advantage that screening of the entire genome is allowed in a
single experiment. Moreover, CGH does not require prior knowledge about the
genetic constitution of the tumors, this in contrast to other molecular genetic
techniques such as LOH. CGH is based on the comparison of two genomic DNA
populations; one derived from the tumor to be analyzed and one from a
karyotypic normal reference (Figure 6). 
Tumor and reference DNA are differentially labeled (e.g. reference in red and
tumor in green) with fluorochromes (direct labeling), or haptens (indirect
labeling), which are later visualized by fluorescence. Both DNAs are mixed in
a 1:1 ratio in the presence of repetitive DNA (COT-1-DNA) and are in situ
hybridized to normal human metaphase chromosomes. During this co-
hybridization, tumor and reference DNA compete for the same targets on
normal metaphase chromosomes. The relative amount of tumor and reference
DNA bound to a given chromosomal region is dependent on the relative
abundance of these sequences in both DNA samples. Therefore, intensity
differences in the fluorescent hybridization patterns of tumor (green) and
reference (red) DNA can be interpreted as copy number differences between
both genomes (e.g. gains will show in green, losses in red, and regions that
are normally present will show in yellow).
The presence and localization of chromosomal imbalances can be detected and
quantified by analyzing the ratio of the fluorescence intensities of tumor and
reference DNA (green/red). These ratios show which chromosomal regions in
the tumor  genome are over- or under-represented relative to the reference
genome. As ratio profiles are calculated along all chromosomes in the normal
metaphase, an overview of the chromosomal imbalances throughout the entire
genome is provided (Figure 7).
The CGH protocol we used has been fully described.142 In our laboratory this
protocol results in reliable and sensitive CGH experiments. In adequate
conventional CGH experiments, chromosomal imbalances as small as 2-5 Mb
can be detected.
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Figure 7. Loss of (part of) chromosome 3 identified by CGH and array CGH. Mixed differential
labeled normal and tumor DNA are in situ hybridized to normal human metaphase chromosomes
(CGH) or mapped genomic clones (array CGH). A copy number loss (loss of a whole chromosome
3) is shown in red (CGH; left). Array CGH shows a micro-deletion on chromosome 3 (right).
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Array-based CGH
The problem of a limited resolution as described for conventional CGH can be
overcome by hybridizing differentially labeled reference and tumor DNAs to an
array of mapped sequences instead of chromosomes (Figure 7).143-145 Such
CGH based micro-array analyses have been described as array CGH, matrix
CGH, or genomic array analysis. For micro-array analysis hundred to thousands
of DNA sequences are printed at a designated position on a microscopic glass
slide using a robotic “arrayer’’.143 Different types of DNA sequences can be
spotted on a slide such as cDNAs, oligonucleotides, or (large) DNA fragments
cloned into yeast artificial chromosomes (YACs), bacterial artificial
chromosomes (BACs), P1-derived artificial chromosomes (PACs), cosmids, or
other vectors. The resolution of array experiments depends on the size of the
inserted fragments and the genomic spacing of the spots. The large amount
of data obtained by array analysis require standardized storage systems as
well as thorough statistical tools for normalization and automated detection of
chromosomal imbalances. The array CGH used in Chapter 4 contains over
32,000 BAC clones, which allow for detection of chromosomal microdeletions
and microamplifications at a resolution of approximately 100 kb.
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Abstract
Hemangioblastomas (HBs) of the central nervous system (CNS) are benign
tumors and occur as sporadic tumors (75%) or as a manifestation of von Hippel-
Lindau (VHL) disease (25%). VHL disease is an autosomal dominant disorder
characterized by HBs of the CNS and retina, renal cell carcinoma (RCC),
phaeochromocytoma, islet tumors of the pancreas, and endolympatic sac
tumors as well as cysts and cystadenoma in the kidney, pancreas and
epididymis. In VHL patients a large spectrum of germline mutations in the VHL
gene has been detected. In sporadic HBs VHL alleles are reported to be
inactivated in up to 50% of the tumors. To our knowledge the involvement of
other genes in sporadic HBs has not been investigated. To elucidate the
oncogenesis of sporadic HBs, we performed CGH on 10 sporadic HBs to screen
for chromosomal imbalances throughout the entire tumor genome. Aberrations
most frequently detected are losses of chromosomes 3 (70%), 6 (50%), 9
(30%) and 18q (30%) and a gain of chromosome 19 (30%). Based on these
frequencies and the co-occurrence of these aberrations in the analyzed tumors
we hypothesize that loss of chromosome 3 (harboring the VHL gene) is an early
event in the oncogenesis of sporadic HBs, followed by loss of 6, and then losses
of chromosomes 9, 18q and gain of chromosome 19. Comparison of the
chromosomal imbalances in sporadic HBs to those previously reported in RCCs
and pheochromocytomas reveals that the pathway of sporadic HBs shows
similarities to both the RCCs and pheochromocytomas.
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Introduction
Hemangioblastomas (HBs) are benign, highly vascularized neoplasms of the
central nervous system (CNS), which account for only 1-2% of all intracranial
tumors. The origin of the tumor cells in sporadic HBs is still unknown.147 HBs
occur as sporadic tumors (75%) or as part of von Hippel-Lindau disease (VHL-
associated HBs, 25%). VHL disease is an autosomal dominant disorder
characterized by HBs of the CNS and retina, renal cell carcinoma (RCC),
phaeochromocytoma, islet tumors of the pancreas, and endolympatic sac
tumors as well as cysts and cystadenomas in the kidney, pancreas and
epididymis.45,148 A large spectrum of germline mutations in the VHL tumor
suppressor gene (TSG), located at chromosome 3p25-26 has been detected
in VHL patients.35,38,60,75,76 The VHL protein (pVHL) is involved in transcription
elongation and in regulation of stability of hypoxia-inducible factors such as
vascular endothelial growth factor (VEGF).149,150 Inactivation of the VHL gene
also plays a role in part of the sporadic counterparts of the tumors observed
in VHL disease. In the stromal component of sporadic HBs somatic mutations
of the VHL gene have been reported in up to 50% and a loss of heterozygosity
(LOH) including the VHL region is reported in approximately 50%.35,38,75,76
To our knowledge the involvement of other genes in sporadic HBs has not been
investigated. We used comparative genomic hybridization (CGH) to screen for
chromosomal imbalances throughout the entire tumor genome of sporadic HBs
to elucidate which chromosomal regions are important in the oncogenesis of
cerebellar sporadic HBs.151,152 In addition we compared these results to those
previously reported in non-papillary clear cell RCCs and pheochromocytomas,
because co-occurrence of these tumors in VHL disease suggests a common
oncogenic pathway.82,85,87,89
Material and Methods
Surgical specimens of the tumors selected for the present study (Table 1) were
obtained from 10 patients treated in the Radboud University Nijmegen Medical
Centre, The Netherlands (patients N240-N244), and the University Hospital in
Leuven, Belgium (patients N245-N249). All tumors were histopathologically
classified as HBs according to the World Health Organization (WHO)
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classification.45 During surgery part of the tumor was snap-frozen in liquid
nitrogen and stored at -80°C. Clinically, the tumors were diagnosed as
sporadic cerebellar HBs based on neurological examination, negative family
history of VHL disease, negative opthalmological examination and
unremarkable abdominal ultrasound and MRI of the brain and spinal cord. The
mean patient age at operation was 52,3 years (range 31-72).  CGH was
performed on all sporadic HBs as previously described by Jeuken et al.153 Briefly,
DNA was extracted by a salting out procedure.154 Control and tumor DNA were
labeled by nick-translation with digoxigenin-dUTP and biotin-dUTP, respectively
(Roche Molecular Biochemicals, The Netherlands), and precipitated in the
presence of human COT-1-DNA (Gibco BRL Life Technologies, Inc., Gaitherburg,
MD, USA) and herring sperm DNA. The probe and the metaphase slides were
denatured simultaneously. After hybridization and post-hybridization washes,
biotin and digoxigenin were detected using streptavidin-FITC and sheep-anti-
digoxigenin-TRITC (Roche Molecular Biochemicals). The chromosomes were
counterstained with 4,6'-diamino-2-phenylindole-dihydrochloride (DAPI)
(Merck, Darmstadt, Germany) and the slides were mounted in Fluoroguard
(Biorad, Veenendaal, The Netherlands). To test the quality of the CGH
hybridizations, a negative and a positive control experiment were included in
each series of CGH hybridizations.153 Chromosomal imbalances of the X
chromosome could only be detected if CGH was performed using tumor and
control DNA of the same gender. For CGH analysis Quips CGH software (Applied
Imaging, United Kingdom) was used. Detection thresholds for losses and gains
were set at 0.8 and 1.2, respectively. 
The frequency of gains and losses involving the individual chromosome arms
detected by CGH in the sporadic HBs analyzed in this study, was compared
with the frequency in RCCs 82,85,87,155 and pheochromocytomas 89 previously
reported by others in the literature. For RCCs we only included non-papillary,
clear cell RCCs as seen in VHL patients.82,85,87 A large CGH study on RCCs only
listing the most frequently found aberrations was included separately in the
RCC figure.155 In this overview we did not distinguish between complete and
partial imbalances of chromosome arms. 
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Results
Comparative genomic hybridization
The chromosomal imbalances detected using CGH in 10 sporadic HBs are
summarized in Table 1 and visualized in Figure 1. Losses (22/33, 67%) were
more frequently detected than gains (11/33, 33%). Although the partial
aberrations of the positive control were all clearly detected, we only detected
aberrations of complete chromosomes or chromosome arms. Aberrations most
frequently detected were losses of chromosomes 3 (70%), 6 (50%), 9 (30%)
and 18q (30%) and a gain of chromosome 19 (30%). Two of the tumor samples
did not contain any aberrations detectable by CGH. Aberrations of the X-
chromosome were clearly detected if a sex mismatch was introduced confirming
the quality of the CGH. The frequency of chromosomal imbalances of the
chromosome arms in sporadic HBs and RCCs and pheochromocytomas is
summarized in Figure 2.
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Table 1 Chromosomal imbalances detected by CGH in sporadic hemangioblastomas
                Chromosomal imbalances
Tumor -3    -6 (+19      -18q      -9)     +17 Other imbalances
N243 * * * * * * +4,+5,+7,+16,-18p,
-22
N244 * * * * * * -18p
N240 * * *
q41-  ,01-  ,q1+***642N
N242 *
N241 *
N245 *
q51+  ,8-**842N
N247
N249
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Discussion
We performed CGH on 10 sporadic HBs to elucidate which chromosomal regions
are involved in their oncogenesis. We found a relatively large amount of
aberrations in this benign and slow growing tumor (WHO grade I). Aberrations
most frequently detected were loss of chromosome 3 (70%) and 6 (50%),
whereas a loss of chromosome 9 and 18q, and a gain of chromosome 19 were
detected in 30% of the tumors. Our results (Table 1) suggest that there is a
sequence of chromosomal imbalances in sporadic HBs in which loss of
chromosome 3 is the initiating event for HBs, which is followed by loss of
chromosome 6 and losses of 18(q) and/or 9, and/or a gain of chromosome 19.
Next to these aberrations others might be present.
Although all sporadic HBs with a loss of chromosome 3 show complete loss of
this chromosome, a review on DNA copy number losses in human neoplasms
in general  most frequently reported a loss of chromosome 3p.156 Four regions
have been reported to harbor a (putative) TSG, 3p12, 3p14.2, 3p21.3, and
3p25. At 3p25-26 the VHL gene has been identified which is reported to be
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Figure 1 Diagram containing a summary of chromosomal imbalances detected by CGH in
sporadic hemangioblastomas. Lines on the left and right of the chromosome indicate losses
and gains of these chromosomal regions, respectively. The sexchromosomes were not ana-
lyzed.
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Figure 2 Bar graphs showing an overview of the frequency of chromosomal imbalances in
our sporadic hemangioblastomas (HBs), and in renal cell carcinomas (RCCs)82,85,87,155 and
pheochromocytomas (PHEOs)89 previously reported by others in the literature. In the bar
graph showing the RCCs, the gray boxes represent three studies82,85,87 which listed all
aberrations found and the white boxes represent a large CGH study only listing the most
frequently found aberrations.155 A positive percentage on the y-axis represents the frequen-
cy of a gain, whereas a negative percentage represents the frequency of a loss. The chro-
mosome arms are indicated on the x-axis.
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involved in HB oncogenesis;60 1) germline mutations of the VHL gene cause
VHL disease predisposing to multiple tumors, most frequently including HBs,
2) aberrations involving the VHL gene are frequently detected by mutation,
SSCP, or LOH analysis in 10% to 50% of the sporadic HBs,36,38,75-77 3)
hypermethylation of a normally unmethylated CpG island of the VHL gene has
been reported as an inactivating mechanism in HBs without VHL mutations.72
Since VHL aberrations are reported in up to 50% of sporadic HBs,75 other
(p)TSGs located on 3p or 3q might be involved in HB oncogenesis. In tumor
N248 CGH did not detect a loss involving chromosome 3, but small losses
undetectable by CGH might be present or alternative other mechanisms such
as hypermethylation might affect genes on chromosome 3 initiating HB
oncogenesis. Interestingly, this tumor is the only tumor containing a loss of
chromosome 8 on which the gene for elongin C is located. pVHL binds to elongin
C which additionally binds elongin B and cullin-2 (CUL2) forming the VCB
complex. This complex induces degradation of their substrates and is involved
in transcription elongation.149 Aberrations of either VHL or elongin C might
result in destabilizing the VCB-complex.  
Similar to chromosome 3, in some sporadic HBs the complete chromosome 6
is lost while in human neoplasms in general a loss of only 6q is most frequently
reported.156 (p)TSGs have been suggested at 6p21.2, 6q23-25, and 6q24-
35.156 Next to TSGs, other genes such as VEGF (6p12) and ezrin (6q25-26)
might be important in HBs. Upregulation of VEGF (transcript and protein) has
been reported in the stromal cells and of the corresponding receptors in the
tumor endothelium suggesting an paracrine mechanism responsible for
angiogenesis in HBs.47,103 Normally, the VCB complex induces degradation of
a transcription factor for hypoxia-inducible factors (HIF) and destabilization of
this complex results in the upregulation of VEGF. As we frequently detected a
loss of chromosome 6 in sporadic HBs, this might suggest that the remaining
VEGF allele is sufficient for upregulation of VEGF. Another gene, Ezrin, located
on 6q25-26 might be important in HBs. The ezrin protein has a diffuse
cytoplasmatic expression in the stromal cells of HBs in contrast to its normal
localization close to the plasma membrane.157 This might be caused by
overexpression of the protein or by expression of an aberrant ezrin protein
with deficient binding to the membrane or cytoskeleton.157
Losses of chromosomes 18q and 9, detected in 30% of the sporadic HBs, were
reported in respectively 37% and 48% of human neoplasms and several known
46
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or putative TSGs have been located on these chromosomes.156 A gain of
chromosome 19, detected in 30% of the sporadic HBs, is reported in 2 to 36%
of a large variety of tumors.158
Two of the HB samples did not contain aberrations detectable by CGH, indicating
that no aberrations larger than 2 Mb are present in these samples. However,
since it was reported that HBs consist of both neoplastic stromal cells and non-
neoplastic cells, including vessels, macrophages, and reactive astrocytes 46,76
it is also possible that aberrations were not detected due to the high percentage
of normal DNA. Similarly, it was reported that the presence of non-neoplastic
cells might obscure LOH scoring in HB tumor samples.76
Since patients with germline mutations in the VHL gene are predisposed to
multiple tumors including HBs, clear cell RCCs and pheochromocytomas, a close
correlation between the oncogenesis of these tumors is to be expected. The
overview of the frequency of aberrations detected by CGH in these tumors
shows that although HBs contain a complete loss of chromosome 3, RCCs most
frequently lost 3p whereas pheochromocytomas lost 3q. Losses of
chromosomes 6 and 9, frequently occur in RCCs but not in pheochromocytomas.
On the other hand, a gain of chromosome 19 is frequently reported for
pheochromocytomas but less frequently for RCCs. Loss of chromosome 18 is
rare in both tumors. Our results show that RCCs and  pheochromocytomas
show different frequencies of chromosomal imbalances implying different
oncogenic pathways. In HBs chromosomal imbalances characteristic for either
RCCs or pheochromocytomas are both detected. Since HBs do not harbor either
loss of 3p or loss of 3q, but a loss of the complete chromosome 3, there seems
to be one pathway for the oncogenesis of HBs, which show similarities to both
the pathways for RCCs and pheochromocytomas.
In conclusion
Losses of chromosomes 3 and 6 were the most frequently detected
chromosomal imbalances in sporadic HBs. Our results suggest that there is a
characteristic pathway of chromosomal imbalances in which loss of
chromosome 3 (harboring the VHL gene) and loss of chromosome 6 occur as
sequential events, followed by a loss of 9 and/or a loss of 18q and/or a gain
of 19. This pathway shows similarities to those of the RCCs and
47
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pheochromocytomas. To further elucidate the oncogenesis of sporadic HBs,
more sporadic HBs should be analyzed and additionally genes located on these
chromosomal regions should be investigated.
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Abstract
Hemangioblastomas (HBs) occur sporadically or as a manifestation of von
Hippel-Lindau (VHL) disease. In the majority of VHL-associated HBs inactivation
of the VHL tumor suppressor gene (TSG), which is located on chromosome
3p25-26, is found. The VHL gene is assumed to be involved also in the
development of sporadic HBs. In a previous study of chromosomal aberrations
of sporadic HBs, multiple chromosomal imbalances were found in the majority
of tumors. The aim of this study was to analyze further both sporadic HBs and
VHL-associated HBs to determine if these histopathologically identical tumors
have a different genetic background. 
Sixteen sporadic HBs and seven VHL-associated HBs were identified by clinical
criteria and analyzed.  Comparative genomic hybridization (CGH) was used to
screen for chromosomal imbalances throughout the entire HB genome.
Additionally, mutation analysis of the VHL gene was performed by direct
sequencing.
Loss of chromosome 3 and multiple other chromosomal imbalances were found
in the sporadic HBs, although only one imbalance, a loss of chromosome 3,
was detected in the seven VHL-associated HBs.  Somatic VHL gene mutations
were found in one-third of sporadic HBs, whereas a mutation of the VHL gene
was detected in all VHL-associated HBs.
These results indicate that the molecular mechanisms underlying sporadic HBs
and VHL-associated HBs are different. Inactivation of the VHL gene is probably
not the most important event in the tumorigenesis of sporadic HBs. Other
mechanisms of inhibition of VHL protein function, or inactivation of other TSGs,
on chromosome 3(p) or on other chromosomes, might be important in the
development of sporadic HBs. 
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Introduction
Hemangioblastomas (HBs) of the central nervous system (CNS) are rare, benign
tumors (WHO Grade 1) that account for 1 to 2% of all intracranial tumors.10,45
They occur predominantly in the cerebellum, and typically appear on
neuroimaging studies as contrast-enhancing nodules with associated cysts.45
Symptoms often arise from an increase in intracranial pressure caused by
impaired cerebrospinal fluid flow. The standard treatment is surgical removal;
radiosurgery is an alternative for deeply located, small HBs.15,40
HBs occur in sporadic form (75%) or as a manifestation of VHL disease (VHL-
associated HBs, 25%).4,10   An autosomal dominant inherited disorder, VHL
disease is caused by a germline mutation of the VHL tumor suppressor gene
(TSG), and is characterized by one or more of the following tumors: HBs of
the cerebellum, spinal cord, and retina; clear cell renal cell carcinomas (RCCs);
pheochromocytomas; and endolymphatic sac tumors.  Additionally, cysts in
the pancreas, kidney, and epididymis are frequently found.27 In approximately
40% of patients with VHL, an HB is the first manifestation of VHL disease.9
Therefore, clinical and radiological screening for other VHL-associated tumors
is recommended in patients presenting with an HB.9,35,37
Histologically, HBs are composed of neoplastic stromal cells and abundant
capillaries.45 The origin of the neoplastic stromal component is still subject of
debate.7,45 The angiogenic phenotype of HBs has been explained by the
involvement of the VHL protein (pVHL) in degradation of the HIFs (HIF-1α and
HIF-2α) by ubiquitination.159 The pVHL forms, with elongin B, elongin C, and
cullin-2, the VCB-CUL2 complex, which targets the HIFs for degradation under
normoxic conditions.94,95,97 In hypoxia, the HIFs are stabilized and induce
angiogenesis by upregulation of angiogenic factors such as vascular endothelial
growth factor (VEGF). Because of inactivation of the VHL gene, the HIFs are
not degraded under normoxic conditions, and subsequently abundant vessel
formation occurs.97,103 Nevertheless, the overexpression of angiogenic factors
does not fully explain the tumorigenesis of HBs. Other factors with growth-
inducing properties may also be important in the development of VHL-
associated tumors.111 Furthermore, the VHL protein may control gene
expression by other mechanisms, for instance by regulation of transcription
elongation,149 although this latter function of the VHL protein has recently been
disputed.159
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The VHL gene maps to chromosome 3p25-26,60 and a broad spectrum of
germline mutations has been reported in 63 to 100% of families in which VHL
disease has been identified.29,30,61,62 In concordance with Knudson’s two-hit
hypothesis,66 the majority of VHL-associated tumors show  the germline
mutation, and loss of heterozygosity (LOH) at 3p, small intragenic mutations,
or hypermethylation of the other allele.61,67 Conflicting results of the importance
of VHL hypermethylation have been reported in HBs of the CNS.61,67,77
Inactivation of the VHL gene has also been reported to play a role in the
sporadically occurring counterparts of the tumors observed in VHL disease.69-71  
Up to 50% of sporadic HBs showed LOH at 3p, whereas somatic mutations of
the VHL gene have been found, on average, in 25%.38,61,75-77 Biallelic
inactivation, however, was found in only one of 13 sporadic HBs investigated
by Gläsker, et al,61 and they suggested that inactivation of other TSGs on
chromosome 3p might be crucial for the development of sporadic HBs. Other
chromosomes might be involved in the tumorigenesis of sporadic HBs, as
indicated by our previous study,160 in which we used comparative genomic
hybridization (CGH) to screen for chromosomal imbalances throughout the
entire tumor genome of 10 sporadic HBs. In the present study, we analyzed
chromosomal imbalances by using CGH, and aberrations of the VHL gene by
mutation analysis in sporadic HBs and VHL-associated HBs to elucidate further
the molecular genetic differences in these histopathologically identical tumors. 
Material and Methods
Twenty-three tumor samples of HBs of the CNS were obtained in 20 patients
who were treated at the Radboud University Nijmegen Medical Centre, The
Netherlands (Tumors N240-N244, N298, N341, N342, N379, and N380), the
Erasmus University Medical Center, Rotterdam, The Netherlands (Tumors N364-
N368, and N370), or the University Hospital Leuven, Belgium (Tumors N245-
N249, N373, and N378). One sporadic HB was a recurrence (Tumors N298 and
N243), and two patients with VHL had two different VHL-associated HBs
(Tumors N379 and N380, and Tumors N364 and N368). Samples of 21 HBs
were collected during surgery, snap-frozen, and stored at -80°C. In two cases
(Tumors N341 and N342) no frozen tissue was available and, therefore,
formalin-fixed and paraffin-embedded tissue was analyzed. Clinical criteria
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provided by the Dutch National VHL Working Group, based on international
guidelines, were used to establish VHL disease.27,35 Criteria for VHL disease
include a single HB and a positive family history of VHL disease, at least two
HBs (including retinal or spinal), or a single HB in association with other typical
VHL-associated tumors such as clear cell RCC or pheochromocytoma.27 All
tumor samples were histopathologically diagnosed according to the criteria of
the World Health Organization (WHO).45
The CGH was performed as previously described by Jeuken et al.153 Briefly,
DNA was extracted by a salting out procedure.154 Control and tumor DNA were
labeled by nick-translation with digoxigenin-dUTP and biotin-dUTP, respectively.
The DNA isolated from paraffin-embedded tissue (Tumors N341 and N342) was
labeled with a rhodamine universal linkage system as described by the
manufacturer, with minor modifications. Labeled DNA was precipitated in the
presence of human COT-1-DNA and herring sperm DNA. Target metaphase
spreads were prepared using standard procedures; the probe and the
metaphase slides were denatured simultaneously. After hybridization and
posthybridization washes, biotin and digoxigenin were detected using
streptavidin-fluorescein isothiocyanate and sheep-antidigoxigenin-tetramethyl
rhodamine isothiocyanate. The chromosomes were counterstained with 4,6’-
diamino-2-phenylindole-dihydrochloride and were finally mounted in
Fluoroguard. Negative and positive control experiments were included in each
series of CGHs to monitor CGH quality. For CGH analysis, commercially available
software was used and detection thresholds for losses and gains were set at
0.8 and 1.2, respectively.
Analysis of VHL gene mutations was performed by direct sequencing, as
described by Bodmer, et al.161 In summary, five primer sets were used to
amplify exons 1 (three overlapping primer sets), 2, and 3 of the VHL gene from
tumor tissue DNA. The polymerase chain reaction (PCR) products were purified
and subsequently sequenced, after which the sequence products were
analyzed. 
Sources of Supplies and Equipment. The digoxigenin-dUTP and the biotin-dUTP
used in the nick-translations were purchased from Roche Molecular
Biochemicals, Almere, The Netherlands, as were the streptavidin-fluorescein
isothiocyanate and sheep-antidigoxigenin-tetramethyl rhodamine isothio-
cyanate. The rhodamine universal linkage system (model ULS/Ulysis) was
acquired from Kreatech  Biotechnology, Amsterdam, The Netherlands. The
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human COT-1-DNA was supplied by Gibco-BRL Life Technologies, Inc.,
Gaithersburg, MD. The 4,6’-diamino-2-phenylindole-dihydrochloride was
purchased from Merck, Darmstadt, Germany, and the Fluoroguard was acquired
from Biorad, Veenendaal, The Netherlands.The Quips CGH software was
purchased from Applied Imaging, Newcastle upon Tyne, UK. The PCR
purification kit (QIAquick) was supplied by Qiagen, Westburg, The Netherlands.
The ABI PRISM BigDye Terminator Cycle sequencing kit was acquired from
Applied Biosystems , Foster City, CA, as was the ABI PRISM DNA analyzer
(model 3700).
Results
In Table 1 we have summarized the clinical characteristics of the patients and
tumors, chromosomal imbalances detected by CGH in the tumors, and VHL
mutations detected by direct sequencing in the tumors. Clinical evaluation
identified 16 sporadic HBs and seven VHL-associated HBs. The 16 sporadic HBs
(obtained in 11 male and four female patients; mean age at surgery 50 years,
range 14-69 years) included one recurrence and one spinal HB. All patients with
VHL disease (two men and three women; mean age at surgery 33 years, range
21-47 years) harbored multiple cerebellar and/or spinal HBs, in two patients
there were also multiple pancreatic and epididymal (Tumors N379 and 380) or
renal (Tumor N378) cysts, in one patient there was a retinal HB (Tumor N370),
and in two patients there was a positive family history for VHL disease (Tumors
N373 and N378). 
The CGH results are depicted in Figure 1. The chromosomal imbalances most
frequently detected in 16 sporadic HBs were loss of chromosome 3 (designated
-3) in 11 tumors (69%); -6 in seven (44%); -18(q) in five (31%); and -9 in
four (25%); and gain of chromosome 19 (designated +19) in four sporadic
HBs (25%). In three sporadic HBs (19%) no abnormalities were detected using
CGH. In the seven VHL-associated HBs only one aberration (-3) was found on
CGH (14%). This patient (Tumor N370) had multiple cerebellar and spinal HBs
and a retinal HB.
Sequencing of the VHL gene identified three somatic frameshift mutations 
and two missense mutations in the sporadic HBs (five (31%) of 16; Table 1).
These mutations, to our knowledge, have not been previously
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described.32,35,38,61,67,75-77,162 Mutations were identified in six (86%) of seven
VHL-associated HBs (Table 1). These mutations are not germline mutations
per se; blood was available for only two VHL-associated HBs (Tumors N379
and N380) in which the germline mutation T152P was confirmed. To our
knowledge, the mutation T152P has not been reported previously.30,62,162 All
were missense mutations, of which S80R, L158V, and N78S were previously
described as germline mutations.30,162 In one VHL-associated HB a
homozygous deletion of exon 2 was found (Table 1). We could not confirm this
deletion by Southern blotting due to the small amount of DNA available.
Germline homozygous deletions have been reported in VHL disease.162
Discussion
Loss of chromosome 3 and mutations of the VHL gene
A complete loss of chromosome 3 (designated -3) was found in 11 (69%) of
16 sporadic HBs, whereas -3 was detected in only one (14%) of seven of VHL-
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Figure 1 Map showing chromosome imbalances detected using CGH in sporadic heman-
gioblastomas (HBs) and VHL-associated HBs. Lines on the left side of the chromosomes rep-
resent regions that are underrepresented in the tumor genome (losses), whereas lines on
the right side of the chromosomes represent regions that are overrepresented (gains). Only
one chromosomal imbalance was detected in the VHL-associated HBs, a loss of chromosome
3. The other imbalances were detected in sporadic HBs.
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associated HBs, and multiple other chromosomal imbalances were detected in
most sporadic HBs, but not in VHL-associated HBs. Furthermore, mutations of
the VHL gene were identified in only five (31%) of 16 sporadic HBs, but in all 
seven VHL-associated HBs (Table 1). Thus, these results show genetic
differences in sporadic compared with VHL-associated HBs. Inactivation of the
VHL TSG at 3p25-26 is considered to be a common oncogenic mechanism in
VHL-associated tumors,61,67 and germline mutations of this gene are reported
to be present in up to 100% of VHL-associated HBs.30,61,62 Until recently, it
was generally assumed that the VHL TSG was also involved in the tumorigenesis
of the sporadic counterparts of the VHL tumors,38,75-77 as was shown in clear
cell RCCs.69-71 Somatic mutations of the VHL gene have been reported, however,
in only 25% of sporadic HBs (17 of 69; range 10-41%),38,61,75-77 whereas LOH
at 3p has been found in 52% of tumors (16 of 31 overall; range 50-
53%).61,76,77 Furthermore, in a recent study inactivation of both alleles of the
VHL gene was found in only one (8%) of 13 sporadic HBs compared with 13
(62%) of 21 VHL-associated HBs, suggesting that biallelic inactivation of the
VHL gene plays a minor role in tumorigenesis of sporadic HBs.61  These latter
findings corroborate our suggestion that the VHL gene might be involved in
only a subset of sporadic HBs and that other TSGs on chromosome 3p might
be important in the development of sporadic HBs. 
Although according to Knudson, inactivation of both alleles of a TSG is required
to cause tumor development.66 TSGs may also cause tumors by giving rise to
dominant negative mutations or haploinsufficiency.163,164 Dominant negative
mutations inhibit the function of the wild-type allele and the production of wild-
type protein. Haploinsufficiency is caused by a relative shortage of the wild-
type protein as a direct result of loss of one of the alleles. Such mechanisms
might be involved in the tumorigenesis of sporadic HBs. As the detection limit
of CGH is 2 to 5 Mb, smaller losses and gains may be present in these tumors. 
Putative TSGs on chromosome 3 
The frequent loss of chromosome 3 in sporadic HBs suggests a prominent role
for genes located on this chromosome in the development of sporadic HBs. In
a review of DNA copy number losses in various human neoplasms it was
reported that a complete or partial loss of chromosome 3p is often found by
LOH and CGH analysis, whereas losses of chromosome 3q are relatively rare.156
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Putative TSGs have been suggested at several regions on 3p: at 3p12-14
containing, among others, the fragile histidine triad gene; at 3p21.3-p22
containing the lung cancer TSG region 1; and in the VHL gene region 3p25-26
containing, among others, the DNA repair gene Xeroderma pigmentosum
C.73,79,80,156 An important role for TSGs at 3p12-14 and 3p21.3 in the
tumorigenesis of sporadic and VHL-associated RCCs has already been
suggested,73,79,80 but the involvement of these putative TSGs in sporadic HBs
or VHL-associated HBs has not yet been reported. 
In three of the sporadic HB samples (Tumors N247, N249, and N367) no
chromosomal aberrations were detected with CGH. Because the detection limit
of CGH is 2 to 5 Mb, these HBs may contain small aberrations not detectable
using this method. It is also possible that chromosomal aberrations were not
detected because the percentage of normal DNA was too high. Nevertheless,
because the VHL-associated HBs and sporadic HBs are phenotypically identical,
there is no reason to assume that the percentage of normal DNA in the sporadic
HBs and the VHL-associated HBs is different.
Involvement of other chromosomes in sporadic HBs
Genes located on other chromosomes may also play a role in the genesis of
sporadic HBs. As reported in our previous study,160 and confirmed by analyzing
this larger group of sporadic HBs, the frequency of the aberrations and their
occurrence in individual sporadic HBs might indicate a pathway of sequential
events in sporadic HBs (see Table 1): -3 may be a primary event, followed by
-6, -18, and –9, and/or +19. Interestingly, a loss of chromosome 8 was detected
in three sporadic HBs, two of them with a normal constitution of chromosome
6. The third sporadic HB containing -8 was a tumor with multiple imbalances
but with a normal chromosome 3. Therefore, eight of 10 sporadic HBs with
multiple chromosomal aberrations had two of the following imbalances: -3, -
6, or -8.   
In human tumors, (putative) TSGs and oncogenes have been reported on
chromosomes 6, 8, 9, 18, and 19.156 Whether these genes are involved in the
development of sporadic HBs is currently unknown. Other imbalances were
less frequently found in sporadic HBs (Table 1). Some of these imbalances were
also infrequently detected in VHL-associated and sporadic clear cell
RCCs.68,88,165 Because of the angiogenic phenotype of HBs, some genes on
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chromosome 6 and 8 are particularly interesting. Brain-specific angiogenesis
inhibitor 3, a gene with angiogenesis-inhibiting properties specifically expressed
in the CNS, is mapped to 6q12.166 Theoretically, inactivation of this gene in
sporadic HBs might contribute to the abundant vessel formation in HBs. Two
of the sporadic HBs without -6 had -8. Chromosome 8 contains two genes
encoding antiangiogenic factors; brain-specific angiogenesis inhibitor 1 is
mapped to 8q24, and angiopoietin 2 is mapped to 8p21.166 Angiopoietin 2 is a
tyrosine kinase receptor antagonist and is expressed at sites of vascular
remodeling and maturation, where it can have both angiogenic and
antiangiogenic properties.167
Further investigation of the genes located on the chromosomes that show
imbalances in sporadic HBs may help elucidate the pathogenesis of the
enigmatic HB.
In conclusion
As detected by CGH, chromosome 3 was lost in the majority of sporadic HBs,
whereas loss of chromosome 3 was found in only one VHL-associated HB.
Additionally, losses of chromosome 6, 9, and 18, and gain of chromosome 19
are often present is sporadic HBs; no other imbalances were found in VHL-
associated HBs. Mutations of the VHL gene were detected in 31% of sporadic
HBs and in all VHL-associated HBs. These findings indicate that inactivation of
the VHL gene is probably not the most important molecular event in sporadic
HBs, and that these tumors and VHL-associated HBs have a different genetic
background. The pathogenetic pathway of sporadic HBs remains to be
elucidated. Other than the VHL gene, TSGs on chromosome 3 and TSGs on
other chromosomes might be instrumental in the development of these tumors.
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Abstract
Hemangioblastomas (HBs) are highly vascular, benign tumors of the central
nervous system (CNS), which occur as sporadic tumors or as a manifestation
of von Hippel-Lindau (VHL) disease. VHL disease is an autosomal dominant
tumor syndrome, resulting from an inherited (germline) mutation in one allele
of the VHL gene, a tumor suppressor gene (TSG) located at chromosome 3p25-
26. Germline mutations of the VHL gene lead to several benign and malignant
tumors, including, besides HBs, clear cell renal cell carcinomas (RCCs) and
pheochromocytomas. Although the VHL gene also plays a role in the
development of sporadic HBs and RCCs, biallelic inactivation of the gene is found
in only a minority of sporadic tumors. Therefore, it has been suggested
previously that additional genes are involved in the tumorigenesis of these
tumors. Aiming at the identification of such genes, we analyzed five HBs,
previously characterized with conventional comparative genomic hybridization
(CGH) and VHL mutation analysis, with a 32K BAC array CGH to identify
microdeletions or microamplifications, which may harbor causative genes. The
array CGH used in this study enables interrogation of the entire human genome
for submicroscopic genomic copy number alterations at over 32,000 loci with
a resolution of less than 100kb. In three sporadic HBs, three subtle and de
novo microdeletions were identified, within cytogenetic bands 2q14.1 (found
in two tumors), 3q13.31, and 8p21.3, respectively. The subtle character of the
genetic intervals affected (in the order of a few hundred kb) and, consequently,
the limited number of genes residing within these deletion intervals, for the
first time allows for a positional functional candidate approach, aiming at
elucidating the oncogenetic triggers leading to HB (and/or RCC) development.
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Introduction
Hemangioblastomas (HBs) are highly vascular, benign tumors of the central
nervous system (CNS), predominantly located in the cerebellum and spinal cord,
and account for 1-2.5% of all intracranial neoplasms.4,45 The majority of HBs
occur as sporadic lesions. However, in approximately 25% of cases they are a
manifestation of von Hippel-Lindau (VHL) disease. HBs are the most common
tumors in VHL disease, occurring in 60-80% of patients.1,168
VHL disease (OMIM #193300, http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=OMIM) is an autosomal dominantly inherited disorder, which, besides
CNS and retinal HBs, is characterized by the development of clear cell renal cell
carcinomas (RCCs), pheochromocytomas, pancreatic islet cell tumors,
endolymphatic sac tumors, and cysts and cystadenomas in the kidney, pancreas,
epididymis, and broad ligament.1,27 VHL disease results from a heterozygous
germline mutation in the VHL gene at 3p25-26, that can be identified in 100%
of VHL families.60,62 The VHL gene is a tumor suppressor gene (TSG) that fits
the two-hit model of Knudson of biallelic inactivation of TSGs.66 Although the
VHL gene is involved in the tumorigenesis (and/or early progression) of the
sporadic counterparts of VHL-associated tumors, e.g. HBs and RCCs, its exact
role in these tumors has not been fully elucidated.2,16,79,169 In sporadic HBs,
inactivation of one allele of the VHL gene by somatic mutation, LOH, or
hypermethylation, has been reported in only approximately 20-50% of
tumors.38,61,75-77 Moreover, in only 10% of sporadic HBs biallelic inactivation of
the VHL gene could be demonstrated.61,169 Other genes are thus likely to be
involved in the development of sporadic HBs, but these gene(s) have not yet
been identified. In previous studies on sporadic HBs, we showed multiple
chromosomal aberrations by comparative genomic hybridization (CGH), including
loss (-) of chromosomes 3, 6, 8, 9, 10, 18, and 22, and gain (+) of chromosomes
4(q), and 19.160,169 Loss of chromosome 3 (69%) and chromosome 6 (44%)
were the most frequent DNA copy number changes found in these tumors.169
Other studies confirmed the potential importance of (a gene on) chromosome
6(q) in the development of sporadic HBs, as loss of the 6q arm was found in 23%
of the cases by CGH, and LOH at 6q was detected in the majority (in 83%) of
the tumors included in these studies, with the minimal deleted region detected
at 6q23-24.170,171 Up till now, loss of chromosome 8(q) has been reported in
five of 34 (15%) HB cases, including three of our own series.14,169,170
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CGH is a useful technique for genome-wide screening of DNA copy number
imbalances by hybridizing differentially labeled test and reference DNA to
normal metaphase spreads. The main disadvantage of CGH, however, is its
relatively low resolution of 2-5 Mb. One possibility to overcome this problem
is offered by the application of array CGH in which differentially labeled
reference and tumor DNAs are co-hybridized onto an array of bacterial artificial
chromosome (BAC)-derived targets instead of chromosomes.143,144,172 Array
CGH has in theory a practically unlimited genomic resolution, but the actual
resolution of the slides used depends on the genomic size and spacing of the
targets present on the array. We have the availability of full human genome
coverage (so-called “Golden Path”) arrays, currently containing over 32,000
well annotated and fully integrated BAC clones, altogether representing well
over 99% of the sequenced human genome (at two-fold coverage). These
“ultimate resolution” genomic arrays are capable of reliably detecting copy
number imbalances affecting genomic intervals as small as 100 kb.145,146,173
In this study, we have used these tiling-resolution 32K BAC arrays for the
identification of novel and small copy number changes in HBs that previously
remained undetected by conventional CGH analysis. Based on our previous
studies and reports from others, we were particularly interested in abnormalities
on chromosomes 3, 6, and 8.169,171 Therefore, a subset of sporadic HBs from
tumors previously analyzed with conventional CGH and VHL gene mutation
analysis were selected in which these aberrations might be expected. This
approach led to the identification of three novel candidate regions on
chromosomes 2, 3, and 8 of which the corresponding genes may be associated
with the development of HBs.
Material and Methods
Tumor samples
Five sporadic HBs obtained from patients treated at the Radboud University
Nijmegen Medical Centre, The Netherlands (N241, N242), the Erasmus
University Medical Center Rotterdam, The Netherlands (N365, N366), and the
University Hospital Leuven, Belgium (N248) were analyzed in this study.
Conventional CGH and VHL gene mutation analysis of these tumors have been
performed previously (Tabel 1).169
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Tiling-resolution array-based CGH
In this study, we have used a tiling-resolution microarray consisting of 32,447
overlapping BAC clones selected to cover the entire genome,145,174 which was
prepared as previously described.146,175 In short, genomic target DNAs were
isolated from bacterial cultures using an AutogenPrep 960 (Autogen, Holliston,
MA) according to the manufacturer’s instructions. Subsequently, 50 ng DNA
from each of the clones was amplified using degenerate oligonucleotide-primed
PCR (DOP-PCR), dissolved at a concentration of 1 µg/µl in 30% DMSO-
containing spotting buffer, and spotted once on a single CMT-ultragaps coated
glass slide (Corning) by use of an Omnigrid 100 arrayer (Genomic Solutions).
Labeling and hybridization
Tumor DNA was extracted from snap-frozen tissue samples using the DNeasy
tissue kit (Qiagen). Subsequently hybridizations were performed basically as
described elsewhere.172 In brief, 500 ng of genomic DNA from tumor sample
and sex-matched reference pool were labeled by random-primed labeling with
Cy3-dUTP or Cy5-dUTP (Amersham Biosciences), respectively. Labeled DNAs
were mixed with 120 µg human Cot-1-DNA (Roche), co-precipitated, and re-
suspended in hybridization solution (50% formamide; 10% dextran sulphate;
2 x sodium saline citrate (SSC); 4% SDS; 10 µg/µl tRNA (Invitrogen)). Slides
were hybridized for 18 hours at 37ºC with active circulation, followed by five
wash cycles in 50% formamide, 2x SSC at 45ºC, and five wash cycles in
phosphate buffer at 20ºC. Next, slides were dried by centrifugation and scanned
on a Genepix Autoloader 4200AL laser scanner (Axon Instruments). Analysis
of the microarray image files was performed with the GenePix Pro 5.0 software
package (Axon Instruments), and all data were uploaded in a database for
normalization and further analysis. Loss and gain regions were detected with
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Table 1 Chromosomal imbalances by CGH and VHL gene mutations in sporadic 
Chromosomal imbalances by CGH Mutation VHL gene
N241 -3         none
N242 -3         none
CCGGled293q51+ ,9- ,8- ,6-842N
N365 -3, -8        none
N366 -3, -8, -10, -11, -18, +19     none
hemangioblastomas
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the aid of a standard hidden Markov model (HMM) as described previously.146
Statistical analysis was performed using aStudent t test. Chromosomal regions
were considered as candidate regions for gain or loss when the average log2
ratio of a chromosomal region of interest was significantly different from the
average log2 ratio of 15 flanking clones on each side (p-value below 0.01). All
identified genomic copy number alterations were compared to both public and
private databases of known disease-unrelated large-scale copy-number
variations (CNVs) (http://projects.tcag.ca/variation/). Gene organization of
the region involved was obtained from public databases (http://genome.
ucsc.edu NCBI genome build 35, May 2004). 
Results
In all five HB samples selected for this study multiple genomic copy number
alterations were detected ranging from the gain or loss of complete
chromosomes to regions as small as 0.26 Mb, although the average log2 ratio
differences were relatively small due to the expected presence of considerable
amounts of non-tumor cells in the samples (Figure 1). Nevertheless, all
chromosomal aberrations identified by conventional CGH (Table 1) could be
confirmed by array CGH, and additional chromosomal gains and losses were
also detected (e.g. loss of chromosome 18 and 21q11.2-21.3 in tumor N241,
and gain of chromosome 15 in tumor N248; Figure 1). Tumor N366 revealed
the most complex genomic profile, showing many chromosomes at intermediate
copy number levels (Figure 1). In addition to whole chromosome alterations,
submicroscopic copy number changes were found throughout the genome,
ranging in size from 0.26-1.84 Mb. However, many of these genomic variations
have previously been identified in healthy individuals and thus should be
considered as disease-unrelated copy number variations (CNVs). On average,
three to seven CNVs were identified per tumor with minimal sizes varying from
0.26 to 0.43 Mb, which illustrates the practical resolution that can be achieved
with these tiling-resolution BAC arrays even in tumor samples with high levels
of non-tumor cell contamination (of normal vascular cells, e.g. endothelial cells,
pericytes). 
In three of the five tumors, we detected in total four novel deletions (Table 2).
A sub-megabase deletion on 2q13-14.1 was detected in two HB cases (N248
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and N366; Figure 2). However, this region appeared to be paralogous (>98%
homology) to three regions on chromosome 9. Consequentely, copy number
changes in any of these loci, like for example the loss of chromosome 9 in
tumor N248, will affect log2 ratios in all paralogous regions. In addition, a
putative 1.38 Mb deletion on 8p21.3 in tumor N365 and a 0.67 Mb deletion on
3q13.31 in tumor N366 were found. Both deletions would be homozygous in
the tumor cells, since these tumors were known to have already a loss of one
copy of these respective chromosomes (Table 1 and Figure 1). Although the
log2 ratio differences of these regions were not readily detected from the
primary profile, these regions were detected by the hidden Markow algorithm
(Materials and Methods section), and the average ratios were significantly lower
relative to the surrounding clones and correlated very well with the extrapolated
values that could be predicted on the basis of the average log2 ratios
corresponding to the loss of a single copy. Interesting candidate TSGs are
present in both regions, namely LSAMP on 3q13.31 and FEZ1/LZTS1 on 8p21.3
(Figure 2).
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Table 2 Candidate microdeletions in hemangioblastomas detected by array CGH
Tumor
No
Chromosome
location
Size
(Mb)
No of
clones
Start clone End clone Candidate genes
N248 2q13-14.1 0.27 5 RP11-638N20 RP11-395L14 CBWD2, FOXD4L1, RABL2A
N365 8p21.3 1.38 12 RP11-563N12 RP11-135I5 FEZ1/LZTS1
N366 2q13-14.1 0.50 6 RP11-638N20 RP11-702P7 CBWD2, FOXD4L1,RABL2A
3q13.31 0.67 9 RP11-170O17 RP11-33E19 LSAMP
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Figure 1 Genomic profiles of five hemangioblastomas. Array containing 32,447 human
BAC clones (indicated by small circles representing the log2-transformed and normalized
test-over-reference intensity ratios), genomically ordered from 1pter to Yqter in the genome
profile, and for individual chromosomes from pter to qter, all on the basis of the physical
mapping positions obtained from the May 2004 freeze (build 35) of the UCSC genome
browser. The profiles of tumors N241, N248, N365, and N366 are based on two merged
experiments.
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Figure 2 Schematic representation of the genomic organisation of the three identified dele-
tions. Gray bars indicate BAC clones with normal ratios, red bars represent BAC clones with
a significantly low ratio. Mapping positions obtained from the May 2004 freeze (build 35) of
the UCSC genome browser.
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Discussion
Since biallelic inactivation of the VHL gene at 3p25-26 is found in only a minority
of sporadic HBs, we and others previously suggested that the development of
these tumors may also be dependent on the (in)activation of other
genes.61,169,171 To identify chromosomal regions of interest that might
potentially harbor such genes, we previously screened the genomes of 16
sporadic HBs by conventional CGH.160,169 Multiple chromosomal aberrations
were detected, supporting the hypothesis of the presence of an alternative,
VHL-independent pathway.169 Although CGH is a useful technique for detecting
larger (> 5 Mb) copy number changes it is not particularly suitable for the
detection of more subtle (smaller) deleted regions, which might contain putative
TSGs or oncogenes. In order to identify such small copy number changes
without focusing on specific known regions/genes, we used the high-resolution
and high-throughput 32 K array CGH technique. In addition to previously
described chromosomal copy number changes, we were able to detect various
small copy number changes, ranging in size from 0.26-1.84 Mb. As could be
expected, most of these genomic variations represent known, disease-
unrelated CNVs. As HBs are extremely well-vascularized and only the stromal
cells are neoplastic, the identification of novel copy number changes in HBs is
hampered in both array CGH and conventional CGH by the relatively large
amount of normal DNA in this tumor type. As a result, tumor-specific copy
number changes were reflected by much lower test-versus reference ratio
differences than those of chromosome X (in sex-matched hybridizations) and
CNVs, which are present in all cells. Nevertheless, in three tumors we identified
four potentially relevant microdeletions within cytogenetic bands 2q13-14.1
(found in two cases), 3q13.3, and 8p21.3 (Table 2). These regions were selected
for further validation by interphase FISH for the following reasons: firstly, none
of these copy number aberrations were known as recurrent disease-unrelated
polymorphic regions. Secondly, although the ratio differences of the identified
regions were only small, they were found to be significant and close to the
values that could be expected in tumors that have a relatively high degree of
non-tumor cell contamination. Finally, among the genes that may be affected
by these microdeletions were several interesting candidate TSGs. 
No submicroscopic alteration were identified on chromosome 6, whereas in
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another study LOH at 6q23-24 has been reported in 9 of 11 (82%) sporadic
HBs.171 Abnormalities on other frequently lost chromosomes in sporadic HBs
were not identified.
The putative homozygously deleted region on chromosome 3q13.3 contains
one single gene, the LSAMP (limbic system-associated membrane protein)
gene.  LSAMP encodes a neuronal surface glycoprotein that belongs to the IgLON
family of cell adhesion molecules and is distributed in the cortical and
subcortical regions of the limbic system.  During development of the limbic
system, the encoded protein is found on axonal membranes and guides the
formation of specific neuronal connections. Interestingly, LSAMP has been
proposed previously as a TSG involved in the genetically related sporadic and
familial clear cell RCCs.176 LSAMP expression has also been reported to be
negatively correlated with overall survival in sporadic epithelial ovarian
tumors.177 Similar mechanisms could apply for tumor N366, where the loss of
chromosome 3 and a microdeletion on the remaining allele would result in
biallelic inactivation of the LSAMP gene.
The short arm of chromosome 8 (8p) is frequently deleted in human cancer.178-
181 One of the genes originally mapped to 8p22 is FEZ1/LZTS1 (leucine zipper,
putative tumor suppressor 1), an apparently broadly acting TSG with altered
expression in various cancers including breast, esophageal, gastric, lung,
prostate, and urinary bladder carcinomas.182,183,184,185 FEZ1/LZTS1 inhibits
tumor cell growth through regulation of mitosis, and inactivation of the gene
leads to an early exit from the M (mitosis) phase of the cell cycle (i.e. abrogation
of the mitotic cell cycle checkpoint) and uncontrolled cell proliferation.186 In
the HB (N365) with loss of 8p21.3 the microdeletion may be the ‘second hit’
of inactivation of the TSG, as the other chromosome 8 was lost as well.
Mutations of the gene have been reported.182,187
A third region (2q13-14.1) with a submicroscopic deletion was observed in two
of the five tumors. This region contains three annotated genes encoding the
cobalamin synthetase W domain-containing protein 2 (CBWD2), the forkhead
box D4-like 1 transcription factor (FOXD4L1), and the RAS oncogene family
member RABL2A, respectively. Whereas the precise function of the proteins
encoded by these genes is currently unknown, members of both the FOX and
RAB families have been implied in cancer.188-193 The interpretation of this finding
is complicated by the fact that the 2q13-14.1 deletion interval surrounds the
site where two ancestral chromosomes fused to form chromosome 2. This
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region is duplicated at several positions elsewhere in the human genome,
primarily in subtelomeric and pericentromeric locations, thus multiple copies
of these genes (low copy repeats; LCRs) have been found.188,189 For example,
a LCR encompassing the CBWD and FOXD4 genes has three extra copies located
at the telomeric region of 9p and at two pericentromeric regions of chromosome
9 (9q13).188,189 A copy number loss in any of these regions, as in tumor N248
which has a loss of the entire chromosome 9, will result in lower ratios in our
array CGH profiles at all respective loci, including the 2q13-14.1 region.
However, since tumor N366 does not have a loss of chromosome 9, we cannot
exclude a possible role for the genes within this LCR in HB development, and
further detailed studies are required to elucidate this possibility.
In conclusion
This study is the first report on tiling resolution array CGH analysis of sporadic
HBs. In three out of five tumors a total of three candidate microdeletions were
identified; on 2q13-14.1, 3q13.31, and 8p21.3, of which the latter two appear
to represent homozygous deletions. Several interesting TSGs (LSAMP,
FEZ1/LZTS1) are located at these cytogenetic intervals. The possible role of
these genes in sporadic HBs remains to be established, and validation of the
array CGH results (by FISH analysis) is currently ongoing. Furthermore,
investigation of a larger group tumors is needed in order to elucidate the full
spectrum of putative genes involved in the tumorigenesis of sporadic HBs as
well as to investigate the statistic validity of our findings for HB tumorigenesis
in general. 
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Abstract
Central nervous system (CNS) hemangioblastomas (HBs) are highly
vascularized tumors occurring in sporadic form or as a manifestation of von
Hippel-Lindau (VHL) disease. The VHL protein (pVHL) regulates various target
genes, one of which is the CCND1 gene, encoding cyclin D1, a protein that plays
a critical role in the control of the cell cycle. Overexpression of cyclin D1 is
found in many cancers. The CCND1 gene contains a common G→A
polymorphism (870G>A) that enhances alternative splicing of the gene. CCND1
genotype is associated with clinical outcome in a number of cancers although
prognostic significance varies with tumor type. In VHL disease, CCND1
genotype has been suggested as a genetic modifier that influences susceptibility
to HBs. 
In order to analyze whether CCND1 genotype plays a role in sporadic CNS HBs,
we investigated CCND1 genotype in tumor tissue of 17 sporadic and also in
five VHL-associated HBs. In addition, in these tumors the extent and localization
of cyclin D1 expression was investigated by immunohistochemistry. We found
no deviation in CCND1 genotype distribution and allele frequencies from
expected values. Also, there was no correlation between age at onset and
CCND1 genotype. The expression of cyclin D1 as detected by
immunohistochemistry was highly variable within and between tumors, without
a clear correlation with CCND1 genotype. We conclude that, whereas variable
but sometimes high cyclin D1 expression is a feature of sporadic HBs, CCND1
genotype is unlikely to be an important genetic modifier in the oncogenesis of
these tumors.
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Introduction 
Central nervous system (CNS) hemangioblastomas (HBs) occur in sporadic form
or as a manifestation of von Hippel-Lindau (VHL) disease. In VHL disease,
germline mutations of the VHL tumor suppressor gene (TSG) and inactivation
of the VHL protein (pVHL) are associated with a susceptibility to HBs, renal
cell carcinomas (RCCs), pheochromocytomas, and multiple cysts in pancreas
and kidney.1 VHL protein targets the hypoxia-inducible transcription factor (HIF)
for ubiquitin dependent proteolysis, and pVHL inactivation results in
overexpression of HIF and HIF target genes including those involved in
angiogenesis, energy metabolism and apoptosis.98 Vascular endothelial growth
factor (VEGF) is regarded as one of the most important targets of HIF because
of its important role in tumor angiogenesis. However, up till now arguments
for a role of VEGF in the neoplastic transformation of cells are scarce,194 and
other HIF-dependent or HIF-independent target genes of pVHL are likely to be
involved.119 One of the recently reported target genes of pVHL is
CCND1.123,126,127 CCND1 encodes a protein (cyclin D1) that plays a critical role
in the control of the cell cycle at the G1/S checkpoint, and that can function
as an oncogene; overexpression of cyclin D1 can release a cell from its normal
cell cycle controls and may thereby cause transformation to a neoplastic
phenotype.124,125 Overexpression of cyclin D1 is a feature of many
cancers,125,195 including VHL-associated RCC cell lines and tumors.123,126,127
Whether or not the upregulation of cyclin D1 alone following inactivation of the
VHL gene is sufficient for tumorigenesis remains to be elucidated. 127
The CCND1 gene contains a common G→A polymorphism (870G>A) within the
splice donor region of exon 4 that modulates mRNA splicing. Transcripts
originating from alleles containing an A appear less likely to be spliced than
those containing a G. Splicing creates an altered carboxy-terminal domain in
the protein, and the unspliced protein may have a longer half-life.195 It has
been suggested that DNA damage in cells with the A allele may bypass the
G1/S checkpoint more easily compared to cells with the G allele.129 A
significant association between the CCND1 A genotype (AA or AG) and early
onset and progression has been reported in various tumors, like squamous cell
carcinoma of the head and neck,130 hereditary and sporadic colorectal
cancer,129,131 prostate cancer,132 and sporadic pituitary adenomas.196 However,
an association between CCND1 GG genotype and poorly differentiated tumors
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and reduced disease-free interval in squamous cell carcinoma of the head and
neck has also been reported.197 Therefore, the effect of CCND1 genotype is
not clear and may differ between various tumors.
One study investigated the role of CCND1 genotype as a possible modifier of
VHL disease.123 It was suggested that the functional effects of cyclin D1
upregulation due to VHL gene inactivation might be influenced by CCND1
genotype.123 The G allele was described to be associated with an increased
susceptibility to retinal and CNS HBs, but not with RCCs.123 In order to
investigate whether CCND1 genotype plays a role in sporadic CNS HBs we
genotyped 17 sporadic HBs for the 870G>A polymorphism, as well as five VHL-
associated HBs. Furthermore, as this CCND1 polymorphism has been associated
with protein turnover, the extent of cyclin D1 expression was investigated by
immunohistochemistry.
Materials and Methods
Tumor samples were obtained from 22 patients who underwent resection of a
cerebellar or spinal HB at the Radboud University Nijmegen Medical Centre,
The Netherlands (N298, N241-N244, N341-N342, N379, N392), Erasmus
University Medical Center Rotterdam, The Netherlands (N364-N367, N369),
and University Hospital Leuven, Belgium (N245-N250, N373, N378). All
tumors were histopathologically classified as HBs according to the World Health
Organization classification.45 Based on established clinical criteria,1 17 tumors
were sporadic cerebellar HBs (Table 1). Five patients had von Hippel-Lindau
disease (N364, N373, N378, N379, N392), which was confirmed by germline
mutation analysis (S80R, L158V, N78S, T152P, C407T). Two of the examined
VHL-associated HBs were spinal tumors (N364, N373). All VHL patients had
multiple cerebellar and spinal HBs, and multiple cysts in abdominal organs.
One VHL patient (N392) had extensive metastatic renal cell cancer. 
CCND1 genotyping
DNA was isolated from fresh-frozen tumor material as described previously by
a salting out procedure.154 Formaline-fixed and paraffin-embedded tissue was
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deparaffinized and washed in ethanol, air-dried, and incubated in P-buffer
(50mM Tris-HCL pH 8.2, 100 mM NaCl, 1mM EDTA, 0.5% Tween-20, 0.5%
NP40, 20 mM DTT) at 90ºC for 15 minutes. Protein digestion was performed
with 0.5 mg/ml proteinase K (Roche Diagnostics GmbH, Mannheim, Germany)
at 37ºC for one day. Subsequently, genomic DNA was isolated using DNeasy
Tissue kit as described by the manufacturer (Qiagen GmbH, Hilden, Germany)
The A>G polymorphism at position 870 (exon 4) of the coding sequence of the
CCND1 gene was analyzed using restriction fragment length polymorphism
(RFLP) analysis. A ScrFI site that is present only in the G allele was used as
described earlier.123 Fragment amplification was performed in 50 µl reaction
volume containing 100-200 ng genomic DNA, 5 ng of each primer (forward-
5’-GTGAAGTTCATTTCCAATCCGC, reverse-5’-GGGACATCACCCTCACTTAC), 10
mM Tris-HCl pH 9.0, 50 mM KCl, 1.5 mM MgCl2, 0.1 % Triton X-100, 0.01 %
(w/v) gelatin, 0.3 mM dNTPs and 2 U Taq DNA polymerase (Invitrogen, Breda,
The Netherlands). Fragment amplification conditions in a PTC-200 (MJ-
Research via Biozym, Landgraaf, The Netherlands) consisted of an initial 3 min
at 94ºC followed by 40 cycles of 1 min 94ºC, 1 min of 63ºC and 1 min of 72ºC.
An additional step of 3 min at 72ºC concluded the program. The 167 bp PCR-
product was purified on MultiscreenTM PCR plates (Millipore, Etten-Leur, The
Netherlands) and taken up in a volume of 20 µl water. The identity of the PCR
product was confirmed by direct sequencing on an ABI PRISM 3700 automated
sequencer using the DyeDeoxy-terminator cycle sequencing kit according to
the protocol of the manufacturer (Applied Biosystems, Nieuwerkerk a/d IJssel,
The Netherlands). Ten µl of purified PCR-product was subsequently subjected
to restriction analysis with the enzyme ScrFI in a total volume of 25 µl containing
2.5 µl of Buffer 4 (New England Biolabs, via Westburg, Leusden, The
Netherlands) and 5 U of ScrFI (New England Biolabs, via Westburg). Digestion
was performed overnight at 37ºC after which the product was run on a 4 %
agarose gel until distinction between cut (145 bp + 22 bp) and uncut (167 bp)
bands could clearly be made. RFLP analysis of this CCND1 variant was validated
by direct sequence analysis for samples representing all three possible
genotypes.
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Immunohistochemistry
After genotyping of the HBs, immunohistochemistry for cyclin D1 was
performed on 10 sporadic HBs (at least two cases of each genotype class) and,
in addition, on two VHL-associated HBs. In brief, 5 µm sections of paraffin-
embedded tissue were dewaxed in xylol for 10 min and rehydrated through
alcohol. Endogenous peroxidase was blocked with 3% hydrogen peroxide in
phosphate-buffered saline (PBS) for 30 min. Subsequently the sections were
rinsed in PBS and then pretreated by 3 cycles of microwave heating in citrate
buffer (pH 6.0) for 5 min and subsequent cooling down for 20 min till room
temperature. After washing with PBS, the primary antibody (cyclin D1; Progen
Biotechnik, Heidelberg, Germany) was applied to the sections for 60 min. After
washing with PBS for 10 min, the sections were incubated for 30 min with the
secondary antibody (poly-HRP-GAM/R/R IgG; Immunologic, Duiven, The
Netherlands). After washing the sections for 10 min in PBS again, the staining
procedure was finished using the CARD method and DAB (5 min), the sections
were rinsed in water, counterstained with hematoxylin, dehydrated and cover-
slipped.
Statistical analysis
The Chi-square test for cross tables was used to test for differences in genotype
distributions between the different control populations reported in the literature,
between cases and the different control populations, and between cases and
the combined control population. Hardy-Weinberg equilibrium (HWE) testing
was performed using standard procedures.
Results
CCND1 genotype
CCND1 genotype distribution of 17 sporadic and five VHL-associated HBs is
summarized in Table 1. Figure 1 shows the results of the RFLP analysis for
several of the samples analyzed. 
CCND1 AA genotype was found in 23.5%, AG genotype in 35.3% and GG
genotype in 41.2% of sporadic HBs.  Allele frequencies were: A = 0.41, and
G = 0.59.  In the five VHL-associated HBs CCND1 AA genotype was found in
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one case, and AG and GG phenotype each in two cases. Allele frequencies were:
A = 0.4, and G = 0.6. These frequencies showed no deviation from HWE. Several
studies have reported the CCND1 genotype distribution in European, Japanese,
and American control populations.130-132,196 Since statistical analysis showed
no significant difference between the genotype distribution in these populations
(n = 1087) (data not shown), we have used the combined data from these
reports in the present study. In the controls, the overall genotype distribution
was AA 17.2%, AG 51.1%, and GG 31.7%. There was no statistical significant
difference between CCND1 genotype in sporadic HBs and the control population
(Table 2), or between the combined sporadic and VHL-associated HBs and the
control population (data not shown).  Also, the allele frequencies in our study
showed no difference compared to the combined controls (A=0.43, G=0.57).
The mean age of the patients with sporadic HBs was 49 years versus 33 years
for patients with VHL-associated HBs. No correlation was found between age
at diagnosis and CCND1 genotype or presence of an A or G allele in sporadic
HBs: patients with AA, AG, or GG genotype had a mean age of 54, 42, and 52
years, patients with an A allele had a mean age of 47 years, with a G allele 48
years. Also, no correlation was found between age and CCND1 genotype or
79
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Figure 1 Products of the restriction fragment length polymorphism (RFLP) analysis of the
G>A polymorphism at position 870 (exon 4) of the coding sequence of the CCND1 gene.
The band of 167 bp represents the A allele, the 145 bp band represents the G allele. Above
the gel the identity of the sample is shown, below the genotype is indicated. (# analysis
repeated; * verfied by sequence analysis; M marker lane)
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Table 1 CCND1 870G>A genotype, age at presentation, and cyclin D1 expression
in central nervous system hemangioblastomas (HBs)
HB CCND1
genotype
HB nr
(patient age)
                    Cyclin D1
Cytoplasmatic             Nuclear
Extenta     Intensityb    Extent        Intensity
Sporadic AA N241 (34)
N342 (48)
N366 (69)
N249 (66)
++
-
++
++
-
+++
+
-
++
++
-
++
AG N242 (56)
N244 (60)
N365 (14)
N245 (31)
N248 (52)
N367 (42)
++
+++
+++
++
++
+
+
+
+++
+
+
++
GG N243 (48)
N298 (51)
N341 (60)
N369 (28)
N246 (56)
N247 (72)
N250 (50)
+++
+++
++
++
++
+++
++
++
+++
++
-
++
+++
+++
-
+++
VHL AA N392 (46)
AG N379 (28)
N373 (21)
++ ++ ++ +++
GG N364 (45)
N378 (36)
+ ++ + ++
a Extent:   - = no expression; + = focal; ++ = dispersed; +++ = extensive
b Intensity: - = no expression; + = low; ++ = moderate; +++ = high. 
Not all samples were available for immunohistochemistry.
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presence of an A or G allele in VHL-associated HBs. The only patient with VHL
disease and CCND1 AA genotype (N392) had multiple cerebellar HBs and died
of extensive metastatic renal carcinoma. The other VHL patients had less
extensive disease.
Immunohistochemistry
Staining for cyclin D1 was variable within and between tumors with regard to
intensity, extent, and localization. The staining results are summarized in Table
1 and examples are shown in Figure 2. The majority of HBs showed partial
cyclin D1 staining in both nucleus and cytoplasm. In some cases, cyclin D1
expression was found almost exclusively in the cytoplasm (Figure 2). No
correlation between genotype and immunohistochemical cyclin D1 expression
was found (Table 1).
Discussion
Cyclin D1 is an important nuclear protein required for progression of cells
through the G1 phase of the cell cycle.124 Cyclin D1 has recently been reported
as a target of pVHL, and overexpression, due to inactivation of the VHL gene
81
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Table 2 Comparison of CCND1 870G>A genotype frequencies in patients with sporadic 
hemangioblastomas and the combined control population
genotype
  AA  AG GG total
Hemangioblastoma
patients
na
%
4
23.5%
       6
35.3%
      7
41.2%
 17
100%
Combined  control
populationb
n
%
  187
17.2%
  555
51.1%
  345
31.7%
    1087
100%
a n = number of hemangioblastomas or controls. 
b ref130-132,196.
 The p-value (=0.433, Chi-square test: 1.865; degrees of freedom: 2) was nonsignificant.
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and subsequent loss of pVHL, might be a key factor in tumorigenesis of VHL-
associated tumors.123,126,127
Polymorphic variation in CCND1 might influence prognosis in various tumors,129-
132,196,197 as well as the phenotypic expression of VHL disease.123 In most
studies, a significant association was found between the CCND1 AA 129-132,196
and AG 129,131 genotypes and early age at onset as well as poor prognosis of
various cancers. However, the GG genotype was also suggested to be associated
with poorly differentiated tumors and reduced disease-free survival.197 In VHL
disease, genetic modifiers may play a role in phenotypic expression, e.g the
risk of occurrence of RCCs, retinal and cerebellar HBs, and pheochromo-
cytomas.123 It has been suggested that the genetic variant 870G>A in CCND1
is such a modifier; the number of retinal HBs was significantly higher in patients
possessing the G allele compared with AA homozygotes, and possession of one
or two G alleles was described to be associated (not statistically significant)
with an almost 2-fold earlier diagnosis of CNS HBs, and increased susceptiblility
to HBs. No association of RCC with CCND1 genotype was found.123 If the CCND1
G allele increases susceptibility to HBs, one might expect to find a higher
frequency of the G allele in HBs.
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Figure 2 Examples of cyclin D1 expression in three hemangioblastomas as detected by
immuno-histochemistry. As described in the Results section, there was a high intra- and inter-
tumor variability in intensity, extent, and location of cyclin D1 staining without clear-cut corre-
lation with the cyclin D1 genotype of tumors. Most tumors showed a combination of nuclear
and cytoplasmic staining, see e.g. N241 (AA genotype) and N298 (GG genotype), while in
some other tumors staining was predominantly cytoplasmic (see e.g. N244, AG genotype).
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In our study of 17 sporadic HBs, no statistical difference was detected in CCND1
genotype distribution compared to a control population. We also found no
correlation between age at presentation and CCND1 genotype. Because we
analyzed only five VHL-associated HBs, statistical analysis for this small group
alone is not conclusive. As might be expected, VHL patients were younger at
diagnosis than the sporadic patients. 
Interestingly, the only patient with VHL disease and the CCND1 AA genotype
(N392), had multiple cerebellar HBs, and died of extensive metastatic renal
cell carcinoma. Possibly, this phenotype increases susceptibility to a more
aggressive disease, as has been shown for other tumors.129-132,196 However,
more studies in VHL patients will be necessary to prove this suggestion.
Cyclin D1 overexpression in tumor cells has been demonstrated predominantly
in the nucleus of tumor cells. However, exclusive cytoplasmic localization has
also been reported recently.198 Normally, cyclin D1 oscillates during the cell
cycle; the protein accumulates in the nucleus during G1 phase and exits into
the cytoplasm during S phase.199 Nuclear expression of cyclin D1 seems to be
a factor predicting poor prognosis in colorectal tumors.198 In this study of 17
sporadic CNS HBs, the results are too diverse to find statistical significant
evidence of an unequivocal correlation between localization of expression and
genotype. Whether the subcellular localization of cyclin D1 in HBs has
prognostic implications has not been studied.
In conclusion
In this study of 17 sporadic CNS HBs, the results are too diverse to find statistical
significant evidence of an unequivocal correlation between CCND1 genotype
and the occurrence of HBs, implicating that the CCND1 genotype is unlikely to
be an important genetic modifier in the oncogenesis of these tumors. Other
factors responsible for the induction of sporadic HBs remain to be elucidated.
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Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant tumor syndrome,
in which hemangioblastomas (HBs), clear cell renal cell carcinomas (RCCs),
and pheochromocytomas are the most frequently encountered tumors. The
differential diagnosis of dedifferentiated tumors in general can be difficult, as
standard histological and immunohistochemical investigations do not always
allow a definitive diagnosis. We used molecular genetic analysis to resolve the
differential diagnosis of sarcomatoid RCC versus pheochromocytoma of a
(peri)renal tumor in a VHL patient. Germline mutation analysis identified the
C407T mutation, which has been related to a VHL phenotype in which
pheochromocytomas are rare. Chromosomal imbalances detected in the tumor
by comparative genomic hybridization (CGH) showed a pattern typical for RCCs
and not for pheochromocytomas. CGH analysis of the multiple tumors of this
VHL patient revealed a comparable karyotype in the metastatic tumors and
the (peri)renal tumor. Concordantly, although the germline mutation was
detected in all analyzed tumors, loss of heterozygosity (LOH) at 3p was only
detected in the (peri)renal mass and most metastases. Overall, based on all
genetic data this tumor corroborated a diagnosis of metastatic sarcomatoid
RCC. In line with these observations is the immunopositivity for the RCC specific
RC38 detected in the (peri)renal mass and the metastases that was not detected
in pheochromocytomas. The RCC specific marker G250 was uninformative as
it stains positive in all types of VHL-tumors. This case report illustrates the
promising role of genetic analysis in the differential diagnosis of histologically
dedifferentiated tumors.
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Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant tumor syndrome
that results from a germline mutation in the VHL tumor suppressor gene (TSG)
located on chromosome 3p25. Manifestations of VHL disease include a variety
of lesions in the central nervous system (CNS) and visceral organs including
hemangioblastomas (HBs) in the CNS and retina, renal cell carcinomas (RCCs),
pheochromocytomas, and pancreatic neuroendocrine tumors.1 The prevalence
of the tumor-types may differ among VHL families and a correlation between
genotype and phenotype has been identified; type 1 without and type 2 with
pheochromocytoma, each type being characterized by specific VHL
mutations.1,30,64
All VHL-associated tumors show a germline mutation of the VHL coding region
whereas the majority harbor an additional loss of heterozygosity (LOH) or a
somatic mutation of the wild-type allele.61,67,200 It has been suggested that
TSGs on chromosome 3p other than the VHL gene also play a role in the
tumorigenesis of VHL-associated tumors and their sporadic counterparts.61,73,79
Furthermore, aberrations other than those of chromosome 3 have been
reported in VHL-associated tumors.81-88 In low-grade VHL-associated RCCs only
few cytogenetic aberrations have been identified, i.e. gains of chromosomes
7 and 10.88 In high-grade sporadic RCCs81-85,87 and in cell lines of VHL-
associated RCCs,87,88 the most frequent aberrations were loss of 3p, 4q, 6q,
8p, 9p, 14q, and gain of 5q, 7, 17q, and Xq. Prognostic significance of some
of these chromosomal aberrations has been suggested for RCCs.83,87 The same
chromosomal regions that are involved in primary RCC were found to be
affected in their metastases but with different frequencies for a few regions.82
Interestingly, chromosomal aberrations detected in pheochromocytomas differ
from those detected in RCCs and involve besides loss of chromosome 3, loss
of chromosome 11 in VHL-associated tumors, and loss of 1q and 3q in sporadic
pheochromocytomas.89,90 Also, sporadic HBs show -3, -6, -8, -9, -18 and +19
in contrast to VHL-HBs, which infrequently show chromosomal
imbalances.169,170 
Immunohistochemical investigations of VHL-associated tumors are usually
reliable. Although both HBs and metastases of RCC show a clear cell phenotype,
the diagnosis is made by their different staining patterns for epithelial
markers.45 The differential diagnosis of RCC and pheochromocytoma can
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usually be resolved by using an antibody panel including pan-keratin, epithelial
membrane antigen (EMA), chromogranin, and synaptophysin (www.
immunoquery.com).  In addition, G250 and RC38 have been described in the
literature as immunohistochemical markers for RCC.100,201 However, the
differential diagnosis of dedifferentiated tumors in advanced VHL disease, as
well as in advanced cancer in general, can be difficult, as dedifferentiated tumors
lose the normal staining patterns.
We report a case of VHL disease in which molecular genetic analysis methods
applied on tumor tissue aided in resolving the differential diagnosis of
metastatic sarcomatoid RCC and metastatic pheochromocytoma.
Case report
A 44-year-old man presented with a generalized epileptic attack. Diagnostic
workup revealed a cystic left cerebellar tumor, which on histological examination
proved to be a HB. The family history was positive for VHL disease, and
screening for other VHL-associated tumors revealed retinal HBs, establishing
the clinical diagnosis of VHL disease in this patient. Identification of a VHL
germline mutation (C407T, Ser65Leu) in a blood sample of the patient
confirmed the diagnosis.
Multiple cerebellar HBs were discovered in the following years, and one left
cerebellar tumor was removed.  Seven years after presentation, two cystic
lesions in the left kidney were found. A partial nephrectomy of the left kidney
was preformed because of growth of these lesions. Histological examination
revealed a well-differentiated clear cell RCC. At that time, urinary excretion of
normetanephrine was increased threefold, suggesting the presence of a
pheochromocytoma. However, the excretion of metanephrine and
catecholamines was normal, plasma catecholamines were not increased, and
a meta-iodobenzylguanidine (123MIBG) scintigraphy was negative. 
One and a half years later, the patient was admitted to the hospital because
of general malaise. There were no symptoms or signs indicating a
pheochromocytoma; in particular, hypertension was absent. A large, recurrent
tumor in the left (peri)renal region was found, with metastases in liver, lung,
and subcutaneous tissue. Histological analysis of a needle biopsy of the
subcutaneous lesion revealed a highly pleiomorphic, partly sarcomatoid tumor;
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the tumor cells were positive for synaptophysin and negative for pan-keratin
AE1/AE3 (consistent with pheochromocytoma), as well as negative for
chromogranin but variably positive for EMA (consistent with dedifferentiated/
sarcomatoid RCC). A second and third needle biopsy of this tumor did not
contain representative tumor tissue for further (immuno)histological or electron
microscopic analysis. The patient deteriorated and died 3 months after the first
needle biopsy of the subcutaneous mass and 10 years after his first epileptic
attack, at the age of 54 years. 
Postmortem examination. General autopsy revealed a large tumor in the left
(peri)renal region, of which, after the partial nephrectomy, the exact origin
could not be identified anymore. Histologically, the tumor consisted of highly
pleiomorphic, often sarcomatoid tumor cells, and the differential diagnosis
included a sarcomatoid pheochromocytoma and sarcomatoid dedifferentiation
of a clear cell RCC.  Additionally, extensive peritoneal carcinomatosis, peritoneal
lymph node metastases, liver metastases (maximum diameter 6 cm), lung
metastases (maximum diameter 2 cm), and cardiac metastases were found.
Also, a well-differentiated pancreatic neuroendocrine tumor of unknown
biological behavior was detected. The cause of death was fatal heart failure
due to cardiac metastases.
Because of the difficult differential diagnosis on the subcutaneous tumor, as
well as the fact that much more material became available of the different
tumors in this patient after autopsy, we decided to investigate the potential
additional diagnostic value of genetic analysis of (dedifferentiated) tumors in
VHL patients.
Material and methods
Formaline-fixed and paraffin-embedded tissue of two left cerebellar HBs,
collected during surgery in 1991 (N329), and 1994 (N332), and paraffin-
embedded tissue of the well-differentiated clear cell RCC, obtained during
nephrectomy in 1998 (N385), were available for further analysis. In addition,
the following tumor tissues were collected during autopsy: a left cerebellar HB
(N392), high grade, pleomorphic, sarcomatoid tumors in the left (peri)renal
region (N393), heart (N394), lung (N395), liver (N396), and mesenterium
(N397),  snap frozen and stored at -80ºC, and a pancreatic neuroendocrine
89
Molecular analysis of VHL disease-related tumors
bw.gijtenbeek  26-04-2006  14:57  Pagina 89
tumor (N386), a right cerebellar HB (N387), a left cerebellar HB (N389), and
the cauda equina HB (N388), formalin-fixed and paraffin-embedded.
From fresh-frozen tumor material DNA was isolated as described previously.154
Sections of paraffin-embedded tissues were deparafinized, washed in ethanol,
air-dried, and incubated in P-buffer (50mM Tris-HCl pH 8.2, 100 mM NaCl, 1mM
EDTA, 0.5% Tween-20, 0.5% NP40, 20 mM DTT) 90ºC for 15 minutes. Protein
digestions were performed with 0.5 mg/ml proteinase K (Roche Diagnostics
GmbH, Mannheim, Germany) at 37ºC for one day. Subsequently, genomic DNA
was isolated using a DNeasy Tissue kit following the instructions of the
manufacturer (Qiagen GmbH, Hilden, Germany). 
VHL gene mutation analysis was performed by direct sequencing, as described
by Bodmer, et al.161 Five primer sets were used to amplify exons 1 (three
overlapping primer sets), 2, and 3 of the VHL gene. The polymerase chain
reaction (PCR) products were subsequently purified and sequenced, using the
BigDye Terminator v2.0 Cycle sequencing kit and a 3730 DNA Analyzer (Applied
Biosystems), after which the sequences were analyzed. 
For loss of heterozygosity (LOH) analyses, markers on chromosome 3p were
used, including the dinucleotide repeat polymorphic markers D3S1317 and
D3S666, which are located close to the VHL locus at 3p25.3.165,202 PCRs, using
6-FAM labeled primers, were performed on DNA extracted from paraffin-
embedded tissues or fresh-frozen tissue samples. The PCR cycles included:
denaturation for 2 min at 94ºC; 35 cycles of 30 sec at 94ºC, 30 sec at 55ºC,
and 45 sec at 72ºC; a final step of 72ºC for 5 min. The PCR products were
analyzed on a 3100 DNA Analyzer (Applied Biosystems, The Netherlands).
Comparative genomic hybridization (CGH) was performed on all tumors as
described previously.153 Briefly, control and tumor DNA were labeled by nick-
translation with digoxigenin-dUTP and biotin-dUTP, respectively (Roche
Molecular Biochemicals, The Netherlands), and precipitated in the presence of
human COT-1-DNA (Gibco BRL Life Technologies, Inc., Gaitherburg, MD, USA)
and herring sperm DNA. The probe and the metaphase slides were denatured
simultaneously. After hybridization and post-hybridization washes, biotin and
digoxigenin were detected using streptavidin-FITC and sheep-anti-digoxigenin-
TRITC (Roche Molecular Biochemicals). The chromosomes were counterstained
with 4,6’-diamino-2-phenylindole-dihydrochloride (DAPI) (Merck, Darmstadt,
Germany) and the slides were mounted in Fluoroguard (Biorad, Veenendaal,
The Netherlands). To test the quality of the CGH hybridizations, negative and
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positive controls were included in each series of CGH hybridizations.153 For
CGH analysis Quips CGH software (Applied Imaging, United Kingdom) was used.
Detection thresholds for losses and gains were set at 0.8 and 1.2, respectively.
Tissues of all tumors were stained with hematoxylin and eosin for histological
examination. Immunohistochemical staining using the G250 antibody
(Department of Urology, University Medical Center Nijmegen, The Netherlands,
dilution 1:10)203 and RC38 antibody (Department of Pathology, University
Medical Center Nijmegen, The Netherlands, dilution 1:20)204 were performed
on snap-frozen tissue obtained during autopsy, as well as on snap-frozen tissue
of five archival (not of this patient) RCCs (including one colon metastasis),
three archival pheochromocytomas (including one lung metastasis), and three
archival VHL-associated HBs, as previously described. In short, air-dried frozen
tissue sections were fixed with acetone, stained by a sensitive indirect
immunoperoxidase procedure using G250 or RC38 as primary antibody and
3-3-Di-Amino-Benzidine (DAB) as substrate. Sections were counterstained with
hematoxylin.
Results
VHL gene mutation and LOH
The VHL germline mutation previously detected in the white blood cells of this
patient was C407T, Ser65Leu. Mutation analysis of all the VHL exons revealed
this germline mutation in exon 1 in all tumors analyzed; however, no additional
somatic mutations were detected (Table 1). In a minority of tumors of which
only paraffin-embedded material was available (N332, N386, N388), mutation
analysis was not performed due to lack of adequate material. LOH at
chromosome 3p was found in only four of the nine tumors analyzed (N393,
N394, N396, N397), including the dedifferentiated (peri)renal tumor and its
metastases (Table 1). 
In the lung metastasis (N395) no LOH at 3p was found, due to contamination
of normal lung tissue in this sample, as confirmed by revising of the H&E slides. 
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Comparative genomic hybridization
The results of the CGH analysis are summarized in Table 1 and depicted in
Figure 1. In five cerebellar HBs and one cauda equina HB, only few chromosomal
aberrations were detected: loss of chromosome 3 (-3) in one (N329), -22 in
two (N329, N332), gain of the X chromosome (+X) in two (N332, N388), and
+2pter-q32 in one (N392). Two HBs (N387, N389) showed no chromosomal
aberrations detectable by CGH. There was no increase of chromosomal
imbalances in early HBs versus tumors removed at autopsy. The well-
differentiated clear cell RCC (N385), removed by nephrectomy in 1998, showed
only loss of chromosome 3p. The (peri)renal tumor at autopsy (N393) and the
(metastatic) tumors in the heart, lung, liver and mesenterium (N394-N397)
showed complex chromosomal aberrations (Table 1). Losses of chromosome
2p, 2q31-qter, 4, 9, 13q, 14q, 16, and 22, and gains of chromosome 2q11-24,
3q, 7, 8q, and X were most frequently found (present in at least three of these
five tumors). The CGH results of the lung metastasis were less clear than those
in the other tumors (visible with detection thresholds at 0.9 and 1.1, but not
at 0.8 and 1.2), due to contamination with normal tissue. The pancreatic
neuroendocrine tumor showed only  + X.
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Figure 1 Chromosomal imbalances as detected by CGH in tumors of a patient with VHL dis-
ease. Lines on the left side of the chromosomes represent regions that are underrepresented in
the tumor genome (losses), whereas lines on the right side of the chromosomes represent
regions that are overrepresented (gains). For explanation of tumornumbers see Table 1.  
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Immunohistochemistry
Immunohistochemistry showed extensive staining of the tumor cell membranes
of the (peri)renal tumor with RC38, as did the tumors from the heart (N394),
lung (N395), liver (N396), and mesenterium (N397) (Figure 2) whereas in the
cerebellar HB (N392) only the microvasculature stained positive (Figure 2). The
same microvascular staining pattern was detected in all three archival VHL-
associated HBs analyzed. As expected, G250 positivity was detected in all tumors
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Figure 2 Histology (H&E staining) and immunohistochemistry (insets) of different tumors
obtained by autopsy on a case of VHL disease: pleiomorphic, sarcomatoid tumor in the left
renal region (A) and liver (B); cerebellar hemangioblastoma (C); pancreatic neuroendocrine
tumor (D). The tumor cells in A and B are extensively positive for RC38 (inset), while in C
only the tumor microvasculature is RC38-positive (inset). The pancreatic tumor shows
immunohistochemically both epithelial and neuroendocrine differentiation (Cam5.2 staining
in I and Chromogranin staining in II, respectively). Note the transition between cerebellar
cortex (asterisk) and hemangioblastoma in C (arrow indicates Purkinje cell). Original magni-
fication in A-D x200.
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of this VHL patient. Furthermore, analyzing different tumors of other patients,
extensive RC38 (and G250) staining was found in five archival non-VHL-
associated RCCs, including one colon metastasis, whereas three archival non-
VHL-associated pheochromocytomas, including one lung metastasis, showed
RC38 expression only in the tumor microvasculature (and no G250 expression)
(data not shown).
Discussion
HBs are the most common and usually early manifestation of VHL disease,
occurring in up to 60% of patients, with a mean age at presentation of 25 years
for retinal, and 33 years for CNS HBs.1 The most frequent malignant tumor in
VHL disease is clear cell RCC, occurring in up to 45% of patients, the mean
age at presentation being 39 years.1 Pheochromocytomas arise in 10-20% of
patients; 5% of these are malignant. Pancreatic neuroendocrine tumors, or
islet cell tumors, occur in 8-17% of VHL patients and have an uncertain
malignant potential with the liver being the most common site of metastases.1
We report on a VHL patient in which the differential diagnosis of a (peri)renal
tumor as metastatic sarcomatoid RCC or pheochromocytoma was addressed
using immunohistochemistry and molecular genetic analysis.
Although a well-differentiated clear cell RCC was diagnosed two years before,
the nature of the recurrent (peri)renal mass was difficult to establish due to a
completely dedifferentiated histology of the subcutaneous metastasis, and the
ambiguous immunohistochemical staining results (synaptophysin+, pan-
keratin AE1/AE3 -, consistent with pheochromocytoma; chromogranin -, EMA
+, consistent with RCC; see also www.immunoquery.com). Pheochromocytoma
could not be excluded because of the elevated urinary normetanephrine
excretion and because the sensitivity of MIBG scanning is only 85%.  At autopsy,
a (peri)renal tumor was found, with pleiomorphic and sarcomatoid features on
histological examination of which the origin (also due to the status post partial
nephrectomy) could not be determined. 
Genotype-phenotype correlations have been identified in families with VHL
disease. In VHL type 1 patients pheochromocytomas are absent whereas VHL
type 2 patients harbor pheochromocytoma.1,30,64 Specific germline mutations
are associated with these different VHL types. The C407T germline mutation
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detected in this patient has been associated with the VHL type 1 phenotype,30,31
making the diagnosis of a pheochromocytoma very unlikely. 
As it has been reported that different tumor types show characteristic
chromosomal imbalances, we used CGH analysis to screen for chromosomal
imbalances in the (peri)renal tumor as well as the other tumors of this VHL
patient. Most of the aberrations as detected by CGH in this (peri)renal tumor
and its metastases have been previously detected in RCCs: -4q (reported in
up to 28% of RCCs), -9p (29-47%), -14q (20-28%), +7 (15-28%), +X  (20-
28%).81,82,84,85 The tumor additionally showed LOH at 3p, which has been
reported in 94% of RCCs.87 Furthermore, typical aberrations found by CGH in
VHL-associated pheochromocytomas, e.g. -3 (94%), and -11 (84%),90 were
not detected, nor were chromosomal aberrations less frequently found in
(sporadic) pheochromocytomas such as –1p (17-83%), and –3q (39%).89,90
Overall, the CGH data of this (peri)renal tumor strongly favor a diagnosis of
RCC over pheochromocytoma. 
In previous reports, specific chromosomal rearrangements were suggested to
have prognostic significance in RCCs; LOH on 8p or 9q, or loss of chromosome
9 may be a predictor of recurrence,85,87 whereas gain of chromosome 5q may
predict a favorable outcome.83 Indeed, in this patient, loss of chromosome 9
was found in the dedifferentiated renal tumor. 
As a well-differentiated renal tumor was surgically removed from the left kidney
before, we expect that the sarcomatoid RCC progressed from this earlier RCC
rather than being a second primary RCC. However, a gain of 3p was found in
the (peri)renal tumor and one of its metastases (the others showed –3p),
whereas the early renal tumor (N385) showed –3p. Amplification of the only
remaining allele during dedifferentiation of the renal tumor, probably as a result
of a mitotic nondisjunction event, has been suggested to occur in primary RCCs
and their metastatic tumors.82 The results of mutation analysis, LOH, and CGH
confirmed that a mitotic nondisjunction event has occurred during progression
of the well-differentiated RCC.
CGH was also used to analyze the genetic basis underlying the various tumors
of VHL disease. In HBs, inactivation of the VHL gene by germline mutations and
LOH at 3p has been reported in 62% of the patients.61 Few additional
chromosomal aberrations have been found by CGH; loss of chromosome 6 in
one of five VHL-associated HBs, and loss of chromosome 3 in one of seven VHL-
HBs.160,169,170 Concordantly, we only detected a few chromosomal imbalances
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in the HBs of this VHL patient. LOH at 3p was not detected in four of six HBs
analyzed.
CGH revealed similarities in the patterns of aberrations detected in the
(peri)renal tumor and the metastases analyzed. Loss of 2p (50%: 2/4
metastases), 2q3-qter (50%), 4 (75%), 5 (50%), 9 (100%), 13q (100%), 14q
(100%), 16 (100%), 17p (50%), 22 (75%), and gains of 2q11-24 (100%),
3q (50%), 7(p)  (100%), 8q (75%), and X (50%) were found in the metastases
as well as in the (peri)renal tumor. This strongly suggests that these metastases
all originate from the (peri)renal tumor. The clonal relationship between primary
RCCs and their metastases has been analyzed in patients with paired
specimens.81  Although most samples showed a high degree of concordance
between primary tumors and their metastases, some metastases had no or
little evidence of a clonal relationship.81
In the pancreatic tumor, we found a well-differentiated histological phenotype
and only a gain of chromosome X. It was previously reported that genomic
changes of neuroendocrine pancreatic tumors detected by CGH were more
frequent in metastatic tumors, whereas non-metastatic tumors showed few
aberrations.205 Although the liver metastasis showed + X as well, additional
chromosomal aberrations were found in this metastasis. Moreover, as 11 of
the 13 imbalances detected in this metastasis were also detected in the
sarcomatoid RCC, it is most likely that it originates from the RCC.
To study the second hit of the VHL gene in the tumors of this VHL patient,
mutation analysis of the VHL gene and LOH analysis of the VHL region were
performed. The germline mutation C407T, Ser65Leu, was detected in all tumors
analyzed, additional somatic mutations were not found. LOH at 3p, which is
the common second hit,61,67 was found in four of nine tumors analyzed,
including the metastasized renal tumor. 
Overall, the post mortem molecular analysis by LOH and CGH indicated that
this tumor was in fact a dedifferentiated, sarcomatoid RCC and not a
pheochromocytoma. Immunohistochemical stainings using RCC specific
antibodies are in line with this diagnosis. Immunohistochemistry showed
extensive staining of RC38 of the tumor cell membranes of the (peri)renal tumor
and the tumors of the mesenterium, heart, lung, and liver. RC38 recognizes
aminopeptidase A, expressed in cells of the proximal tubulus of the kidney, in
pericytes of angiogenic blood vessels, and in tumor cells of clear cell RCC.204,206
RC38 is a marker for RCCs, but has not been analyzed previously in
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pheochromocytomas.201,206 We found RC38 expression only in the
microvasculature of three archival pheochromocytomas, whereas five archival
RCCs showed extensive staining of tumor cell membranes, indicating that RC38
can be used to differentiate between pheochromocytoma and RCC. The staining
pattern in this patient favors a diagnosis of metastatic RCC. Interestingly, RC38
was also positive in the tumor vasculature, but not in the stromal cells of the
analyzed HB of this patient (Figure 2) and in three archival VHL-associated
HBs.204
Although G250 (CA IX) is a marker for clear cell RCC,203 it does not differentiate
between RCC and pheochromocytoma in VHL disease, because G250 is over-
expressed in all VHL-associated tumors. This overexpression is attributed to
the absence of pVHL, which regulates the degradation of hypoxible-inducible
factors (HIF) 1 and 2, and their target genes including the G250 gene.100
In conclusion
In this patient with VHL disease, the combination of mutation analysis, CGH,
and immunohistochemistry further clarified the differential diagnosis of
metastatic sarcomatoid RCC versus pheochromocytoma. The germline
mutation indicating a VHL type 1 phenotype, the genetic analysis by CGH, and
the immunohistochemical staining of the tumors with RC38, led to the
diagnosis of metastatic RCC. This case illustrates that, now that information
on the genetic background of tumors is rapidly increasing, genetic analysis can
be a powerful tool in establishing a final diagnosis, especially in situations where
histology and immunohistochemistry are not conclusive. In this way, the
management of individual patients can be optimized. 
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Abstract
Three-dimensional (3D) visualization of microscopic structures may provide
useful information about the exact 3D configuration, and offers a useful tool
to examine the spatial relationship between different components in tissues.
A promising field for 3D investigation is the microvascular architecture in normal
and pathological tissue, especially because pathological angiogenesis plays a
key role in tumor growth and metastasis formation. This paper describes an
improved method for 3D reconstruction of microvessels and other microscopic
structures in transmitted light microscopy. Serial tissue sections were stained
for the endothelial marker CD34 to highlight microvessels and corresponding
images were selected and aligned. Alignment of stored images was further
improved by automated non-rigid image registration, and automated
segmentation of microvessels was performed. Using this technique, 3D
reconstructions were produced of the vasculature of the normal brain. Also, to
illustrate the complexity of tumor vasculature, 3D reconstructions of two brain
tumors were performed: a hemangioblastoma (HB) and a glioblastoma
multiforme (GBM). The possibility of multiple component visualization was
shown in a 3D reconstruction of endothelium and pericytes of normal cerebellar
cortex and a HB, using alternate staining for CD34 and α-smooth muscle actin
in serial sections, and of a GBM using immunohistochemical double staining.
In conclusion, the described 3D reconstruction procedure provides a promising
tool for simultaneous visualization of microscopic structures.
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Introduction
The microscopic features of tissues are generally assessed in two-dimensional
(2D) histological slides, which for most purposes suffices. However, the actual
three-dimensional (3D) shape of microscopic structures cannot be extrapolated
on the basis of examination of 2D sections alone. In some situations, 3D
reconstruction may provide useful information about the exact 3D configuration
of microscopic structures. Moreover, 3D reconstruction offers a useful tool to
examine the spatial relationship between different components in tissues.207
Several applications of 3D visualization of histological features have already
proved valuable in different areas of pathology.207-213 For example, 3D
reconstruction was used to visualize intraductal extension of invasive breast
carcinomas,214 bone marrow vascularity in acute lymphoblastic leukaemia,215
and bone marrow infiltration of non-Hodgkin’s lymphoma.216
As pathological angiogenesis plays a key role in tumor growth and metastasis
formation, 3D visualization may be a powerful tool to investigate the
microvascular architecture in normal and pathological tissue. The structural
and functional abnormalities of tumor vessels are likely to determine the efficacy
of anti-angiogenic therapies in cancer.217 Microvascular parameters like
microvessel density have been shown to be a predictive factor for metastasis
formation and survival in various tumors.210,218
For many years, vascular corrosion casting in combination with scanning
electron microscopy, and confocal laser scanning microscopy have been used
to investigate 3D vascular patterns of normal and pathological
tissues.208,209,219,220 Vascular corrosion casting is a complex technique,
requiring fresh material, and quantitative data need to be interpreted with
care.220 Confocal laser scanning microscopy needs immunofluorescent staining,
and its use is limited to tissue samples no thicker than 30-40 µm.209,212
Several techniques for automated 3D reconstruction using serial sections have
recently been developed.210,212,213 The use of serial histological sections has
the advantage that standard (immuno)histochemical staining can be applied
on archival, paraffin-embedded material for recognition of the elements of
interest, and that the thickness of the tissue that can be examined is not
restricted by technical limits. Important considerations for automated 3D
reconstruction are: tissue preparation (e.g. paraffin-embedded or fresh-
frozen material) and sectioning, staining and counterstaining procedures, the
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use of semi or fully automated segmentation of the structure(s) of interest,
alignment of the serial sections (image registration), and the reconstruction
method.207,210,212,213
The aim of our investigation was to develop a technique for 3D reconstruction
of microvessels (and other structures) in the brain from serial sections of
archival material, to allow visualization and analysis of complex vascular
patterns in tumors, and to visualize the relationship between different
components, e.g. between endothelium and activated pericytes. 
Paraffin-embedded tissue was used because of superior morphology, and serial
tissue sections of 3 or 4 µm were cut using a section method allowing for minimal
distortion and minimalization of section loss. Standard and double
immunohistochemical staining methods were performed to highlight the
structures of interest. 
Materials and methods
Tissue preparation
Paraffin-embedded samples of cerebral white and neocortical grey matter and
of cerebellar cortex of a normal human brain obtained by autopsy, as well as
samples of a cerebellar hemangioblastoma (HB) and of glioblastoma multiforme
(GBM) were selected from the archives of the Department of Pathology,
Radboud University Nijmegen Medical Centre.
To allow for the serial sectioning of the paraffin block with equal thickness and
minimal distortion and loss of sections, sectioning was performed on an
electronic, motorized, rotary microtome (Microm HM 355S, MICROM
International GmbH, Walldorf, Germany) (Figure 1). In this microtome, the
block holder is replaced with a freezing device, which enables fast cooling of
specimens to -45ºC. A Section Transfer System (Microm STS, MICROM
International GmbH) was mounted directly on the microtome to guide the
sections via a continuous laminar flow of water from the knife-edge into the
heated water bath without manual manipulation. The paraffin-blocks were
attached to the fast freezing unit with acid free vaseline and rapidly cooled to
-45ºC. As soon as the block was firmly attached to the freezing unit the
temperature was raised to -15ºC, resulting in a firm paraffin-block with a stable
temperature and allowing for the cutting of sections with identical thickness.
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We chose to produce serial sections with a thickness of 3 or 4 µm at a low
speed (1,5 mm/s) on a disposable blade carrier (including a Feather S22 blade,
Klinipath, Duiven, The Netherlands) with laminar flow of warm water (45ºC)
between cutting edge and heated water bath. In this situation, section
stretching occurs immediately and in a reproducible way after contact of the
section with the water as a result of water surface tension. During the
continuous sectioning and based on the size of the selected paraffin-embedded
tissue block, we chose to separate rows of 5 sections from each other with a
razorblade in case of single component analysis. These 5-section rows were
transported over the water bridge to the water bath, after which they were
dragged up on Menzel Superfrost Plus slides (Boom, Meppel, The Netherlands).
Visualization of multiple components was performed in two different ways. First,
alternating tissue sections were stained for two different components using
standard immunohistochemistry with two monoclonal antibodies. For this
purpose, even and uneven numbered 3 µm sections were separated from each
other and dragged up on different slides. Alternatively, an immuno-double
staining was performed on serial 4µ sections. For single component analysis
also 4 µm sections were used.
Fifty serial sections of normal cerebral white matter and neocortex, and of a
HB and GBM, were stained for endothelial cells with a MAb to CD34 (mouse
monoclonal, 1: 750, Neomarkers, Fremont, USA). Additionally, 60 serial
sections of normal cerebellar cortex and 20 sections of a HB were stained
alternately for CD34 and α-smooth muscle actin (mouse monoclonal, 1:15,000,
Sigma Chemical Co, St. Louis, USA). Alpha-smooth muscle actin is a marker
for activated pericytes in the tumor microvasculature, while quiescent pericytes
are α-smooth muscle negative, and vascular smooth muscle cells in the wall
of larger blood vessels constitutively express this protein. Immuno-double
staining was performed on 49 sections of a GBM using the same two antibodies.
Immunostaining was performed using the avidin-biotin-complex method, the
chromagen used to highlight vessels was 3.3’-Diaminobenzidine
tetrahydrochloride (DAB), resulting in a brown product. For the immuno-double
staining, activated pericytes were stained using DAB and the endothelium was
visualized using Fast Blue. In order to improve the signal to noise ratio during
image acquisition, no counterstaining was used.
103
3D reconstruction of tumor microvasculature
bw.gijtenbeek  26-04-2006  14:57  Pagina 103
Image acquisition and segmentation
Red-green-blue (RGB) color images of consecutive serial sections were
acquired using a 3 CCD RGB camera (Sony DXC950P, Sony Corporation, Japan),
attached to a conventional transmitted light microscope (AxioSkop 2 Imaging,
Carl Zeiss, Germany). Images were grabbed using a frame grabber (Matrox
Meteor II MC, Matrox Electronic Systems Ltd, Dorval, Canada) installed in a
Microsoft Windows pc. Image acquisition, segmentation and interactive
correction were facilitated by custom written macros in KS400 image analysis
software (version 3.0, Carl Zeiss, Germany). Images of consecutive sections
were manually aligned (image registration) using the revolving stage of the
104
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Figure 1. The electronic, motorized rotary microtome (A) that was used for preparation of
high-quality serial sections (see Materials and Methods for more details). The holder of the
paraffin-block is replaced by a fast freezing device, which enables fast cooling of the 
specimen to -45ºC. The serial sections are guided via a continuous laminar water flow
directly from the knife-edge into the heated water-bath without manual manipulation (B),
after which the sections can be mounted on a glass slide.
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microscope, by comparing a live color image of the section under examination
with contours of vascular profiles from the previous section in an overlay display.
Images were acquired using a 10x objective (Plan Neofluar, n.a.=0.30;
specimen level pixel size 1.3 x 1.3 µm2) for single component analysis and a
20x objective (Plan Apochromat, n.a. = 0.6; specimen level pixel size 0.65 x
0.65 µm2) for double component analysis, and stored as 24 bit RGB TIFF images
(size 760 x 571 pixels). Prior to acquisition of a series of images of serial
sections, an image of an empty microscopic field was acquired for shading
correction. All subsequently grabbed images were corrected for unequal
illumination using this empty field image. All acquired images were averaged
over 4 grabbed images to reduce camera noise.
Automatic recognition of CD34 positive stained vascular profiles was performed
by applying a fixed threshold value to the ratio between the log-converted red
and green image channels (multiplied by a constant). In case of multiple
component visualization in double-immuno stained sections, the second
component (stained using the Fast Blue precipitate) was recognized using the
ratio between the log-converted red and blue image channels. Objects in the
resulting binary image were dilated, holes in objects were filled and the objects
were eroded back to their original size.221 This resulted in almost perfect
discrimination between endothelium or pericytes and background, with objects
representing entire vascular profiles (including the lumen). 
Subsequently, results of the automatic segmentation were shown as an overlay
in the original color images after which interactive correction of segmentation
errors was possible. Interactive correction was necessary only in cases with very
weakly stained endothelium or in some cases where artifacts were present. A
similar procedure was used for the α-smooth muscle actin stained slides.
Image registration
Alignment of consecutive serial sections (image registration) was a two-step
process. First, during image acquisition the revolving microscope stage was
used to perform a ‘rough’ initial registration, correcting for shifts and rotations
of sections on the glass slides. Correction for stretching of sections is not
possible during this phase. The subsequent automated registration procedure
is used for more accurate alignment, including correction for stretching of
sections. Automatic registration was performed using the Insight Segmentation
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and Registration Toolkit (ITK version 1.4, open source software developed as
an initiative of the US National Library of Medicine, freely available at
www.itk.org). This software enables image registration using a variety of
techniques.
Automated image registration can be formulated as a mathematical problem,
in which a cost function is minimized by finding the optimal combination of
parameter values for the selected transform. In the present study, a centered
affine transform was used for projection of pixels from the image to be
registered onto a fixed image. This transform corrects for rotational and
translational as well as stretching effects between consecutive images, and is
parameterized with 8 parameters: a 2 x 2 transformation matrix defining both
scaling and rotation, 2 parameters defining the center of rotation (x,y) and 2
parameters defining a translation (x,y).
A normalized correlation metric was used as cost function, determining the
‘goodness of fit’ of a set of transform parameter values. This function is defined
as the pixel wise cross-correlation normalized by the square root of the
autocorrelation. This metric is very accurate for small misalignments between
images, which is well suited for images in this study because of the manual
pre-alignment. As the normalized correlation metric is only defined for
monochromatic images, RGB color images were transformed to monochromatic
images by averaging the R, G and B values. Application of the affine transform
may map pixels (which represent discrete intensity values at fixed grid
positions) to non-grid positions. An interpolation is required to calculate
intensity values for grid positions after the transform. In the present study a
3rd order B-spline interpolation was used.
An optimization algorithm was used for minimizing the cost function. The ‘One
plus one evolutionary optimizer’ (information available from Image Science
Lab, Zurich, Germany) was used for this purpose, which was found to be both
efficient and robust for our purpose. The efficiency of this optimizer highly
depends on the choice of optimizer parameters: the so-called grow and shrink
values were both set to -0.05, initial radius to 1. These values were empirically
chosen, based on optimization of a number of test images. The translation was
initialized with the center of the image as the center of rotation, and the unity
matrix as transformation matrix. A maximum of 75 iterations was allowed. The
optimal (‘best fit’) transform was applied to the monochromatic image used in
the optimization as well as to the corresponding segmented (binary) image.
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To reduce the possibility of erroneous transformations, images were processed
in a pair wise fashion in the following manner. Image 2 was fit to image 1, next
image 4 was fit to 3, then 3 was fit to 2 and the resulting transform was applied
to both images 3 and 4. In this way transformation steps were kept as small
as possible.
Three-dimensional reconstruction
KS400 was used to cut sub images (size 380 x 285 pixels) from the binary
images resulting from the registration procedure. Also, all binary objects in an
image without connection with corresponding objects in adjacent images were
removed. 
Three-dimensional surface rendering was performed using the Visualization
Toolkit (VTK version 4.2, an open source software mainly developed by Kitware
Inc, freely available at www.vtk.org). VTK procedures were written in Tcl/Tk
(Version 8.3, Scriptics Corp; precompiled windows binaries freely available
through www.tcl.tk). For each type of tissue, a volume consisting of 50 binary
images was read from TIFF files, with (relative) pixel spacing for single
component analysis set to 1 x 1 x 3.1. Using VTK, the 3D binary volume was
first eroded (kernel size 3 x 3 x 1) after which a Gaussian smoothing was applied
(standard deviation 3 x 3 x 1 pixels). A second binary erosion was applied
(kernel size 5 x 5 x 1) after thresholding the output of the Gaussian smoother
(lower bound 200). These filter steps and parameters were selected in such a
way that the complexity of the 3D surface was reduced without compromising
on the image quality. Based on visual inspection of a number of test images,
filter parameters were selected that preserve the original size of the 3D
structures.
Next, the VTK Marching Cubes function was used to construct a set of iso-
surfaces encompassing the binary vascular 3D structure. The 3D structure was
visualized using VTK surface rendering, calculating a 2D projection of the 3D
surface structure with emulation of a light and camera standpoint. Also, the
RGB image of the first tissue section was rendered in the same scene to facilitate
comprehension of the 3D structure.
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Multiple component visualization
Simultaneous visualization of two components was performed mainly as
described above. Sections were immunohistochemically stained using two
different antibodies. In case of alternate staining of two components, manual
alignment and image acquisition was first performed for one component (storing
images of sections 1, 3, 5, etc), based on contours of structures in the previous
section in the overlay. Images of the second component were then manually
aligned based on the stored images of the first component.
Image segmentation and registration were performed as described above for
a single component. Visualization using VTK was performed for both
components independently. The opacity and color of the two components could
be determined independent of each other. For alternately stained sections,
subimage size 179 x 193 pixels was used for the HB sections and subimage
size 450 x 390 pixels for the normal cerebellar cortex. As each section is 3 µm
thick, the resolution in z-direction now becomes 6 µm, resulting in relative pixel
spacing 1 x 1 x 9.2. For immuno-double stained, 4 µm sections of a GBM,
subimages of size 662 x 477 pixels were used, with relative pixel spacing 1 x
1 x 6.2.
Results
The vasculature of white and neocortical grey matter of the normal brain was
reconstructed from serial sections stained for CD34 (Figure 2C and D).
Examples of corresponding 2D histological sections are shown in Figure 2A and
B. To visualize the differences in pathological vessel architecture in brain tumors,
one HB and one GBM were analyzed. (Figure 3A and B show 2D slides, 3C and
D show 3D reconstructions). HBs are highly vascularized, and although 2D
histological sections stained for CD34 already show this phenomenon (Figure
3A), the complexity of the vascular architecture can only be truly appreciated
by 3D visualization of the vessels (Figure 3C). Glomeroid microvascular
proliferations are a pathological hallmark of GBM.  As shown in Figure 3B and
D, the spatial presentation of this aberrant vasculature is much easier to
comprehend in 3D than in 2D images. 
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To show the interrelation of two different components, microvessels of normal
cerebellar cortex, a HB, and a GBM are reconstructed. The relation between
endothelium and surrounding activated pericytes is shown in Figure 4 and 5.
Alternately stained sections were used for a HB and normal cerebellar cortex,
a doublestaining technique was used for a GBM. In contrast to normal
cerebellar tissue (Figure 4C), in the area of GBM shown in Figure 5 very few
activated pericytes are present in the wall of capillary vessels. An occasional
larger blood vessel (arteriole/venule) in the sample of normal cerebellar cortex
and of the GBM contains α-smooth muscle actin positive vascular smooth
muscle cells in its wall. In the HB, almost all tumor capillaries show extensive
coverage of α-smooth muscle actin positive pericytes, demonstrating the
activated state of the vessels in this tumor (Figure 4D). 
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Figure 2 2D histological sections of normal cerebral white (A) and neocortical grey matter
(B) stained for endothelium with antibodies to CD34. Corresponding 3D reconstructions of
the microvascular architecture (C and D). The 3D reconstructions are based on analysis of a
stack of 50 serial sections, the first of which is shown in A and B. Volume indicated by box:
494 x 370 x 200 µm. 
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Manual alignment, performed for all samples, proved to be accurate and
relativelyfast (up to 3 minutes to align a complicated image). After automated
segmentation,manual interactive correction of segmentation errors was
necessaryonly in a few cases with very weakly stained endothelium or in a few
cases whenartefacts were present. Although manual alignment proved to be
accurate, automated fine-alignment was used because this reduces possible
observer bias. Automated alignment of an image took 15 minutes computer
time (PC 2.4 GHz). Using alternately stained sections for simultaneous
visualization of two components hampers the z-resolution, because only half
of the sections are stained for each component. To reduce this problem, slightly
thinner sections were used for this technique. In contrast, using immuno-double
110
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Figure 3 2D histological sections of a hemangioblastoma (A) and a glioblastoma multiforme
(B) stained for endothelium with antibodies to CD34. Corresponding 3D reconstructions of
the microvascular architecture (C and D). Note the extremely high vascular density in a
hemangioblastoma, and the glomeruloid microvascular proliferation in a glioblastoma. 
Volume of box: 494 x 370 x 200 µm.
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staining results in full resolution for both components. This latter technique is
however technically somewhat more challenging in terms of immuno-
histochemistry and image analysis.
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Figure 4 2D histological section (CD34 staining) of normal cerebellar cortex (A) and a
hemangioblastoma (B). For this study the sections were alternately stained for endothelium
with antibodies to CD34 and for activated pericytes with antibodies to α-smooth muscle
actin. The spatial relationship between endothelium (red) and activated pericytes (transpar-
ent green) is shown in C and D. Because of the extremely intricate architecture of the
microvasculature in a hemangioblastoma (see also fig. 3C), in figure 4B,D a more detailed
image is presented showing the different cellular components of its microvasculature.
Volume of box in A and C: 293 x 254 x 180 µm, in B and D: 116 x 125 x 60 µm. Note the
extensive presence of activated pericytes in capillaries of a hemangioblastoma, while in nor-
mal cerebellar cortex α-smooth muscle actin positive cells are only found in the wall of
somewhat larger vessels (consistent with vascular smooth muscle cells in arterioles or
venules which are known to constitutively express α-smooth muscle actin).
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Discussion
We describe a novel method for 3D visualization of microscopic structures in
normal brain and in brain tumors. The method was found to be reliable and
robust, and is applicable on archival, paraffin-embedded material. Besides 3D
reconstruction of normal vessels in neocortical and white matter of the
cerebrum, reconstructions were made of two well-vascularized brain tumors:
a HB and a GBM. HBs are benign tumors, characterized by stromal cells and
a very rich capillary network.45 GBMs, on the other hand, are high-grade
malignant glial tumors, with florid, and sometimes glomeruloid microvascular
proliferations as a major histopathological hallmark.222,223 The microvascular
patterns in both tumors are routinely assessed in 2D slides, and 3D images of
the microvasculature in these tumors have only sporadically been published
before. Furthermore, we present examples of the spatial relationship between
endothelium and activated pericytes in the capillary walls in normal cerebellar
cortex, a HB, and a GBM.
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Figure 5 2D histological section of a glioblastoma multiforme (A) doublestained for
endothelium with antibodies to CD34 (blue) and for actived pericytes with antibodies to α-
smooth muscle actin (brown). Corresponding 3D reconstruction in B, with endothelium in
red and activated pericytes as well as vascular smooth muscle cells in transparant green.
Volume of box: 430 x 310 x 196 µm. In contrast to the area shown in fig. 3B and 3D, in
this area of a glioblastoma the microvascular architecture is still relatively normal. Apart
from α-smooth muscle actin positive vascular smooth muscle cells in the wall of a larger
blood vessel, also dispersed α-smooth muscle actin positive cells indicating activated peri-
cytes are present in the capillaries (the latter are not found in the normal cerebellar
microvasculature as seen in fig. 4C).
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For 3D reconstruction, archival paraffin-embedded samples were serially
sectioned at 3 or 4 µm using a unique section method in order to limit loss and
distortion of sections to a minimum. Other serial section techniques may
account for a loss of sections of up to 5%, such lost sections may be replaced
with interpolated images.213 However, automated interpolating of lost images
raises concern about unforeseen distortions to align the sections. In our
procedure, segmentation was easy and accurate because of high quality of the
histological sections and the bright immunohistochemical staining without
counterstaining; manual correction of the segmentation was only sporadically
necessary, this in contrast to other methods that need manual correction of
obvious errors,210,212 occurring in approximately 5% of sections.210
In 3D reconstruction using serial histological sections, accurate alignment of
the sections is a major challenge. Therefore, a number of techniques have
been described which circumvent the use of sections. Use of confocal laser
scanning microscopy makes use of optical sections, eliminating the need for
registration.207,209 However, due to optical limitations this technique is limited
to 50-100 µm thick tissue fragments.207 A second method to prevent image
distortion caused by cutting sections is by using the cut face of the tissue block
instead of the sections themselves.224 Images are recorded by using the
autofluorescence of the tissue. A major drawback of this technique is that no
specific visualization of microscopic structures can be applied (such as
immunohistochemistry), enabling only reconstruction of gross structures. In
the present study, image registration was a two-step process. During image
acquisition, manual alignment was performed to correct for shifts and rotations
of the tissue as much as possible, without the possibility to correct for tissue
stretching. Next, a fully automated registration procedure was used, which
optimized the alignment accuracy of the manual method. Only slight
improvement was seen comparing the results of automated and manual
alignment. Still, as we are studying microstructures, even this slight
improvement may be critical. Manually and automated alignment procedures
have been compared previously, and similar results have been reported.213,225
Fully automated methods of alignment eliminates the bias introduced by
manual alignment.207,210,212,213,225
The endothelium of capillaries is surrounded by pericytes, which are regarded
as the microvascular equivalent of smooth muscle cells. The functions of these
cells are variable and complex.  Activated pericytes may play a role in the
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formation of angiogenic sprouts during the early phases of both normal and
pathologic angiogenesis.226,227 In later phases of neovascularization, major
functions of pericytes are participation in stabilization of vessel walls and
regulation of several endothelial functions, such as permeability, proliferation,
and vascular branching.228 Pericyte coverage may differ between tumors and
normal vessels. The amount of activated pericytes on vessels in different tumor
types is reported to be highly variable, e.g. extensive in florid microvascular
proliferations in GBMs, but little in renal cell carcinomas.226,229 In cerebellar
HBs pericyte coverage as detected by electron microscopy and computerized
morphometric techniques, is described to range from 30-97% (mean 69%),
which is much higher compared to normal cerebral grey matter.49 To visualize
the coverage by activated pericytes in the complex vasculature of HBs and
GBMs we performed 3D visualization of serial sections stained for CD34 and
a-smooth muscle actin. Our 3D reconstruction showed nearly complete
coverage of α-smooth muscle actin positive pericytes in a HB.  A 3D
reconstruction model of the relation between endothelium and pericytes in
capillaries using electron micrographs of serial sections has been published
before.230 However, computer based techniques were not available at that time.
Although in the present study resolution in the z-direction (6µm) was less when
multiple components were visualized using the alternate staining approach,
accurate visualization could still be obtained. The use of immuno-double
staining, however, greatly facilitates the 3D reconstruction of different
components in the same tissue sections. 
In conclusion
The results of the 3D reconstruction as described shed unprecedented light on
morphological features of normal and pathological microvasculature. The
procedure is applicable on serial sections of all kinds of tissues and structures.
The potential of the procedure is mainly limited by the possibility to specifically
visualize the object(s) of interest by immunohistochemical or other techniques,
and the quality and thickness of the serial sections. We are currently assessing
the 3D morphology of the microvasculature in a series of other human brain
tumors, as well as using this approach to monitor the (sometimes subtle)
changes after chemotherapeutic (e.g. anti-angiogenic) treatment in murine
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intracerebral xenograft models for human malignant melanoma and GBM.231,232
Finally, we expect the information obtained by our 3D reconstruction method
to significantly contribute to a better understanding of the radiological images
of brain tumors, e.g. in situations where the effect of anti-angiogenic treatment
of experimental brain tumors is monitored by radiology.233
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Summary and general discussion 
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Hemangioblastomas (HBs) of the central nervous system (CNS) are benign
tumors with unique histological and molecular genetic features. The genetic
pathways underlying the development of sporadic HBs are currently not
completely clear. Therefore, the goal of our studies was to elucidate the genetic
background of sporadic HBs. We screened the genome of these tumors for
chromosomal abnormalities, and tried to identify putative genes involved in
the development of these tumors. Since inactivation of the VHL tumor
suppressor gene (TSG) underlies the development of hereditary HBs, we
discussed the role of this gene in the tumorigenesis of both hereditary and
sporadic tumors. As the cyclin D1 gene (CCND1) is a target gene of pVHL, we
analyzed cyclin D1 expression and CCND1 genotype in order to evaluate whether
CCND1 genotype influences the susceptibility to HBs.
The VHL gene, VHL protein, and target genes 
HBs are a major manifestation of VHL disease, and a germline mutation of the
VHL gene at 3p25-26 can be determined in all patients with a VHL-associated
HB.62 A critical role of the VHL gene in the development of these tumors is well
established, as inactivation of both alleles of the VHL gene has been reported
in 62-66% of VHL-associated HBs.67,61 According to Knudson’s two-hit
hypothesis, biallelic inactivation is expected in 100% tumors, but limitations
of the common molecular genetic techniques hamper detection of biallelic
inactivation in some of these tumors. To date it is not clear whether mutations
of other genes are required for HB development. Unraveling of the molecular
basis of VHL disease and the functions of the VHL protein (pVHL) provided
insight into the pathobiology of VHL-associated tumors. The main function of
pVHL is its critical role in the oxygen-sensing pathway of the cell by regulation
of hypoxia-inducible factor (HIF-1).97 HIF-1 has a key role in the cellular
response to hypoxia, including the regulation of genes involved in cellular
metabolism, angiogenesis and apoptosis.234 Loss of function of the pVHL
induces upregulation of HIF-1 and, subsequently, overexpression of angiogenic
and growth factors, like vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF-B). The presence of such factors explains the
hypervascularity of HBs and renal cell carcinomas (RCCs), because they are
potent mitogens for endothelial cells and pericytes. 
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However, the overexpression of angiogenic factors does not explain tumor
initiation. Therefore, other pathways than HIF regulation are likely to be
involved in the processes that lead to the development of tumors in VHL disease. 
Moreover, genotype-phenotype correlations in VHL disease suggest that pVHL
has functions other than the regulation of HIF; e.g. in type 2C VHL disease
(pheochromocytomas only) the ability to regulate HIF is retained. Most
mutations leading to type 2 VHL disease are missense mutations, whereas in
type 1 families deletions, microdeletions/ insertions, splice site or nonsense
mutations as well as missense mutations (in 27%) are found, leading to a
truncated protein that has lost its normal function, or to complete lack of
pVHL.62 In case of a specific missense mutation (in type 2C VHL) the change
of one amino acid may lead to a pVHL gain of function, e.g. a pVHL that binds
to and modulates other proteins than HIF.39
Extensive investigations have been undertaken to elucidate the pathways of
tumor development in VHL disease. Novel target genes of pVHL, regulated by
both HIF-dependent and HIF-independent mechanisms, have been identified.
In addition, pVHL has been implicated in various cellular processes including
cell cycle control and extracellular matrix regulation. A review of the literature
is provided in Chapter 1.
One of the target genes of pVHL is CCND1, encoding cyclin D1, a protein
implicated in the control of the cell cycle at the G1/S checkpoint.123,124
Overexpression of cyclin D1 may release the cell from its normal cell cycle
control, and may induce malignant transformation.125 Overexpression of cyclin
D1 is a feature of many cancers. In sporadic as well as in VHL-associated HBs
we found variable, but sometimes high cyclin D1 expression (Chapter 5). The
CCND1 gene contains a common G→A polymorphism located within the splice
donor region of exon 4 which modulates splicing of mRNA. The unspliced protein
variant (transcripts from the A-allele) has a longer half-life, and DNA damage
in cells with the unspliced protein may bypass the G1/S checkpoint more easily
than cells with the spliced variant (transcripts from the G-allele). The G→A
polymorphism influences age of onset and clinical outcome of various cancers.
In most studies, the CCND1 AA and AG genotypes are associated with early
age of onset and poor prognosis. In VHL disease, genetic modifiers may play
a role in phenotypic expression, e.g. the risk of occurrence of HBs, RCCs, and
pheochromocytomas, and it has been suggested that the CCND1 polymorphism
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is one of these modifiers. In patients with VHL disease, the number of retinal
HBs was significantly higher in patients harboring the G-allele compared to
AA-homozygotes, and the presence of a G-allele was associated with an earlier
diagnosis of CNS HBs by almost two-fold, whereas no increased susceptibility
to RCCs was found.123 If the CCND1 G allele indeed increases susceptibility to
HBs, a higher frequency of the G allele is to be expected in these tumors.
Therefore, we analyzed 17 sporadic and five VHL-associated HBs for CCND1
genotype. We found no deviation in CCND1 genotype distribution and allele
frequencies from expected values of normal populations (Chapter 5).
Therefore, we could not confirm the suggested modifier effect of CCND1
genotype for HBs. However, our study population was small, and a larger study
is needed to draw firm conclusions.
Chromosomal imbalances in sporadic tumors
Inactivation of the VHL gene has been linked to the development of sporadic
RCCs and HBs.2 Somatic VHL mutations, hypermethylation of the promoter, or
LOH at 3p have been found in the majority of sporadic RCCs.69-73,235 According
to Knudson’s two-hit hypothesis of TSGs, inactivation of both alleles of the VHL
gene is required for tumor development. In most studies, biallelic inactivation
is not established. In those studies reporting biallelic inactivation, the frequency
was unexpectedly low; in 33-46% of tumors somatic mutation of one VHL allele
combined with LOH at 3p was found,69,70 and 44% of tumors showed biallelic
inactivation when results of somatic mutation, LOH, and hypermethylation were
combined.74 Therefore, VHL-independent pathways involving TSGs on 3p12-
21 have been suggested to play a primary role in the tumorigenesis of RCCs.73,79
Genes on other chromosomes than 3p may be involved as well, because
additional chromosomal aberrations are frequently reported, such as loss (-)
of 4q, 6q, 8p, 9p, 14q, and gain (+) of 5q, 7, 17q, and Xq.81-85,87 Some of
these chromosomal abnormalities may have prognostic significance; e.g. +5q
is reported to be associated with a favourable prognosis, whereas LOH at 8p
or 9p correlated with recurrence.83,87
We screened the genome of 16 sporadic HBs by CGH for chromosomal
aberrations.  Aberrant chromosomal regions (with a loss or gain of DNA) might
contain TSGs or oncogenes involved in the development of these tumors.
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Interestingly, we detected multiple chromosomal abnormalities in these benign
tumors (Chapter 2 and 3). 
The most frequently detected aberrations were loss of chromosome 3 (-3) in
69% (11/16 tumors), -6 in 44% (7/16), -18 or -18q (designated 18(q)) in
31% (5/16), and –9, and +19 in 25% (4/16) (Figure 1). In 31% (5/16) of
tumors combined –3 and –6 was detected, whereas an additional -8 was found
in 3 tumors. Interestingly, the tumors with –8 had either –3 or a somatic VHL
mutation, and two tumors had a normal constitution of chromosome 6. Overall,
eight of 10 sporadic HBs with multiple chromosomal abnormalities had two of
the following imbalances: -3, -6, or -8 (Chapter 3). 
We compared the chromosomal imbalances in sporadic HBs with chromosomal
imbalances in sporadic RCCs and pheochromocytomas as reported in the
literature. The most common changes by CGH in pheochromocytomas include
–1q, -3q, -6q, -11p, and +19q.89,236 Relatively common chromosomal
imbalances in either RCCs or pheochromocytomas are also detected in sporadic
HBs; -3p, -6(q), -9 for RCCs, -3q, -6(q), +19 for pheochromocytomas. Our
findings may suggest a sequence of chromosomal imbalances in sporadic HBs;
-3 (harboring the VHL gene) followed by –6, and then -18, and/or –9, and/or
+19 (Chapter 2).
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Figure 1 Map showing chromosomal imbalances most frequently detected by CGH.  
The asterisks indicate the additional aberrations identified by array CGH.
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Inactivation of the VHL gene in sporadic HBs
The role of the VHL gene in the development of sporadic HBs is not clear, as
somatic VHL gene inactivation by somatic mutation or LOH is found in only 20-
50% of sporadic HBs (Table 1).38,61,75-77,171 Hypermethylation seems to be an
infrequent feature of sporadic HBs, as it could not be demonstrated in two
studies.61,77
We found somatic mutations of the VHL gene in five sporadic HBs (31%),
including three frameshift and two missense mutations, all of these had not
been published before (Chapter 3). Similar frequencies of somatic mutations
have been reported by others (Table 1). Two of the tumors with somatic
mutations had also –3, two tumors had also –6, whereas in one tumor with a
somatic mutation no additional losses or gains were detected by CGH.
Additionally, in 5/16 (31%) of tumors combined –3 and –6 was found. Thus,
all tumors with –6 had either –3, or a somatic mutation of the VHL gene
(Chapter 3).
In most studies, inactivation of both alleles of the VHL gene is not determined
(Table 1). One recent study combined somatic mutation analysis, LOH, and
hypermethylation analysis, and found biallelic inactivation in only one of 13
(8%) sporadic HBs.61 We could confirm biallelic inactivation in only two tumors
(2/16; 13%). These tumors showed a somatic mutation combined with loss
of chromosome 3 (Chapter 3). We did not perform LOH and hypermethylation
analysis, so we might have underestimated the frequency of biallelic inactivation
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Table 1 Somatic VHL gene mutations, LOH at 3p, and hypermethylation of VHL
promoter in sporadic Hbs
Author VHL mutation Loss of 3p
(LOH  or CGH#)
Hypermethylation
VHL promotor
Confirmed biallelic
inactivation VHL
Kanno75 3/13 (23%)
Oberstrass38 7/17 (41%)
Tse77 2/5   (40%) 1/2    (50%) 0/5  0/2
Lee76 2/20 (10%)   10/19  (53%)  0/20
Glasker61 3/13 (23%) 5/10   (50%) 0/13  1/13 (8%)
Lemeta171 11/11 (100%)
This thesis 5/16 (31%)   11/16  (69%)#  2/16 (13%)
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in our studies. However, the results of our studies and those of other
investigators suggest that biallelic inactivation of the VHL gene may not be a
common mechanism in the development of sporadic HBs, and that the role of
VHL is limited in these tumors. Therefore, other TSGs or oncogenes are likely
involved in the oncogenesis of sporadic HBs. These genes may act in
collaboration with VHL in the subset of sporadic HBs with monoallelic or biallelic
inactivation of the VHL gene. Such genes involved in sporadic HBs might also
act in collaboration with the VHL gene in VHL-associated tumors. 
Genetic heterogeneity of sporadic and hereditary HBs
A striking contrast was found in CGH results of seven VHL-associated HBs; only
one –3 was detected (Chapter 3), while in all tumors a VHL mutation was
determined. Although no blood samples were available for most of these cases,
these mutations were likely to be germline mutations. Since we did not perform
LOH or hypermethylation analysis we could not determine the frequency of
biallelic inactivation in VHL-associated HBs. 
CGH analysis of six HBs of a single VHL-patient with a known VHL germline
mutation also revealed few chromosomal abnormalities in the VHL-associated
HBs; –3 and -22 in one HB, -22 and +X in a recurrence of this tumor, + X in
a cauda equina HB, and +2pter-q32 in one HB obtained at autopsy. Two HBs
did not show abnormalities by CGH (Chapter 6). There was no increase in
chromosomal imbalances in HBs presenting early in the disease versus tumors
removed at autopsy. LOH analysis for 3p was performed in four tumors (three
without –3) and was found to be negative. The germline mutation could be
determined in four tumors, and no somatic mutations were found (Chapter
6). In this patient, multiple chromosomal abnormalities were found in the renal
tumor and its metastasis (Chapter 6). 
The striking contrast of the multiple chromosomal aberrations in sporadic HBs
with the low frequency of abnormalities in VHL-associated HBs as detected by
CGH in our study underscores that their molecular genetic pathways are
distinct.  We investigated a subset of sporadic HBs for micro-deletions or
amplifications by array CGH.
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The role of putative TSGs in sporadic HBs
After the publication of our initial study, other investigators confirmed that loss
of chromosome 6 (or 6q) might be of relevance in HBs. Loss of chromosome
6(q) was reported by them in 24% (four of 17; -6 in two, and –6q in two)
sporadic, and in one of five VHL-associated HBs.170 Additionally, -3 was found
in two tumors with –6q, and another sporadic HB had only –8.170 Twelve
sporadic and four VHL-associated HBs had no chromosomal abnormalities
detected by CGH, and the authors concluded that large deletions of 3p occur
in a minority of tumors. These findings are in contrast with our results, as we
found loss of a whole chromosome 3 in 69% of tumors, and multiple,
additional abnormalities.  These differences might be explained by the fact that
we used snap-frozen material in the majority of tumors, while others used
paraffin-embedded tissue, the latter generally leading to less robust CGH
results.142,170 Furthermore, for those cases from which only paraffin-embedded
tissue was available normal DNA also isolated from paraffin-embedded non-
tumor tissue was used. In our experience, this leads to more reliable CGH
results.
In subsequent LOH studies, LOH at 6q was found in 82% of 11 sporadic HBs,
with a minimal deleted region at 6q23-24, and LOH at 3p was detected in all
tumors.171 Based on our results, and confirmed by the studies of others,170,171
it seems likely that the development of sporadic HBs is dependent on the
inactivation of TSGs on 3p and 6(q). However, in five sporadic HBs analyzed
by array CGH we did not detect a microdeletion on chromosome 6 
(Chapter 4). 
We did not detect loss of chromosome 6 by CGH in VHL-associated HBs (Chapter
3 and 6). Others reported loss of chromosome 6 in only one of five VHL-
associated HBs, and LOH at 6q in 2 of 4 VHL-associated HBs.170,171
Similarly, -8, -9, –18q, and +19 are reported in a variety of tumors. Many
putative TSGs have been suggested on these chromosomes, as well as on
chromosome 3p apart from the VHL gene on 3p25-26.156 An important role
for candidate TSGs at 3p12-14, containing for instance the FHIT (fragile histidine
triad) gene, and at 3p21.3, containing RASSF1A (RAS-association domain family
1) among others, has already been suggested in the tumorigenesis of sporadic
and VHL-associated RCCs.73,79,237 TSGs at chromosome 6q23-24, for instance
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LATSI (large tumor suppressor 1), which suppresses tumor growth by regulating
cell proliferation and survival, and ZAC (zinc finger protein), which inhibits tumor
growth by induction of apoptotic cell death, have been speculated to be involved
in the tumorigenesis of HBs.171 However, the role of these TSGs in HBs remains
to be determined.
Array CGH of sporadic HBs
The results of our studies and reports in the literature, prompted us to extend
our investigations in an attempt to find putative genes involved in the
tumorigenesis of sporadic HBs. 
Although GCH has the advantage of genome-wide screening of DNA copy
number changes in a single experiment, the technique is limited by the
detection limit of 2-5Mb, and especially small deletions are difficult to detect.
Therefore, we analyzed HBs with 32K array CGH. Array CGH allows high-
resolution screening of the genome for small chromosomal abnormalities with
a detection limit of approximately 100 kb, by using thousands of genomic clones
as targets for hybridization instead of whole chromosomes. Informative array
CGH results were obtained from five sporadic HBs (Chapter 4). The study was
hampered by the amount of normal tissue in HBs; the stromal cells are the
neoplastic component, whereas the rich capillary network contains non-
neoplastic endothelial cell and pericytes. Results of conventional CGH and
mutation analysis of the VHL gene were available in all cases (Chapter 3).
Overall, the abnormalities detected by CGH were also identified by array CGH.
Some minor differences were found, several of which were in retrospect visible
with conventional CGH. No additional abnormalities were detected at 6q23-
24, nor at other regions of chromosome 6 or 3p. 
In three tumors, candidate chromosomal microdeletions were detected,
including 2q13-14.1 in two tumors, and 8p21.3 and 3q13.31 in one tumor each.
The identified regions on 8p and 3q are of special interest as these
chromosomes are frequently affected in HBs (Chapter 3). Both deletions would
be homozygous, since these tumors had already loss of one copy of
chromosome 8 and 3, respectively. The short arm of chromosoom 8 (8p) is
frequently deleted in cancer.178-181 One of the genes located at this region is
FEZ1/LZTS1 (leucine zipper, putative tumor suppressor 1), a tumor suppressor
gene that inhibits tumor growth through regulation of mitosis, and that has
125
Summary and general discussion
bw.gijtenbeek  26-04-2006  14:57  Pagina 125
been suggested to play a role in the development of various tumors including
prostate, urinary bladder, breast, esophageal, and lung cancer.182-184,186
Chromosome 3q13 is also an interesting region, as it contains LSAMP (limbic
system-associated membrane protein), a gene that is a candidate TSG for clear
cell RCCs, the other tumor type frequently associated with VHL disease.176
LSAMP encodes a neuronal surface glycoprotein expressed in the limbic
system, and regulates the formation of specific neuronal connections. The
mechanism of suppression of tumor growth in RCCs is unclear.237 The results
of array CGH are preliminary, as only five HBs were analyzed, and validation
of the results (e.g. by FISH) is required.
Molecular genetic analysis and the differential diagnosis of tumors
The molecular genetic techniques used in our studies are described briefly in
the introduction chapter of this thesis (Chapter 1). CGH, LOH, and mutation
analysis are commonly used, and results of these techniques are
complementary. VHL patients often harbor multiple tumors, and
dedifferentiation of these tumors occurs often in the later stages of the disease.
Dedifferentiated tumors can be difficult to characterize histologically. Nowadays,
information on the genetic background of tumors is rapidly increasing. This
information can aid in establishing a definitive diagnosis when standard
histological and immunohistochemical investigations are not conclusive. This
is illustrated in a patient with VHL disease in which molecular genetic analysis
resolved the differential diagnosis of metastatic sarcomatoid RCC and
pheochromocytoma (Chapter 6).
An extreme example of angiogenesis
HBs are histologically characterized by neoplastic stromal cells and a very rich
capillary network. Histopathologically, sporadic and hereditairy HBs are
identical. The vasculature of HBs contains capillaries with endothelial cells and
pericytes. The positive staining for α-smooth muscle actin indicates that the
pericytes are activated; this might be due to the ongoing production of
angiogenic and growth factors in these tumors.
We developed a novel method for simultaneous 3D visualization of multiple
tissue components (Chapter 7). Since we were interested in tumor vasculature
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we used the technique to reconstruct microvessels in both normal and
pathological tissue. 3D images were reconstructed from 2D paraffin-embedded
serial sections, using immunohistochemical staining with CD34 (for
endothelium) and α-smooth muscle actin (for activated pericytes). HBs are an
extreme example of angiogenesis, as is strikingly illustrated in the three
dimensional images. Using this procedure, we were also able to demonstrate
extensive coverage of the HB capillaries by activated pericytes (Figure 2). 
We will use the technique to assess the 3D morphology of the microvessels in
other human brain tumors, as well as to monitor the microvascular changes
after anti-angiogenic therapy in murine intracerebral xenograft models for
different tumors, e.g. GBM and malignant melanoma. 
In summary, the molecular genetic studies revealed that:
• Striking differences exist in frequency of chromosomal abnormalities 
detected by CGH between sporadic and VHL-associated HBs;
• Multiple chromosomal aberrations as detected by CGH are present in 
sporadic HBs, including –3, -6, -8, -9, -18, and +19 
• Loss of a whole chromosome 3 is more frequently detected in sporadic
HBs than in VHL–associated HBs (in VHL-associated HBs more often LOH)
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Figure 2 3D reconstruction of capillary network of a hemangioblastoma (A). Extensive cover-
age of capillaries by activated pericytes (B; detail of A).
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• Loss of chromosome 6 is a frequent event in sporadic HBs and usually 
associated with -3 or a somatic mutation of the VHL gene, as well as with 
multiple other chromosomal imbalances
• Somatic VHL mutations occur in approximately 31% of sporadic HBs
• Three candidate microdeletions (on chromosome 2, 3, and 8) were 
identified by array CGH, which may be associated with HBs development
These findings indicate that inactivation of the VHL gene is not the most
important molecular event in sporadic HBs, and that sporadic and VHL-
associated HBs have a different genetic background. 
Future perspectives 
The results of the molecular genetic studies discussed in this thesis confirm
our hypothesis of a distinct molecular pathway in sporadic HBs compared to
VHL-associated HBs. However, many questions remain to be answered. 
It is currently unknown why VHL mutations in VHL disease lead to the occurrence
of only particular tumor types, nor is it clear why HBs preferentially occur in
the cerebellum. Insight into pVHL functions other than inhibiting HIF, and the
understanding of how these functions act together might provide answers to
those questions.  Evidence is accumulating that the VHL gene alone does not
explain the tumorigenesis of sporadic and hereditary HBs, as biallelic
inactivation is only found in part of the tumors. It will be important to identify
other genes that cooperate with VHL inactivation to cause specific tumors such
as HBs. We used a combination of molecular genetic techniques to further
elucidate the genetic background of sporadic HBs. Although striking differences
with VHL-associated HBs were found and a pathway of subsequent
chromosomal abnormalities was suggested, the genes involved in the
development of sporadic HBs remain to be identified. The technique we used
in our studies, CGH, is a useful tool to screen for chromosomal abnormalities
in tumors, and is currently used in our laboratory in a variety of tumors in
experimental settings. Array-based CGH is a powerful tool to screen the genome
for putative genes, and although promising results can be obtained, analysis
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of the obtained large data sets and confirmation of the putative genes is still
challenging. In HBs, array CGH is hampered by the relatively large amount of
normal DNA. Laser microdissection methods may enhance the yield of array
CGH. Gene expression profiling, e.g. transcriptional profiling analysis involving
messenger RNAs (mRNA) or post-transcriptional profiling involving the recently
discovered microRNAs, may be a promising alternative to identify candidate
genes.238,239 MicroRNAs are thought to controle gene expression at the post-
transcriptional level by degrading target mRNA, and thereby reducing the
amount of protein encoded by these mRNAs.239 Many oncogenes and TSGs
are potentially regulated by microRNAs, and there is also evidence that
microRNAs can act themselves as oncogenes or TSGs.239
Another novel approach to elucidate the pathways involved in various diseases
including cancer is proteomics. Since inactivation or overexpression of genes
ultimately lead to an altered expression of proteins, the identification of
individual proteins or clusters of proteins expressed in various diseases may
be more relevant for establishing the diagnosis, prognosis and therapeutic
targets than the identification of genes alone. The identification of differences
in protein patterns between different tumors, e.g. between sporadic HBs and
VHL-associated HBs, may enhance the understanding of differences in pathways
involved in these tumors.240 HBs can probably be identified by their protein
pattern, since a study using selective tissue microdissection and proteomic
profiling showed a markedly different protein profile between a HB and RCC
in one VHL patient.241
Finally, the technique of 3D reconstruction of the microvasculature will be
further applied in the experimental setting to study different aspects of
angiogenesis and anti-angiogenic therapy in intracerebral xenograft models of
various tumors.
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Achtergrond bij dit proefschrift
Hemangioblastomen (HBs) zijn goedaardige tumoren van het centrale
zenuwstelsel, die vooral voorkomen in de kleine hersenen. De bijzondere his-
tologische kenmerken van HBs en de intrigerende genetische achtergrond
zijn de aanleiding geweest om de studies te verrichten die in dit proefschrift
staan beschreven. 
In het merendeel van de HBs is er sprake van een sporadische tumor, dat wil
zeggen dat er geen associatie is met andere tumoren in het lichaam. Bij
ongeveer 25% van de patiënten met een HBs blijkt er echter sprake te zijn
van de ziekte van Von Hippel-Lindau (VHL), een erfelijke aandoening die
wordt veroorzaakt door een kiembaanmutatie in het VHL tumor suppressor
gen. Het VHL-gen speelt ook een rol in de sporadische tumoren. Er zijn ech-
ter verschillende aanwijzingen dat naast het VHL-gen andere genen belang-
rijk zijn voor het ontstaan van sporadische HBs.
We hebben ervoor gekozen ons met name te richten op sporadische HBs,
omdat die het meest frequent voorkomen en omdat de genetische achter-
grond van deze tumoren niet is opgehelderd. Ontrafeling van de genetische
gebeurtenissen die leiden tot HBs kan inzicht geven in de mechanismen die
betrokken zijn bij het ontstaan van tumoren in het algemeen, en kan uitein-
delijk leiden tot nieuwe behandelstrategieën. 
Naast genetische studies worden in dit proefschrift een aantal andere onder-
zoeken beschreven die betrekking hebben op HBs. Om de achtergrond van
de studies uit dit proefschrift beter te begrijpen volgt in het kort een
beschrijving van de klinische verschijnselen van HBs en van de ziekte van
Von Hippel-Lindau.
Hemangioblastomen
HBs zijn vrij zeldzaam; ze maken ongeveer 2% van alle tumoren in de her-
senen uit. HBs bestaan uit tumorcellen waartussen talrijke bloedvaatjes
gelegen zijn. De tumor zelf is meestal klein, maar kan een grote cyste vor-
men (zie Figuur 1 in Hoofdstuk 1). De tumor met cyste neemt veel ruimte
in en veroorzaakt klachten, die bepaald worden door de precieze plaats van
de tumor. Omdat HBs vaak voorkomen in de kleine hersenen zijn de meest
optredende klachten coördinatiestoornissen, o.a. bij lopen. Daarnaast kan
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door druk op de vierde ventrikel een hydrocephalus ontstaan, met klachten
van hoofdpijn, misselijkheid en braken. Deze situatie is soms levensbedrei-
gend. De behandeling bestaat uit chirurgische verwijdering van de tumor. In
geval van een sporadisch HB is de patiënt met deze ingreep definitief te
genezen.
De ziekte van Von Hippel-Lindau
VHL is genoemd naar de Duitse oogarts Eugen von Hippel, die begin twin-
tigste eeuw een HB in het netvlies beschreef, en naar de Zweedse patholoog
Arvid Lindau, die in 1926 onderkende dat HBs in netvlies en hersenen samen
met bepaalde andere tumoren in het lichaam voorkomen in het kader van
één syndroom. VHL is een autosomaal dominant overervende aandoening,
gekenmerkt door vaatrijke tumoren en cysten in verschillende organen.  
De meest voorkomend zijn HBs in netvlies, kleine hersenen en ruggenmerg,
niercelcarcinomen, feochromocytomen (tumoren van de bijnieren), goedaar-
dige tumoren/cysten in nieren, alvleesklier, bijbal, bindweefsel rond de baar-
moeder en tumoren van het binnenoor. 
VHL komt bij ongeveer 1:36.000 personen voor. HBs in het netvlies of in het
centrale zenuwstelsel zijn vaak de eerste manifestatie van VHL en openba-
ren zich gemiddeld op een leeftijd van ongeveer 30 jaar. De meeste patiën-
ten overlijden uiteindelijk aan de gevolgen van een niercelcarcinoom of van
een HB in de kleine hersenen. De diagnose VHL is meestal te stellen doordat
een patiënt verschillende bij VHL voorkomende tumoren heeft, en omdat de
ziekte in zijn familie voorkomt.
Het VHL-gen is een tumor suppressor gen, een gen dat in actieve vorm het
ontstaan van tumoren onderdrukt. Dit gen is gelokaliseerd op de korte arm
van chromosoom 3 (3p25-26). Met DNA diagnostiek kunnen tegenwoordig
bijna alle gevallen van VHL worden geïdentificeerd. Hierdoor is een vroege
diagnose mogelijk, zelfs voordat een patiënt klachten krijgt. Er zijn richtlij-
nen opgesteld over welke patiënten voor genetische screening in aanmerking
komen. Omdat in 40% van de gevallen een HB de eerste manifestatie van
VHL is, wordt geadviseerd om bij alle patiënten met een HB onder de 50 jaar
(ook bij afwezigheid van andere tumoren) genetische screening  te verrich-
ten. VHL patiënten en patiënten met een hoog risico op VHL, maar bij wie de
aandoening nog niet is vastgesteld, dienen volgens vastgestelde richtlijnen
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regelmatig onderzocht te worden op het ontstaan van (nieuwe) tumoren,
o.a. middels een MRI scan van de hersenen en het ruggenmerg. De ver-
wachting is dat met vroegtijdige opsporing en behandeling van VHL tumoren
de levensverwachting toeneemt en de kwaliteit van leven aanzienlijk wordt
verbeterd. 
Sporadische versus VHL-geassocieerde hemangioblastomen
Histologisch zijn er geen verschillen tussen sporadische HBs en HBs in het
kader van VHL. VHL-geassocieerde HBs ontstaan op jongere leeftijd (gemid-
deld 33 jaar), komen meestal multipel voor en zijn vaak gelokaliseerd op
verschillende plaatsen in het centrale zenuwstelsel (kleine hersenen, her-
senstam, ruggenmerg). Bovendien komen bij deze patiënten dikwijls tumo-
ren in andere organen voor, en recidiveren HBs vaker na operatie. De gemid-
delde leeftijd van patiënten met een sporadisch HB is 45 jaar. Bij deze
patiënten is de tumor meestal gelokaliseerd in de kleine hersenen en worden
geen andere tumoren gevonden. De genetische verschillen tussen sporadi-
sche en VHL-geassocieerde HBs zijn onderwerp van dit proefschrift.
Genetische achtergrond
Het VHL-gen is een tumor suppressor gen, dat in actieve toestand de vorming
van tumoren tegengaat. Wanneer het gen niet meer functioneert krijgen nor-
male cellen de kans te transformeren tot een tumorcel. Een gen is gelegen op
een chromosoom en omdat een celkern van elk chromosoom (behalve van het
Y-chromosoom) twee exemplaren bevat, komt een gen in tweevoud voor (één
allel per chromosoom). Volgens de ‘2-hit’ hypothese van Knudson moeten
beide allelen geïnactiveerd worden voordat een tumor suppressor gen volle-
dig is uitgeschakeld. Een patiënt met VHL erft van één van zijn ouders een
afwijkend (gemuteerd) allel (eerste ‘hit’), dat in alle cellen voorkomt (kiem-
baanmutatie). In de loop van de tijd kan spontaan in het andere allel een
afwijking (een zogenaamde somatische mutatie) optreden (tweede ‘hit’),
zodat beide allelen zijn uitgeschakeld en de cellen ongeremd kunnen gaan
groeien. Een persoon met een kiembaanmutatie ontwikkelt niet altijd tumo-
ren, maar loopt daarop wel een grote kans.
Bij patiënten met een sporadische tumor (die dus geen afwijkend allel geërfd
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hebben) moet er in het loop van het leven tweemaal een ‘hit’ optreden, die
leidt tot twee afwijkende allelen en daardoor inactivatie van het VHL-gen.
Meestal treedt in het ene allel een mutatie op en gaat het andere allel verlo-
ren door verlies van een groter chromosoomdeel waarop dit allel gelegen is.
Afwijkingen in het VHL-gen worden ook aangetroffen in sporadische HBs, ech-
ter minder frequent. In 20-50% van de sporadische HBs wordt een mutatie
of verlies van één allel van het VHL-gen aangetoond. Inactivatie van beide
allelen kan tot nu toe echter maar in ongeveer 10% van de HBs worden aan-
getoond. Daarom wordt vermoed dat in sporadische HBs andere genen een
(grote) rol spelen. 
De functies van het VHL-eiwit 
Het VHL-gen codeert voor een eiwit dat als belangrijkste functie de regulatie
van een transcriptie-factor heeft, de ‘hypoxia-inducible factor’ (HIF-1α). In tij-
den van zuurstoftekort in de cellen (hypoxie) stimuleert HIF-1α de expressie
van allerlei genen die ervoor zorgen dat de cellen efficiënt met de beschikba-
re zuurstof omgaan en dat er extra bloedvaatjes worden gevormd. De vorming
van nieuwe bloedvaatjes (angiogenese) wordt o.a. veroorzaakt door verhoog-
de expressie van  ‘vasculaire endotheliale groeifactor’ (VEGF). Tijdens norma-
le zuurstof-concentraties bindt HIF aan het VHL-eiwit en wordt dan afgebroken
door het proteosoom (een enzymcomplex dat eiwitten afbreekt). Indien het
VHL-gen geïnactiveerd is wordt er geen VHL-eiwit gevormd en wordt HIF-1α
niet afgebroken. De cel gedraagt zich dan alsof er onvoldoende zuurstof aan-
wezig is en produceert o.a. VEGF. Dit verklaart waarom VHL-geassocieerde
tumoren zoals HBs en niercelcarcinomen zo vaatrijk zijn. Andere genen die
verhoogd tot expressie worden gebracht reguleren o.a. het suikermetabolisme
en de groei van cellen. Het VHL-eiwit reguleert ook de productie van eiwitten
die betrokken zijn bij de afbraak van de extracellulaire matrix en bij de regu-
latie van de cel cyclus (o.a. cycline D1). Het is tot op heden echter nog niet
volledig duidelijk of afwezigheid van het VHL-eiwit voldoende verklaring is voor
het onstaan van de VHL-geassocieerde tumoren. Diverse studies suggereren
dat andere genen ook belangrijk zijn voor de ontwikkeling van HBs, niercel-
carcinomen en feochromocytomen.
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Om de genetische achtergrond van sporadische HBs te verduidelijken heb-
ben we gebruik gemaakt van een moleculair genetische techniek ‘compara-
tive genomic hybridization’ (CGH), waarmee het mogelijk is alle 46 chromo-
somen van tumorcellen te screenen op afwijkingen. Met CGH kan verlies
(loss) of winst (gain) van (een deel van) een chromosoom worden aange-
toond. Zo’n (deel van een) chromosoom kan een gen bevatten dat een rol
speelt bij het ontstaan van de tumor. 
Samenvatting van het proefschrift
In Hoofdstuk 1 worden het doel en de inhoud van het proefschrift omschre-
ven. Daarnaast bevat het hoofdstuk een overzicht van de klinische ver-
schijnselen en de histopathologische karakteristieken van HBs. De huidige
inzichten met betrekking tot de moleculair genetische aspecten van VHL-
geassocieerde HBs komen uitgebeid aan de orde. Een verkorte vorm van het
literatuur overzicht is in deze Nederlandse samenvatting weergegeven. De
moleculair genetische technieken waarvan we gebruikt hebben gemaakt in
de studies staan kort beschreven in het laatste deel van hoofdstuk 1.
Het genoom van 10 sporadische HBs werd mbv CGH gescreend op afwijkingen
in de chromosomen. In Hoofdstuk 2 worden de resultaten van deze analyse
beschreven. In 8 van de 10 tumoren werden chromosomale afwijkingen
gevonden; 5 tumoren hadden zelfs afwijkingen op meerdere chromosomen. 
In 7 van de 10 HBs (70%) werd een verlies van een heel chromosoom 3 (-
3) gedetecteerd, in 50% was er sprake van -6, in 30% van -18 of –9, en
winst (+) van chromosoom 19 werd eveneens in 30% van de HBs aange-
toond. De studie beschreven in hoofdstuk 2 is de eerste studie van zijn soort
geweest die CGH analyse van sporadische HBs rapporteert. Op grond van de
resultaten hebben we geopperd dat in sporadische HBs een patroon van ach-
tereenvolgende afwijkingen van chromosomen optreedt: verlies van chro-
mosoom 3 (waar het VHL-gen zich bevindt), gevolgd door -6, en daarna  –9
en/of –18 en/of +19. Dit patroon vertoont gelijkenissen met chromosomale
afwijkingen zoals die in de literatuur gerapporteerd zijn in sporadische nier-
celcarcinomen en feochromocytomen, tumoren die net als HBs ook kunnen
voorkomen in het kader van VHL.
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Omdat uit ons eerste onderzoek naar voren kwam dat in sporadische HBs
mogelijk andere chromosomale regio’s dan chromosoom 3 (met het VHL-
gen) mede betrokken zijn bij het onstaan van deze tumoren, hebben we het
onderzoek in die richting uitgebreid en een grotere groep sporadische HBs
vergeleken met VHL-geassocieerde HBs. De CGH resultaten zoals besproken
worden in Hoofdstuk 3 bevestigen de eerder gevonden frequenties van
chromosomale afwijkingen: 69% van de 16 sporadische HBs had verlies van
chromosoom 3, -6 werd aangetoond in 44% van de tumoren, -18 (of 18q)
in 31%, –9 en +19 elk in 25%, en –8 in 19%. Daarnaast kwamen multipe-
le andere chromosomale afwijkingen voor (Tabel 1, Hoofdstuk 3). Er was
een opvallend verschil met de 7 VHL-geassocieerde HBs; slechts in één
tumor werd een –3 gedetecteerd. In deze studie werd ook mutatie analyse
van het VHL-gen verricht. In alle VHL-geassocieerde HBs kon een (kiem-
baan)mutatie worden aangetoond, zoals verwacht op grond van het feit dat
patiënten met VHL de geërfde mutatie in alle cellen meedragen. Inactivatie
van beide allelen van het VHL-gen is nodig om het gen uit te schakelen. In
één allel treedt meestal een mutatie op, het andere allel gaat vaak verloren.
Zo’n verlies kan alleen worden aangetoond met CGH als een groter deel van
het chromosoom verloren gaat.  In één VHL-geassocieerd HB was een geheel
chromosoom 3 verloren gegaan (inclusief het VHL-gen), en in die tumor kon
dus met zekerheid inactivatie van het VHL-gen worden aangetoond. In 5 spo-
radische HBs (31%)  werd een somatische mutatie in het VHL-gen gedetec-
teerd. Omdat  2 van deze tumoren ook verlies van chromosoom 3 (met o.a.
het andere VHL-allel) hadden, kon uiteindelijk in 2 van de 16 sporadische
HBs inactivatie van beide allelen van het VHL-gen worden aangetoond. In de
andere tumoren met –3 werden geen somatische mutaties gevonden.
Het grote verschil in chromosomale afwijkingen en mutaties wijst erop dat
sporadische HBs een andere genetische achtergrond hebben, dat wil zeggen
dat naast het VHL-gen op chromosoom 3 andere genen een rol spelen, ter-
wijl in VHL-geassocieerde HBs het VHL-gen de belangrijkste factor is in het
ontstaan.
Om te kunnen achterhalen welke genen op de afwijkende chomosomen  be-
langrijk zijn in het ontstaan van sporadische HBs, werd in Hoofdstuk 4 array
CGH analyse verricht. Met array CGH kunnen chromosomen op kleine afwij-
kingen worden gescreend, gedetailleerder dan met conventionele CGH
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mogelijk is. Een afwijkend gebiedje kan één of meerdere genen bevattend
die betrokken zijn bij het ontstaan van de tumor. In 5 sporadische HBs wer-
den 3 regio’s gevonden die mogelijk relevante genen bevatten. Twee genen
zijn met name interessant: het LSAMP gen (limbic system-associated mem-
brane protein) dat op chromosoom 3q13.3 ligt en mogelijk een rol speelt bij
het niercelcarcinoom, en het FEZ1/LZTS1 gen (leucine zipper, putative tumor
suppressor 1) op chromosoom 8p22 dat betrokken is bij de celdeling en dat
de groei van verschillende typen tumoren blijkt te beïnvloeden. De resulta-
ten van de array CGH analyse dienen nog te worden bevestigd.
In de afgelopen jaren is aangetoond dat het VHL-eiwit behalve HIF-1α ook
een aantal andere genen reguleert, waaronder het CCND1 gen dat codeert
voor het eiwit cycline D1. Dit eiwit is betrokken bij de regulatie van de cel
cyclus en de celdeling. Overexpressie van cycline D1 leidt tot ongecontro-
leerde celgroei en de vorming van tumoren. In Hoofstuk 5 hebben we
onderzocht of in HBs een verhoogde expressie van cycline D1 aanwezig was.
In sporadische HBs vonden we een zeer wisselende en soms sterk verhoog-
de aanwezigheid van cycline D1. Het CCND1 gen bevat een veel voorkomend
G→A polymorfisme (normaal voorkomende variant), dat geassocieerd is met
een vroeg ontstaan en een slechte prognose van verschillende maligniteiten.
In de literatuur is gesuggereerd dat VHL patiënten met een of twee G-allelen
meer HBs in het netvlies en een verhoogde gevoeligheid voor HBs in het
zenuwstelsel hebben dan patiënten met A-allelen. Dit zou betekenen dat in
HBs vaker een G-allel wordt aangetroffen dan op grond van de verdeling in
de algemene populatie mag worden verwacht. In onze (kleine) studie was
dat niet het geval, zodat we niet kunnen bevestigen dat het CCND1 genoty-
pe het voorkomen van HBs beïnvloedt.
Er zijn verschillende moleculair genetische technieken beschikbaar om afwij-
kingen op chromosomen of in genen aan te tonen. Een kleine afwijking in
een gen, zoals een kiembaanmutatie, wordt met mutatie analyse aange-
toond. Verlies van (een deel van) een chromosoom kan worden aangetoond
met CGH of met LOH (loss of heterozygosity). Deze technieken staan kort
beschreven in het eerste hoofdstuk. In Hoofdstuk 6 beschrijven we een
patiënt met VHL die in de loop der jaren verschillende tumoren ontwikkelde,
waaronder meerdere HBs en een niercelcarcinoom. Aan het eind van zijn
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leven was er sprake van een grote weinig gedifferentieerde tumor in de nier-
regio met meerdere uitzaaiingen, waarvan niet duidelijk was of het oor-
spronkelijk een niercelcarcinoom betrof of een feochromocytoom (een tumor
uitgaande van de bijnieren). Gededifferentieerde tumoren zijn soms moeilijk
histologisch te categoriseren. Omdat tegenwoordig steeds meer informatie
beschikbaar komt over de specifieke genetische afwijkingen die in tumoren
worden gevonden, hebben we de tumoren van deze patiënt gekarakteriseerd
met behulp van CGH, LOH en mutatie analyse van het VHL-gen. De resulta-
ten van de moleculair genetische analyses bevestigden dat deze patiënt een
gededifferentieerd niercelcarcinoom had. Deze casus illustreert dat molecu-
lair genetisch onderzoek een waardevol hulpmiddel kan zijn bij het stellen
van een diagnose wanneer dat met standaard histologisch en immunohisto-
chemisch onderzoek niet mogelijk is. Het stellen van de juiste diagnose kan
leiden tot eerdere en betere behandeling van de patiënt.
In Hoofdstuk 7 wordt een nieuwe computer methode beschreven waarmee
microscopische weefselstructuren 3-dimensionaal in beeld gebracht kunnen
worden. In series van (2D) histologische coupes wordt met een (immuno-
histochemische) marker de structuur waarvan een 3D reconstructie moet
worden gemaakt geaccentueerd. Vervolgens worden deze beelden één voor
één opgeslagen en verwerkt tot een 3D figuur.
Wij hebben ons, vanwege onze interesse in bloedvatvorming in tumoren,
vooral gericht op de 3D reconstructie van bloedvaatjes. In tumoren worden
continu nieuwe bloedvaatjes gevormd (angiogenese), omdat tumorcellen
voor hun groei afhankelijk zijn van voldoende aanvoer van zuurstof en voe-
dingstoffen. Angiogenese is een belangrijk onderzoeksgebied voor de ont-
wikkeling van nieuwe middelen tegen tumoren, en medicamenten die bloed-
vatnieuwvorming tegengaan worden momenteel bij de behandeling van
patiënten met bepaalde tumoren toegepast.
De wand van de bloedvaten is opgebouwd uit endotheelcellen, die omgeven
zijn door steuncellen, de pericyten. Beide onderdelen van de vaatwand wer-
den zichtbaar gemaakt met specifieke markers (anti-CD34 voor endothee-
lcellen; α-smooth muscle actin voor geactiveerde pericyten). Er werden 3D
reconstructies gemaakt van het vaatbed van normale witte en grijze stof van
de hersenen, van een HB en van een glioblastoma multiforme (GBM). Een
GBM is een kwaadaardige hersentumor die o.a. gekenmerkt wordt door de
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aanwezigheid van bijzondere vaatstructuren, zogenaamde ‘glomeroïde micro-
vasculaire proliferaties’. De 3D reconstructies illustreren de typische vascu-
laire netwerken van beide tumoren (zie Figuur 2, Hoofdstuk 7) en geven
meer inzicht in de microvascularisatie van tumoren. 
Met deze nieuwe methode is het tevens mogelijk van meerdere microscopi-
sche structuren simultaan een 3D reconstructie te vervaardigen. De onder-
linge 3-dimensionale samenhang tussen verschillende structuren worden
daardoor zichtbaar gemaakt.  Voorbeelden hiervan zijn de relatie tussen
endotheelcellen en geactiveerde pericyten (gladde spiercellen) in de vaat-
wandjes van de normale cerebellaire grijze stof, in een HB en in een GBM
(Figuur 4 en 5, Hoofdstuk 7). Opvallend is de uitgebreide aanwezigheid van
geactiveerde pericyten rondom de endotheelcellen in het HB, hetgeen past
bij een actief proces van bloedvatnieuwvorming.
In Hoofdstuk 8 ten slotte wordt een samenvatting van de studies gegeven
en worden de resultaten bediscussieerd.
Conclusies en toekomstig onderzoek
Samenvattend hebben de studies uit dit proefschrift het volgende aange-
toond:
• Er bestaan grote verschillen in het voorkomen van chromosomale
afwijkingen in sporadische HBs ten opzichte van VHL-geassocieerde HBs,
aangetoond met CGH
• Er zijn multipele chromosomale afwijkingen aanwezig in sporadische HBs,
met name verlies van chromosoom 3, 6, 8, 18, 9 en winst van chromo-
soom 19
• Verlies van een heel chromosoom 3 komt vaker voor in sporadische dan
in VHL-geassocieerde HBs
• Verlies van chromosoom 6 is, na –3, de meest voorkomende afwijking in
sporadische HBs
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• Verlies van chromosoom 6 is geassocieerd met –3 of met een somatische
mutatie van het VHL-gen, hetgeen zou kunnen duiden op een belangrijke
rol van genen op dit chromosoom 6 in het ontstaan van sporadische HBs. 
• Somatische VHL mutaties treden op in ongeveer 31% van sporadische
HBs.
• Drie kandidaat chromosomale regio’s, geïdentificeerd met behulp van
array CGH, bevatten genen die mogelijk betrokken zijn bij HBs.
Deze resultaten wijzen erop dat inactivatie van het VHL-gen onvoldoende is
voor het ontstaan van sporadische HBs, en dat VHL-geassocieerde HBs en
sporadische HBs deels een andere genetische achtergrond hebben.
De studies beschreven in dit proefschrift hebben de moleculair genetische
gebeurtenissen die ten grondslag liggen aan het ontstaan van sporadische
HBs niet geheel kunnen ophelderen. Door de komst van nieuwe methoden
om het pad van DNA (chromosoom/gen) naar RNA naar eiwit in kaart te
brengen zijn er meerdere mogelijkheden voor verder onderzoek. Een veel-
belovende methode om inzicht te krijgen in de processen die aanleiding
geven tot tumorgroei is bijvoorbeeld proteomics, waarmee eiwitprofielen van
tumoren kunnen worden gemaakt. Omdat het uiteindelijk de eiwitten zijn die
een cel aansturen ligt het voor de hand te onderzoeken welke eiwitten in een
bepaalde tumorcel al dan niet aanwezig zijn, en wat hun functie is.
Verschillen in eiwitprofielen tussen sporadische en VHL-geassocieerde HBs
kunnen mogelijk opheldering geven over de processen die leiden tot deze
tumoren.
De door ons ontwikkelde techniek van 3D reconstructie van bloedvaatjes zal
worden gebruikt voor het verder bestuderen van vaatnieuwvorming en het
effect van (anti-angiogenese) therapie in experimentele tumormodellen.
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Dit proefschrift is tot stand gekomen dankzij de enthousiaste samenwerking
van verschillende disciplines. Graag wil ik op deze plaats allen die een bij-
drage hebben geleverd hartelijk bedanken.
Mijn promotor en hoofd van onze afdeling, George Padberg, ben ik zeer
erkentelijk voor de ruimte en steun die ik heb gekregen bij het verrichten van
de studies beschreven in dit proefschrift. Beste George, met onvermoeibare
inzet probeer jij voor eenieder van ons de optimale werkomgeving te 
creëren, waarin alle ambities kunnen worden verwezenlijkt. Veel dank 
daarvoor, en voor je bereidheid mee te denken als de zaken vast dreigden te
lopen.
Mijn copromotores Pieter Wesseling en Judith Jeuken ben ik veel dank ver-
schuldigd. Zij zijn de inspirators van het onderzoek geweest. Beste Pieter,
jouw fascinatie met de pathobiologie van hersentumoren en met hemangio-
blastomen in het bijzonder werkte zeer aanstekelijk. Dit proefschrift is het
resultaat van de door jou aangezette poging het ‘enigma’ hemangioblastoom
op te lossen. Heel veel dank voor je enthousiaste en uitstekende begeleiding. 
Judith Jeuken en Sandra Boots-Sprenger, mijn ‘co-copromotor’, wil ik heel
hartelijk danken voor de waardevolle lessen in de moleculaire genetica en in
het verrichten van wetenschappelijk onderzoek. Beste Judith en Sandra,
dank voor alle uren discussie over de valkuilen van de moleculair genetische
diagnostiek. Veel dank voor alle arbeid in het lab en voor jullie onmisbare bij-
dragen aan de artikelen. Met jullie enthousiasme, doorzettingsvermogen en
precisie zijn jullie een voorbeeld voor eenieder die wetenschappelijk onder-
zoek doet.
Alle coauteurs wil ik hartelijk danken voor hun waardevolle bijdragen. De
expertise van de medeonderzoekers en de deskundigheid van de analisten
op de afdelingen Pathologie en Antropogenetica zijn van onschatbare waar-
de geweest voor het onderzoek. 
Enkele medeonderzoekers wil ik met name noemen, zonder de anderen te
kort te willen doen. Bram Jacobs, beste Bram, dank voor je noeste arbeid in
het lab. Pas achteraf realiseer ik me dat je het vast niet altijd makkelijk hebt
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gehad met drie veeleisende dames op de achtergrond. Veel succes met je
huidige onderzoek.
Cathy Maass verdient veel lof voor haar immunohistochemische kleuringen.
Beste Cathy, je zag het steeds opnieuw als een uitdaging om aan onze hoog-
gespannen verwachtingen tegemoet te komen, heel veel dank daarvoor.
Jeroen van der Laak, beste Jeroen, ik ben je veel dank verschuldigd voor je
geduldige uitleg over het digitaliseren van de histologische coupes. De prach-
tige 3D beelden zijn voornamelijk aan jouw inventiviteit op software gebied te
danken.
Roland Kuiper, beste Roland, dank voor je onmisbare expertise op het gebied
van de array CGH. Het is prettig te beseffen dat we dit onderzoek voorlopig
nog voort kunnen zetten.
De Nederlandse samenvatting is gecorrigeerd door Dorien Langenkamp.
Beste Dorien, veel dank daarvoor en voor de uitstekende secretariële onder-
steuning van jou en je collega’s op de poli en vijfde verdieping.
Mijn collega’s dank ik voor hun interesse in mijn proefschrift en voor het
creëren van ruimte om het af te kunnen ronden. Beste collega’s, dank voor
de inspirerende, vriendschappelijke en collegiale sfeer op onze afdeling. De
arts-assistenten dragen in belangrijke mate aan deze positieve werkomge-
ving bij. Dankzij jullie allen is onze afdeling Neurologie een fantastische plek
om te werken, dank daarvoor. Mijn collega neuro-oncoloog Arnoud Kappelle
wil ik in het bijzonder bedanken. Beste Arnoud, dank voor de uitstekende
samenwerking en voor de vele uren (maanden) waarneming als ik om uit-
eenlopende redenen afwezig was. 
Mijn paranimfen, Agnita Boon en Trudy Jonges, dank ik voor hun vriendschap
en hun bereidheid mij tijdens de promotie bij te staan. Beste Agnita en
Trudy, als vriendinnen, moeders van kleine kids, en als neuroloog respectie-
velijk patholoog, hebben we veel stof om regelmatig bij te praten. Ik hoop
dat ik daarvoor nu iets meer tijd krijg. 
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Dit proefschrift is opgedragen aan mijn ouders, als blijk van mijn dank voor
de liefdevolle zorg waarmee zij mij altijd hebben omringd. Lieve pa en ma,
dankzij jullie grenzeloze steun en vertrouwen ben ik uiteindelijk neuroloog
geworden, en heb ik dit proefschrift kunnen schrijven. Ik dank jullie voor
alles.
Ten slotte dank ik mijn drie allerliefste mannen Hugo, Sem en Sander voor
hun vertrouwen en hun liefde.
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